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A B S T R A C T
Background
Erythropoiesis-stimulating agents (ESAs) reduce anemia in cancer patients and may improve quality of life, but there are concerns that
ESAs might increase mortality.
Objectives
Our objectives were to examine the effect of ESAs and identify factors that modify the effects of ESAs on overall survival, progression free
survival, thromboembolic and cardiovascular events as well as need for transfusions and other important safety and efficacy outcomes
in cancer patients.
Search strategy
We searched the Cochrane Library, Medline, Embase and conference proceedings for eligible trials. Manufacturers of ESAs were
contacted to identify additional trials.
Selection criteria
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We included randomized controlled trials comparing epoetin or darbepoetin plus red blood cell transfusions (as necessary) versus red
blood cell transfusions (as necessary) alone, to prevent or treat anemia in adult or pediatric cancer patients with or without concurrent
antineoplastic therapy.
Data collection and analysis
We performed a meta-analysis of randomized controlled trials comparing epoetin alpha, epoetin beta or darbepoetin alpha plus red
blood cell transfusions versus transfusion alone, for prophylaxis or therapy of anemia while or after receiving anti-cancer treatment.
Patient-level data were obtained and analyzed by independent statisticians at two academic departments, using fixed-effects and random-
effects meta-analysis. Analyses were according to the intention-to-treat principle. Primary endpoints were on study mortality and overall
survival during the longest available follow-up, regardless of anticancer treatment, and in patients receiving chemotherapy. Tests for
interactions were used to identify differences in effects of ESAs on mortality across pre-specified subgroups. The present review reports
only the results for the primary endpoint.
Main results
A total of 13933 cancer patients from 53 trials were analyzed, 1530 patients died on-study and 4993 overall. ESAs increased on study
mortality (combined hazard ratio [cHR] 1.17; 95% CI 1.06-1.30) and worsened overall survival (cHR 1.06; 95% CI 1.00-1.12),
with little heterogeneity between trials (I2 0%, p=0.87 and I2 7.1%, p=0.33, respectively). Thirty-eight trials enrolled 10441 patients
receiving chemotherapy. The cHR for on studymortality was 1.10 (95%CI 0.98-1.24) and 1.04; 95%CI 0.97-1.11) for overall survival.
There was little evidence for a difference between trials of patients receiving different cancer treatments (P for interaction=0.42).
Authors’ conclusions
ESA treatment in cancer patients increased on study mortality and worsened overall survival. For patients undergoing chemotherapy
the increase was less pronounced, but an adverse effect could not be excluded.
P L A I N L A N G U A G E S U M M A R Y
Anti-anemia drugs shorten survival for some cancer patients
People with cancer may develop a blood problem called anemia, due to the treatment or from the disease itself. They will have very
low levels of healthy red blood cells, causing additional health problems. For years, doctors have tried to prevent or treat anemia with
injections of erythropoiesis stimulating agents (ESAs) in order to spare cancer patients the many serious harms associated with a red-
blood cell transfusion (such as hepatitis, transfusion-related acute lung injury, infection). Earlier reviews of the research showed that
ESA treatment reduces the need for transfusion but, in recent years, several studies have shown that ESAs themselves cause harm.
The drug may, for example, stimulate tumor growth and cause potentially fatal blood clots. In 2007, new studies reported that ESAs
shortens survival in people with breast, non-small cell lung, head and neck, lymphoid and cervical cancers.
A new systematic review was needed to evaluate the old and the new evidence together and determine the impact of ESAs on survival
in cancer patients to see if there are groups of patients who are at increased or decreased risk compared to the average. To accomplish
this the authors of this meta-analysis conducted an in-depth assessment of the individual patient data generated by the care of nearly
14,000 patients from 53 trials conducted worldwide. Data on each of these patients were provided by three companies that make
ESAs: Amgen, Johnson & Johnson, and Roche, and by several independent researchers. (The drug companies, however, had no role in
conducting the meta-analysis.) The trials investigated one of two types of ESAs, epoetin or darbepoetin, and compared the use of one
of these drugs plus red blood cell transfusion (as needed), with red blood cell transfusion alone (as needed). Most patients were given
their treatment while undergoing anti-cancer therapy (chemotherapy and/or radiotherapy); but others received the treatment after they
had completed their anti-cancer therapy. Some patients already had anemia; others were treated in order to prevent it. The patients had
many different forms of cancer and many different anti-cancer treatments.
The authors of this new meta-analysis concluded that ESA treatment shortens survival. They could not identify with certainty any
subgroup of patients at either increased or decreased risk of dying when taking ESAs. With their doctors’ help, cancer patients should
consider the risks of taking ESA against the risks of a blood transfusion. Be aware, however, that uncertainties remain about the
magnitude of each.
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B A C K G R O U N D
Description of the condition
Tumor anemia
Anemia is defined as a deficiency in red blood cells (RBC) and is
a widely prevalent complication among cancer patients (Ludwig
2004). A commonly used classification of anemia according to
hemoglobin levels (National Cancer Institute) is shown in the
following table (Groopman 1999):
Category Women Men
Grade 0 (normal) 12.0 to 16.0 g/dl 14.0 to 18.0 g/dl
Grade 1 (mild) 10.0 to <12.0 g/dl 10.0 to <14.0 g/dl
Grade 2 (moderate) 8.0 to <10.0 g/dl 8.0 to <10.0 g/dl
Grade 3 (severe) 6.5 to <8.0 g/dl 6.5 to <8.0 g/dl
Grade 4 (life threatening) <6.5 g/dl <6.5 g/dl
The pathophysiology of tumor anemia is multifactorial (Spivak
2005). Tumor-associated factors such as tumor bleeding, hemol-
ysis, deficiency in folic acid and vitamin B12, can be acute or
chronic. In the advanced stages of hematological malignancies,
bone marrow involvement often leads to progressive anemia. In
addition, interaction between tumor-cell populations and the im-
mune system can lead to the release of cytokines, especially inter-
feron-gamma, interleukin-1 and tumor necrosis factor. This dis-
rupts endogenous erythropoietin synthesis in the kidney and sup-
presses differentiation of erythroid precursor cells in the bone mar-
row. As a result, patients with tumor anemia may have relatively
low levels of erythropoietin for the grade of anemia observed (
Spivak 2005). Moreover, activation of macrophages can lead to a
shorter erythrocyte half-life and a decrease in iron utilization. Cy-
tostatic therapy and radiation further aggravates anemia in cancer
patients. Platinum-based chemotherapy regimens may diminish
endogenous erythropoietin production by damaging renal tubu-
lar cells (Wood 1995) and myelotoxic anticancer drugs can com-
promise erythroid precursor cells. As a consequence, dose-intensi-
fied treatment regimens or shortened treatment intervals as well as
multimodal therapies are associated with a higher degree of ane-
mia. Mild or moderate (grade 1 and 2) anemia in patients with
solid cancers may affect about 60% of patients after platinum-
based chemotherapy (Groopman 1999). Severe (grade 3) anemia
in elderly patients with hematological malignancies may occur in
up to 74% in patients with Non-Hodgkin lymphoma after stan-
dard CHOP treatment (Groopman 1999). In addition, some of
the newer chemotherapeutic agents such as taxanes or vinorelbine
are strongly myelosuppressive and frequently cause severe anemia
(Groopman 1999).
The clinical manifestation and severity of anemia can vary con-
siderably among individual patients. Mild to moderate anemia
can typically cause signs and symptoms such as headache, palpi-
tations, tachycardia and shortness of breath. Chronic anemia can
result in severe organ damage affecting the cardiovascular system,
immune system, lungs, kidneys and the central nervous system (
Ludwig 2001). In addition to physical symptoms, the subjective
impact of cancer-related anemia on quality of life (QoL), men-
tal health and social activities may be substantial. Clinical studies
have reported correlations between hemoglobin (Hb) levels and
QoL (Cella 1997; Holzner 2002; Lind 2002). A common anemia-
related problem is fatigue, which impairs the patient’s ability to
perform normal daily activities (Ludwig 2001; Vogelzang 1997;
Cramp 2008).
Another aspect of anemia in patients with malignant disease is the
effect on the tumor itself. For several cancers, including cervical
carcinoma, head and neck, prostate, bladder and lung cancer as
well as lymphoma, anemia is known to be a factor associated with
a worse prognosis (Caro 2001). This is partly due to confound-
ing factors because advanced cancers usually present with lower
Hb levels at diagnosis compared with early-stage cancers and also
have poorer survival outcomes. Besides this, one causal explana-
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tion might be the improved oxygenation of tumor tissue at higher
Hb levels. Since tumor cells become resistant by tumor hypoxia,
improved oxygenation may prevent hypoxia maintaining tumor
cells sensitive to radiation and most cytostatic drugs. Due to an
abnormal microenvironment, solid tumor tissue is often hypoxic.
Hypoxia may be more prevalent in anemic patients than in pa-
tients with normal Hb levels (Vaupel 2005). Tumor hypoxia may
impair the effectiveness of radiotherapy and oxygen-dependent
chemotherapies (Vaupel 2005; Schrijvers 1999; Hockel 1993).
Anemia is associated with a poor outcome in patients treated with
radiotherapy, most likely because anemia results in poor tumor
oxygenation (Vaupel 2001). Radiobiological studies have shown
that tumor hypoxia leads to less radiation induced cytotoxic free
radicals resulting in less radiation-induced DNA damage and tu-
mor cell kill. Tumor oxygenation is also impaired by hemoglobin
levels >14 g/dl in women and >15 g/dl in men which result in in-
creased viscosity and a drop in nutritive perfusion (Vaupel 2002).
It was therefore suggested to keep the hemoglobin levels during
radiotherapy within a potentially optimal range of 12-14 g/dl for
women and 13-15 g/dl for men in order to achieve maximum
tumor oxygenation (Vaupel 2002). These observations generated
the hypothesis that strategies to diminish cancer-related anemia
might not only alleviate anemia-related symptoms but also im-
prove tumor response and overall survival.
Description of the intervention
Recombinant human erythropoietins
Conventionally, blood transfusions are used to treat severe can-
cer-related anemia. Homologous blood transfusion is the fastest
method to alleviate symptoms. Potential complications include
transmission of infectious diseases, transfusion reactions, alloim-
munization, lung injury, over-transfusion and immune modula-
tion with possible adverse effects on tumor growth (Goodnough
2005; Toy 2005). The risks of transfusion-related transmissions
are 1:180,000 per units of blood transfused for hepatitis B virus,
1:1,600,000 for hepatitis C virus and 1:1,900,000 for HIV in the
US (Goodnough 2003).
Short and long-acting preparations of recombinant human ery-
thropoietins (ESAs) offer an alternative treatment option. Hu-
man erythropoietin is an acidic glycoprotein hormone and the pri-
mary regulator of human erythropoiesis. Human erythropoietin
is mainly synthesized in the kidney and to a minor degree in the
liver (Lai 1986; Koury 1991; Koury 1988). Tissue hypoxia trig-
gers the synthesis and release of erythropoietin into the plasma.
The effects of erythropoietin in the bone marrow are mediated by
a specific surface erythropoietin receptor located mainly on RBC
precursor cells (D’Andrea 1989). Erythropoietin has two major
functions: stimulating proliferation of erythroid progenitor cells
and maintaining their viability (Koury 1990). Recombinant hu-
man erythropoietin was first approved for the treatment of anemia
in patients with chronic renal disease. In 1993, the use of erythro-
poietin was approved by the FDA for the treatment of anemia in
cancer patients. Three different recombinant erythropoietins are
available to date: epoetin alfa (Procrit®,OrthoBiotech; Epogen®,
Amgen), epoetin beta (NeoRecormon®, Roche) and darbepoetin
alfa (Aranesp®, Amgen). All three erythropoietins have similar
clinical efficacy (Halstenson 1991; Storring 1998; Glaspy 2005).
Another substance called CERA® (Continuous Erythropoietin
Receptor Activator, Roche) is currently being investigated in phase
I and II clinical trials. Epoetin delta (Shire plc) differs from re-
combinant erythropoietins as it is produced in a human cell line
using gene-activation technology. A randomized controlled trial
of epoetin delta was recently presented (Zajda 2007).
How the intervention might work
Efficacy and safety
Multiple studies and subsequentmeta-analyses have demonstrated
that ESA treatment increases hemoglobin (Hb) levels and reduces
the proportion of patients receiving red blood cell transfusions in
cancer patients (Seidenfeld 2001; Bottomley 2002; Clark 2002;
Bohlius 2006; Sehata 2007). In our previous meta-analysis includ-
ing 42 studies with 6,510 patients the relative risk to receive RBC
transfusions was 0.67 [95% confidence interval (CI) 0.60, 0.68]
(Bohlius 2006).
Concern regarding the impact of ESAs on survival has been
raised by several studies in oncology and hematology patients that
have reported increased mortality in patients treated with ESAs (
Leyland-Jones 2003; Henke 2003; Smith 2008; Hedenus 2003;
Overgaard 2007; Wright 2007; Goss 2005. Three clinical studies
reported increased tumor progression or death due to tumor pro-
gression in patients receiving ESAs (Henke 2003; Leyland-Jones
2003; Overgaard 2007). However, this effect was not consistently
observed and several studies did not show an increased risk for
tumor progression for patients receiving ESAs (Machtay 2007;
Chang 2005; EPO-GBR-7;Moebus 2007;Hedenus 2003). In ad-
dition, an increased risk for thromboembolic events has been con-
sistently observed in various patient populations (Leyland-Jones
2003; Henke 2003; Thomas 2008; Goss 2005; Rosenzweig 2004;
Smith 2008).
However, because erythropoietin receptors have been detected in
numerous cancers (Arcasoy 2003; Arcasoy 2005; Dagnon 2005;
McBroom 2005; Leo 2006), it is also possible that endogenously
produced or exogenously administered erythropoietin promotes
the proliferation and survival of erythropoietin receptor express-
ing cancer cells (Feldman 2006; Yasuda 2003; Mohyeldin 2005;
Henke 2006). There is an ongoing debate about the validity of
those studies, because the antibodies usedmost often lacked EPO-
R specificity (Elliott 2006; Osterborg 2007). Thus, the interpre-
tation of the observations made in many of those studies is ques-
tionable.
Besides this, other researchers have postulated an anti-apoptotic
effect of ESAs on other tissues including neural (Brines 2004;
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Brines 2000) and cancer cells (Um 2007). In addition, it has been
proposed that there is a link between endogenous erythropoietin
and angiogenesis in vivo (Ribatti 2007b; Ribatti 2007a; Hardee
2007). Possibly, endogenous erythropoietin is needed to promote
tumor angiogenesis and to maintain the viability of endothelial
cells. However, the clinical implications of these findings have not
been clarified to date. Apart from the direct tumor growth stimula-
tion, a pathophysiological relationship between thromboembolic
events and cancer has been described. Studies have implicated the
tumor-mediated activation of the hemostatic system in both the
formation of tumor stroma and in tumormetastasis (Francis 1998;
Levine 2003).
In summary, a direct relationship between the presence of erythro-
poietin receptors on tumor cells and tumor proliferation in re-
sponse to exogenous ESAs has not been established to date. Over-
all, the evidence from both in vitro and in vivo studies as well
as clinical trials is insufficient to draw firm conclusions whether
ESAs promote tumor proliferation or not.
Three Oncologic Drugs Advisory Committee (ODAC) hearings
took place to discuss the safety of erythropoietins in cancer pa-
tients. After the first hearing in May 2004 the FDA concluded
the Hb target for ESA treatment should not be higher than Hb
12 g/dL (Luksenburg 2004). Package inserts in the USA were
amended to include this recommendation. Since then, another
two randomized controlled trials showed detrimental effects for
patients receiving ESAs.One studywas conducted in patients with
head and neck cancer undergoing radiotherapy (Overgaard 2007),
another study was conducted with palliative intent for patients
with advanced stage cancers not receiving chemotherapy (Smith
2008). The second ODAC hearing was held on May 10th 2007.
In March 2007 a black box warning was added to the package in-
serts in the USA. This warning recommends that 1) ESAs should
be used at the lowest dose that will gradually increase the Hb con-
centration to the lowest level sufficient to avoid the need for RBC
transfusions, 2) ESAs should not be used in patients with active
malignant disease not receiving chemotherapy or radiotherapy and
3) the target Hb should be 12 g/dL and not higher. In November
2007 another warning was released, declaring that “the risks of
shortened survival and tumor progression have not been excluded
when ESAs are dosed to target hemoglobin of < 12 g/dL.” Follow-
ing the release of study data from two additional studies (Thomas
2008; Untch 2008), a third ODAC hearing was held in March
2008. At that meeting it was discussed whether the indication for
ESAs in cancer patients receiving chemotherapy should be with-
drawn, whether the drugs should not be used in cancer patient
who are likely to be cured, which suggests the drugs should only
be used as part of a best-supportive care regimen in patients with
advanced cancer. It was also discussed that the drug should not
be used in advanced or metastatic breast cancer as well as patients
with head and neck cancer.
Why it is important to do this review
Rationale
We previously conducted a Cochrane Review on the effectiveness
of ESAs which included trials published through 2001. This anal-
ysis suggested a survival benefit for patients receiving ESAs com-
pared to patients only receiving red blood cell transfusions (hazard
ratio (HR) 0.81, 95% confidence interval (CI) 0.67 to 0.99, n
= 2865) (Bohlius 2005). This review was subsequently updated
with studies published through April 2005. The updated review
included 57 trials with 9353 patients (Bohlius 2006). In contrast
to our previous findings, the results of the updated review sug-
gested detrimental survival effects in patients receiving erythro-
poietin or darbepoetin compared to patients only receiving red
blood cell transfusions (HR 1.08; 95%-CI 0.99-1.18; 42 trials, n
= 8167) (Bohlius 2006). In addition, use of ESAs was statistically
significantly associated with an increased risk for thromboembolic
events (relative risk 1.67, 95%-CI 1.35-2.06; 35 trials, n = 6769)
(Bohlius 2006).
However, to date it has not been convincingly shown whether ESA
treatment increases or decreases tumor progression and overall
survival. Risk factors to develop TEEs (thromboembolic events)
under ESA treatment have not been identified yet.
The need for an individual patient data meta-analysis
The meta-analyses conducted so far are limited to published data
aggregated across trials at the level of randomized groups (active
treatment versus control). Pooled time-to-event analyses allow the
examination of potential confounding and interaction, and are
generally more efficient than analyses based on aggregated data.
We therefore expanded our prior aggregated data meta-analysis
to individual patient data (IPD). This will allow us to assess the
associations between ESA treatment and risk for thromboembolic
events, disease progression, quality of life and deaths in cancer
patients and would provide a unique opportunity to shed light on
the important questions discussed above.
O B J E C T I V E S
1. To examine the effect of ESAs on overall survival, progression
free survival, thromboembolic and cardiovascular events as well
as need for transfusions and other important safety and efficacy
outcomes in cancer patients.
2. To identify factors that modify the effect of ESAs on overall
survival, progression free survival, thromboembolic and cardiovas-
cular events, need for transfusions and other important safety and
efficacy outcomes in cancer patients.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
In accordance with best practice in reviews of the effects of in-
terventions, we included all eligible randomized controlled trials
(Higgins 2006), for which individual patient data were available.
Studies were included regardless of publication status, i.e. unpub-
lished studies were included as well. We considered only studies
that were planned to include at least 50 patients per study arm
or at least 100 patients in total. Studies that were terminated pre-
maturely and did therefore not reach the planned study size were
included as well. A sensitivity analysis was conducted to test the
influence of prematurely terminated studies. Placebo control was
not required for inclusion but was recorded in the context of trial
quality (see below). For the endpoints overall survival we included
any eligible trial, regardless whether the study was designed for the
endpoint survival or not.
Studies that did not collect or report data for any of the primary
and secondary outcomes of this project (see below) were excluded.
Ongoing studies, i.e. studies that were not completed according
to the study specific protocol (e.g. complete follow-up for primary
outcome), were included if the following criteria weremet: recruit-
ing phase completed, interim analyses conducted with in depth
validation of the data, all initially randomized patients included
in the interim analysis. Any other ongoing study was excluded
from the present analysis but will be included in a later update of
this analysis (e.g. German Hodgkin Study Group HD 15). Some
studies offered ESA treatment to patients in the control arm after
a defined period, e.g. after 12 weeks of study duration and allowed
cross-over to the treatment arm after this defined period. For those
studies we evaluated only the trial phase, where patients allocated
to the control arm did not receive ESAs and patients allocated to
the treatment arm received ESAs. For on study mortality we ana-
lyzed only data while the patient was on trial treatment plus a short
follow-up period (four weeks or 28 days). For overall survival we
collected the longest follow-up available, including the time after
the end of study drug treatment.
Types of participants
Pediatric and adult, male and female patients with a clinically
or histologically confirmed diagnosis of cancer receiving or not
receiving chemotherapy or radiotherapy or combined modality
treatment were included. Both patients with solid and hematolog-
ical malignancies were eligible.
Studies on high-dose myeloablative chemotherapy regimens fol-
lowed by bone marrow or peripheral blood stem cell transplanta-
tion, myelodysplastic syndromes or acute leukemia as well as trials
using ESAs for short-term preoperative treatment were excluded.
Studies were excluded if more than 20% of the entire patient pop-
ulation presents with an ineligible condition. However, if the re-
spective study was randomized using a stratification technique and
includes single strata that do fulfill the inclusion criteria, these
strata were included in the analysis.
Types of interventions
Cancer patients in the experimental group must have received
short or long acting ESAs to prevent or reduce anemia, given
singly or concomitantly with chemotherapy, radiotherapy, combi-
nation therapy or no therapy. ESAs had to be administered sub-
cutaneously or intravenously. No minimum treatment duration
or minimum ESA dosage was required for inclusion. Patients in
both the control group and the experimental group(s) were to re-
ceive red blood cell transfusions if necessary. Studies with active
controls i.e. head-to-head comparisons of different ESA types or
dosages were excluded. Supportive care such as iron given either
as necessary or following a fixed schedule was allowed. Apart from
administration of ESAs, participants in experimental and control
groups must have intended to receive identical care. For purposes
of this analysis, patients receiving chemotherapy were considered
to be receiving identical care, even if the regimens they received
may have included different chemotherapy drugs. In the proto-
col we had stated that there was to be one exception: studies that
compared ESA plus iron compared to no ESA and no iron were
included. However, in the present review we also included two
studies with different start of radiotherapy in the ESA and the
control arm (Strauss 2008) and different transfusion trigger in the
ESA and the control arm (Thomas 2008). The impact of these
studies on the overall analysis was explored in a sensitivity analysis.
Types of outcome measures
Primary outcomes
On study mortality
Populations of interest, defined at study level (see below: Other
definitions, Population of interest):
• cancer patients receiving chemotherapy or combined
modality treatment regardless of Hb level
• all cancer patients receiving chemotherapy/combined
modality treatment, radiotherapy/radio-chemotherapy
or no anticancer treatment regardless of Hb level
Type of information: time-to-event, definition of event: death
from any cause, starting time point: date of randomization, date
of last follow-up to be considered: see Statistics section. Aminimal
follow-up time was not required for inclusion.
Overall survival
6Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Populations of interest, defined at study level (see below: Other
definitions, Population of interest):
• cancer patients receiving chemotherapy or combined
modality treatment regardless of Hb level
• all cancer patients receiving chemotherapy/combined
modality treatment, radiotherapy/radio-chemotherapy
or no anticancer treatment regardless of Hb level
Type of information: time-to-event, definition of event: death
from any cause, starting time point: date of randomization, date
of last follow-up to be considered: longest follow-up available. A
minimal follow-up time was not required for inclusion.
Secondary outcomes
On study mortality and overall survival
Populations of interest, defined at study level (see below: Other
definitions, Population of interest):
• cancer patients receiving radiotherapy/radio-chemo-
therapy treatment regardless of Hb level
• cancer patients receiving no anticancer treatment re-
gardless of Hb level
Note: these and all other secondary outcomes (not listed here)
reported in the protocol (Bohlius 2008) were postponed and are
not part of the present report. For details see protocol.
Other time points of interest
In addition to the time points specified above, we specifically ex-
amined the following points in time: 4, 8, 12, 24, 36, 60 months
after randomization. These time points were calculated for the
overall population as well as separately for the populations che-
motherapy, radio(chemo)therapy, “mixed” and none.
Other definitions
Populations of interest
Highest priority was given to the analyses of cancer patients re-
ceiving concomitant chemotherapy and cancer patients receiving
ESAs irrespective of concomitant anticancer treatment. The re-
spective treatment strategies (chemotherapy/combined modality
treatment versus radiotherapy/radiochemotherapy versus “mixed”
versus no treatment) were explored in subset analyses. Note: the
no treatment and the radio(chemo)therapy populations have not
been analyzed separately.
Definitions of anticancer treatment populations: The definition of
anticancer treatment populations was referring to the anticancer
treatment at study level and not to the anticancer treatment an
individual patient had actually received. A cut of 70% was chosen
to define the different anticancer treatment populations at study
level. I.e. if in a given study 70% of the patients had received che-
motherapy, the study was classified as “chemotherapy population”.
“Chemotherapy“ refers to patients receiving a myelosuppressive
chemotherapy. Combined modality treatment was defined as che-
motherapy followed by radiotherapy. Radiochemotherapy was de-
fined as treatment strategy where radiotherapy and chemotherapy
were given at the same time. Radiotherapy was defined as popu-
lation of patients receiving mainly radiotherapy only. “None” was
defined as patients population were more than 70% of patients
did not receive a myelosuppressive chemo/and or radiotherapy. Of
note: “none” does not mean, that these patients did not receive
any anticancer treatment. Patients in this population did receive
corticosteroids, hormonal therapies, low dose chemotherapies and
radiotherapies and other substances. However, this information
is only available from the clinical study reports and the specific
treatment per patient is not available.
Baseline variables
Hb and Hct
Baseline Hb and Hct were defined as Hb or Hct measurement up
to 30 days before date of randomization or up to seven days after
randomization.
Baseline age
Baseline age refers to age at date of randomization calculated based
on the birth date provided per patient. For two studies (Thomas
2008; Machtay 2007) birth dates were not reported; age at ran-
domization or age at study entry was provided instead.
Other baseline variables
All other baseline values refer to the baseline as provided by the
investigators.
Terminology
Subgroup” and “subset” analyses
Any analyses that relate to information on the individual patient
level are termed “subgroup analyses”. Any analyses that relate to
information at study level are termed “subset analyses”.
“Missing” and “not reported” data
“Missing” means that the data were not provided in the requested
standardized data format for this analysis, however, the data might
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be on file at the investigators´ site. “Not reported” means that the
data are not on file at the investigators’ site.
Study numbers
A five digit study number was assigned randomly to each trial.
A complete list of corresponding study numbers, study protocols
and publications is on file and is not provided in this report.
Search methods for identification of studies
For the first and the updated version of this review (01/1985
to 12/2001 and 1/2002 to 04/2005) we identified relevant tri-
als through electronic searches of the Cochrane Library, MED-
LINE and EMBASE. For the planned IPDmeta-analysis the same
databases were searched for 2005 until December 2007. The first
search was conducted inMarch 2007. The update search was con-
ducted in January 2008. In addition, we searched relevant trials
through searches of the conference proceedings of the American
Society of Clinical Oncology, American Society of Hematology
and European Society of Medical Oncology. Searches of confer-
ence proceedings were either done online, with CD-ROMs or by
handsearching. For the present IPDmeta-analysis we searched ab-
stracts in the conference proceedings reported above for the years
2005 to end of 2007.
Reference lists of identified guidelines, systematic reviews and clin-
ical trials were checked for additional information. Documents
posted for the ODAC hearings in 2004 and 2007 were evaluated,
documents posted for the ODAC hearing in March 2008 were
not evaluated. Data bases of ongoing studies were searched as well.
Previous searches of ongoing studies were updated to June 2007.
Any accidentally identified trials were evaluated as well. Lists of
identified studies were sent to the pharmaceutical companies who
manufacture ESAs. Companies were asked to review and complete
these lists. For a detailed description of the literature searches see
below.
Electronic searches
For the individual patient data (IPD) meta-analysis on the effects
of erythropoiesis-stimulating agents in cancer patients the results
of electronic database search from two previous published reviews
(Bohlius 2004; Bohlius 2006) which include the period 01/1985
to12/2001 and01/2002 to 9/2004 and an additional searchwhich
gives an update of published studies up to 12/2007 were used. A
total of potential relevant hits 5546 (includingduplicates caused by
an overlap of these three searches) identified from these literature
databases. For search strategies see Appendix 1.
Cochrane Review 2004
The first version of the Cochrane Review (Bohlius 2004) based
on a main search period from 01/1985 to 12/2001.
Following databases are used:
• Cochrane Central Register of Controlled Trials Register
(CENTRAL)
• MEDLINE (01/1985 to 12/2001)
• Cancer Lit (01/1985 to 12/2001)
• EMBASE (01/1985 to 12/2001)
• Medikat (01/1985 to 12/2001)
• Russmed Articles (01/1988 to 12/2001)
• SOMED (01/1985 to 12/2001)
• Toxline (01/1985 to 12/2001)
• BIOSIS Previews (01/1985 to 12/2001)
• LILACS (01/1986 to 12/2001)
The initial literature search in March 2002 retrieved 1,592 refer-
ences.
Update Cochrane Review 2006
For the first update of the Cochrane Review (Bohlius 2006)
the search strategy for epoetin alpha and beta was adapted from
the previous Cochrane search strategy and run from 2000 until
September 2004. In the case of darbepoetin alpha the search ran
from 1996, the year before phase I studies were initiated on it.
Searches ended in September 2004.
The following bibliographic databases were searched:
• Cochrane Central Register of Controlled Trials Register
(CENTRAL) (01/2002 to 9/2004)
• MEDLINE (01/2002 to 9/2004)
• EMBASE (01/2002 to 9/2004)
• Science Citation Index (01/2002 to 9/2004)
In addition, all PubMed was screened on a daily basis by one
reviewer (JB) until April 2005; all studies identified up to April
2005 were included in this review.
In addition to the initial literature search fromMarch 2002, which
retrieved 1,592 references, 1,859 references have been identified
and screened.
Literature search update for the IPD meta-analysis
For this IPD meta-analysis additional database searches were per-
formed for two periods.
The first search performed in March 2007 included all studies
published later than 2000 until February 2007 (date of Index in
database). The second search completed in January 2008 ensures
an update of the information about available publications up to
end of 2007.
The following bibliographic databases were searched:
• Cochrane Central Register of Controlled Trials Register
(CENTRAL 01/2000 to 01/2008)
• MEDLINE (01/2000 to 12/2007)
• EMBASE (01/2005 to 12/2007)
• Science Citation Index (01/2000 to 12/2007)
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This literature search retrieved 1,851 references for search con-
ducted in March 2007 and 244 for the update search up to end
of 2007 conducted in January 2008.
A total of 5546 hits (including duplicates caused by an overlap of
these three searches) were identified from the literature databases.
Out of the 5546 references identified 447 full text publications
were retrieved for assessment.
Studies identified by database search
Thirty-two studies included in the IPD meta-analysis were iden-
tified by the database search:
Aapro 2008; Abels 1993; Boogaerts 2003; Case 1993; Cazzola
1995; Chang 2005; Charu 2007; Dammacco 2001; Grote
2005; Hedenus 2003; Henke 2003; Henry 1995; Kotasek
2003; Leyland-Jones 2003; Littlewood 2001; Machtay 2007;
O’Shaugnessy 2005; Oberhoff 1998; Osterborg 1996; Osterborg
2002; Pirker 2008; Razzouk 2006; Savonije 2005; Smith 2008;
Strauss 2008; Ten Bokkel Huinink 1998; Thatcher 1999; Thomas
2008; Vansteenkiste 2002;Wilkinson 2006; Witzig 2005; Wright
2007.
The other publications are additional references to already in-
cluded or excluded studies (see ’Studies and references’ table).
Searching other resources
Conference proceedings
For the first and the updated version of of the previously published
Cochrane review (Bohlius 2006) we identified relevant studies
through searches of the conference proceedings of the American
Society of Clinical Oncology, American Society of Hematology
and European Society of Medical Oncology (01/1985 to 12/2001
and 1/2002 to 04/2005). Searches of conference proceedings were
either done online, with CD-ROMs or by handsearching.
For the IPDmeta-analysis, we have searched the same conferences
for the years 2005 to end of June 2007. The search was updated
during the project in January 2008, extending the search to end
of December 2007.
Handsearching was performed for the conference proceedings:
• European Hematology Association (2001 to 2007)
• American Society of Clinical Oncology (1989 to 1996)
• European Society of Medical Oncology (1989 to 2008)
• American Society of Hematology (1989 to 1997)
Electronic searching of the conference proceedings:
• Annual Meeting of the American Society of Clinical
Oncology (1997 to 2008)
• Annual Meeting of the American Society of Hematol-
ogy (1998 to 2008)
Out of 96 potential relevant abstracts from RCTs 21 studies ful-
fill the inclusion criteria of the IPD meta-analysis were published
until December 2007 and were identified by systematic screening
of conference proceedings (ASCO, ASH, EHA and ESMO). The
other abstract publications are additional references to already in-
cluded or excluded studies (see ’Studies and references’ section).
Thirteen studies are published as abstract only and eligible for the
IPD meta-analysis:
Gordon 2006; Goss 2005; Huddart 2002; Kotasek 2002;Moebus
2007; Pronzato 2002, Quirt 1996; Ray-Coquard 2006; Rose
1994; Taylor 2005; Thomas 2008; Untch 2008; Vadhan-Raj
2004.
Reference lists
The reference lists from following evidence based guidelines, sys-
tematic reviews and HTA reports were checked to identify poten-
tial relevant clinical studies:
Guidelines
ASCO / ASH 2007: Rizzo 2008
FNLCC 2007: Fédération nationale des centres de lutte con-
tre le cancer. Recommandations pour la pratique clinique: Stan-
dards, Options et Recommandations 2007 pour l’indication de
l’agent stimulant l’érythropoïèse (ASE: époétine alpha, époétine
bêta et darbepoétine) dans la prise en charge de l’anémie en
cancérologie (Available: http:/ / www.fnclcc.fr/ sor/ structure/
index- sorspecialistes.html)
HTA Reports
Seidenfeld 2006, Wilson 2007
Reviews
Bennett 2008
There was no additional relevant study identified.
ODAC documents
Documents posted for the ODAC hearings in 2004 and 2007
were evaluated. These documents include briefing document plus
additional power point presentation prepared bymedical reviewers
of the Food and Drug Administration (FDA) and the companies
Roche, Johnson&Johnson andAmgen. All of these documents are
publicly available through the FDA briefing document at ODAC
hearing 2004, briefing documents from FDA, Roche, Johnson &
Johnson and Amgen:
Slides: http:/ / www.fda.gov/ ohrms/ dockets/ ac/ 04/ slides/
4037s2.htm,
Briefing documents: http:/ / www.fda.gov/ ohrms/ dockets/ ac/
04/ briefing/ 4037b2.htm
(Last time URL checked: 27 March 2009)
ODAC hearing 2007, briefing documents from FDA, Johnson &
Johnson and Amgen
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Slides: http:/ / www.fda.gov/ ohrms/ dockets/ ac/ 07/ slides/
2007- 4301s2- 00- index.htm
Briefing documents: http:/ / www.fda.gov/ ohrms/ dockets/
ac/ 07/ briefing/ 2007- 4301b2- 00- index.htm (last time URL
checked: 27 March 2009)
Following nine eligible studies primarily identified by screening
of the FDA web sites:
EPO-GBR-7; EPO-CAN-15 (Goss 2005) ; EPO-CAN-20 (
Wright 2007); GOG-191 (Thomas 2008); EPO-INT-1; EPO-
INT-3; N93 004 (Grote 2005); CC2574-P-174; EPO-GER-22 (
Debus 2006).
Five of them are published in meantime and also identified by
systematic search of databases and abstracts:
• (EPO-CAN-15, 2004) (Goss 2005)
• (EPO-CAN-20, 2004) (Wright 2007)
• (EPO-GER-22, 2007) (Debus 2006)
• (GOG-191, 2004) (Thomas 2008)
• (N93 004, 2004) (Grote 2005)
Register of ongoing studies
Further potential relevant studies and ongoing trials identi-
fied by using the metaRegister of Controlled Trials (mRCT)
http://www.controlled-trials.com/- which include information of
eight active registers. The last search was done June 30 2008 to al-
low an current status of the identified studies.The electronic search
using the terms (epo* OR darb* OR erythrop* OR aranesp OR
nesp* results in 671 hits, 95 of them are studies investigate ESAs in
cancer patients. Forty-five studies fulfill the inclusion criteria for
the IPDmeta-analysis and 50 studies investigate ESA in cancer do
not fulfill the inclusion criteria (intervention / control or disease).
Out of the 45 studies which are potential eligible 22 can be as-
signed to at least one publication and 15 studies can not associated
to any publication, 3 of 15 are stated as terminated. Further eight
studies are declared as ongoing. For two trials interim results were
published in local conferences (Debus 2006; Pronzato 2002).
Accidentally identified studies
Accidentally identified studies were evaluated as well.
Press release
One study (Untch 2008)was identifiedwith a press release (Amgen
2007)
Contact with companies
Lists of identified completed and ongoing studies were sent to
the pharmaceutical companies who manufacture ESAs. The three
responsible companies Amgen, Hoffmann-LaRoche, Johnson &
Johnson were asked to review and complete these lists:
• One additional reference (Milroy 2003) was identified
in a list of trials conducted by the companies.
• Two previously not identified studies were also identi-
fied: (EPO-GER-20; OBE/EPO-INT-03)
Contact to authors
All authors of published RCTs were contacted to clarify the po-
tential eligibility for the IPD meta-analysis (esp. the criterion on
number of patients planned to be randomized).
Studies included in the IPD meta-analysis
Out of the different searches a total of 53 studies can be included
in the meta-analysis of the effects of erythropoiesis-stimulating
agents in cancer patients based on individual patient data.
Individual patient data are available and used from following 53
studies:
(EPO-GBR-7; EPO-INT-1; EPO-INT-3;CC2574-P-174; EPO-
GER-20; OBE/EPO-INT-03; Aapro 2008; Abels 1993;
Boogaerts 2003; Case 1993; Cazzola 1995; Chang 2005; Charu
2007; Dammacco 2001; Debus 2006; Gordon 2006; Goss
2005; Grote 2005; Hedenus 2003; Henke 2003; Henry 1995;
Huddart 2002; Kotasek 2002; Kotasek 2003; Leyland-Jones 2003;
Littlewood 2001; Machtay 2007; Milroy 2003; Moebus 2007;
O’Shaugnessy 2005; Oberhoff 1998; Osterborg 1996; Osterborg
2002; Pirker 2008; Pronzato 2002; Quirt 1996; Ray-Coquard
2006; Razzouk 2006; Rose 1994; Savonije 2005; Smith 2008;
Strauss 2008; Taylor 2005; Ten Bokkel Huinink 1998; Thatcher
1999; Thomas 2008; Thomas 2002; Untch 2008; Vadhan-Raj
2004; Vansteenkiste 2002;Wilkinson 2006; Witzig 2005; Wright
2007)
Data collection and analysis
Selection of studies
Trials identified through the update literature searches were
screened independently by two reviewers (JB, OW) for the eligi-
bility criteria stated previously. If eligibility could not be assessed
satisfactorily from the title and abstract, a full text version was ob-
tained for assessment. Studies that appeared to meet the inclusion
criteria in the initial screening were further assessed for eligibility
with the following questions:
Q1. Is the study described as randomized?
Q2. Did the participants in the study have a previously treated or
untreated malignant disease?
Q3.Was one group givenEpoetin-alfa or Epoetin-beta or Epoetin-
delta or Darbepoetin-alfa or any other erythropoiesis-stimulating
agent subcutaneously or intravenously?
Q4. Did the control group receive the same care (e.g. chemother-
apy and supportive therapies) with or without placebo? Exception:
iron, see Types of studies.
Q5. Did the study document any of the following outcomes: over-
all survival or thromboembolic / cardiovascular events or tumor
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progression or a similar endpoint or QoL measured with a vali-
dated instrument?
Q6.Did the study plan to include at least 50 patients per treatment
arm or at least 100 patients in total?
Q7. Is the study completed by its own study protocol definition or
has the study been terminated prematurely? For ongoing studies: is
patient recruitment terminated andhas a validated interim analysis
been done? (see ’Criteria for considering studies for this review’)
To be eligible, studies had to meet all of the criteria stated above.
If there was insufficient information to judge eligibility, the first
author of the report was contacted for clarification.
Studies excluded from the previous Cochrane Reviews were re-
assessed, because the eligibility criteria for the present IPD meta-
analysis were not identical to those of the Cochrane Review. For
example, studies with iron supplementation in one study arm only
had been excluded from the previous Cochrane Reviews. Eligibil-
ity of these studies had to be reassessed for the present analysis. To
assess Q6 (Did the study plan to include at least 50 patients per
treatment arm or at least 100 patients in total?) we contacted the
sponsoring companies and independent investigators of studies
that had evaluated less than 100 patients to clarify whether they
had intended to include more than 100 patients. Lists of eligible
studies were sent to the companies/investigators for confirmation
of study eligibility. Studies evaluating less than 50 patients were
excluded from the analysis. This criterion was discussed with the
Steering Committee in January 2008 but had not been included
in the final version of the protocol. If the two reviewers (JB, OW)
could not reach consensus the principal investigator (AE) and the
Steering Committee were involved. Any disagreements between
the reviewers regarding eligibility were resolved by discussion.
Data extraction and management
Materials
The following documents were requested for each of the included
studies
• Study protocol
• Clinical study report
• Case report form including Quality of Life instruments
used
• Publications
• Individual patient data
Data sets had to include the individual patient data as defined for
this project of all patients initially randomized.
Data Extraction and Compilation
Data submitted by the sponsors/investigators
Information were collected both at the level of the trial and at
the patient level. The following study level characteristics were
requested from the sponsors/independent investigators:
Study level information
Components of methodological quality, source of funding, com-
pletion of study, planned follow-up duration, duration of study,
ESAs (type, dose, frequency and route of administration, crite-
ria for stopping study drug), Hb/ hematocrit (Hct) target, policy
regarding iron supplementation, planned and administered anti-
cancer treatment.
Individual patient level information
Age, sex, type of tumor, type of antineoplastic therapy received
(chemotherapy during ESA study yes/no/not reported, radiother-
apy during ESA study yes/no/not reported), ESA dose received,
red blood cell transfusions received, Hb and Hct values at baseline
and during follow-up, date of death or date last time seen alive.
Based on these information additional variables were derived. A
detailed list of variables including the coding scheme for each
variable is on file.
Data extraction from available study documents
The investigators of the studies provided protocols, clinical study
reports and case report forms for the included studies. For infor-
mation at study level that was not provided by the investigators
two reviewers (JB, SK) independently extracted the information
from study protocols, clinical study reports, case report forms and
publications if necessary. Data extractions were compared and in-
consistencies discussed until consensus was reached. If necessary,
the sponsor or independent investigator submitting the data was
contacted for clarification.
The following study characteristics were extracted:
• Was the study designed for long-term follow-up (de-
fined as follow-up of at least 12 months after end of
study phase)?
• Did the study have a prespecified cancer treatment pro-
tocol?
• Treatment category: chemotherapy, combinedmodality
treatment, radiotherapy, radiochemotherapy, none or
mixed.
• “cross-over”, i.e. whether patients in the control group
were allowed to receive ESAs after a specified study pe-
riod.
Data extraction not in duplicate
Data that were used for descriptive purposes in tables only and
that were not used in any of the statistical analysis were extracted
by one person only (JB).
Coding of the variable “metastatic disease”
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For the present analysis we had requested two variables to describe
the disease stage of the patients, i.e. whether the patient had exten-
sive disease ormetastatic disease or neither extensive normetastatic
disease. This simplified scheme did not work for the majority of
trials and cancer types included and as a result for about 80% of
patients we had no structured information on disease stage as re-
quested. In addition, we had requested a free text entry describing
the disease stage for each individual patient. Based on the free text
entries and the available clinical study reports, for each patient the
information “metastatic solid cancer or advanced hematological
malignancies” yes versus no or not reported/unclear was assigned.
The assignment was done by one reviewer (JB). The assigned cat-
egories were checked for consistency across trials in conjunction
with the clinical study reports (JB).
The general coding rules were as follows:
Patients with solid cancers and metastatic disease or stage IV were
coded as “metastatic”, all other patients were categorized as “non
metastatic”. Patients with hematological malignancies in Ann Ar-
bor stage III or IV were categorized as “advanced”; all other pa-
tients were categorized as “not advanced”. For patients with small
cell lung cancer we differentiated “extensive disease” versus ”lim-
ited disease”. If for a given study no information was available at
patient level, but the clinical study report stated that for example
all patients included in the study had metastatic disease, each pa-
tient of that particular study was coded as “metastatic”.
This procedure included several limitations; the main limitation is
the inconsistency of tumor coding between trials. For some studies
we received only the data entry “metastatic” and “non-metastatic”
without specification of the TNM stages. In this case “metastatic”
was classified “metastatic” for the coding system for the present
analysis and “non-metastatic” was classified “other than metastatic
for solid cancers”. For hematological malignancies “metastatic”
was classified “advanced stage” and “non-metastatic” was classified
“not advanced”. For other studies we received only TNM stages,
e.g. stage I, II, III, or IV. However, not in all tumor types stage
“IV” and “metastatic” are identical, i.e. only patients in stage IVB
are metastatic whereas patients in stage IVA are not. Only for few
cancer entities this problem does not exist, e.g. in breast cancer all
patients with stage IV are metastatic. This inconsistency between
the coding in the different studies is a limitation of the current data
set. However, the variables “metastatic” versus “non metastatic”
serves as a proxy to see whether baseline imbalances or interaction
between disease stage and study drug with effect on the outcome
mortality exist.
Data management
Data were entered in a dedicated database. The format of the data
requested is on file. Data were checked for accuracy, consistency,
and completeness of follow-up (Stewart 1995). We used descrip-
tive statistics to describe baseline characteristics of patients in each
trial and to identify outliers. Accepted ranges for continuous vari-
ables were defined in advance. All data identified as missing, im-
plausible or inconsistent were listed and sent to the investigators
or company providing the data for the respective trial for clarifi-
cation where possible. Overall survival and on study mortality of
the different treatment groups in each trial were derived using the
Kaplan-Meier method and standard Cox regression analysis and
comparedwith published survival estimates. Any discrepancies be-
tween published data and provided individual patient data was re-
ported to and discussed with the original investigator or company
providing the data. A detailed report of the data management is
provided on file.
Monitoring
The following step described in the protocol was considered not
feasible and has not been done:
“To assess the quality of the codingwewill review investigator com-
ments and investigator texts as reported in the case report forms of
approximately 200 patients experiencing thromboembolic events,
200 patients not experiencing thromboembolic events, and 200
patients who died. Once absolute numbers of thromboembolic
events and deaths are available percentages of events to be reviewed
will be calculated. Patients will be selected by random stratified
by company. Which discrepancy rate will be accepted and which
measures will be taken if the discrepancy rates is exceeded requires
further discussion. In general, error rates during the process of
data collection and data entry tend to be low. For example, error
rates during data collection were estimated to be between 0.5%
to 1.0% (Eisenstein 2005). In randomized controlled trials with
blinding of study participants and study personnel, errors during
data collection and data entry will be distributed randomly be-
tween groups and are unlikely to affect point estimates of differ-
ence between comparison groups. Computer simulations of anal-
yses of moderate to large randomized controlled trials with real-
time validation checks during data entry have found that error
rates up to 10% had little effect (Mcentegart 1999). If and to
which extend data submitted not by sponsoring companies but by
independent investigators are monitored requires further discus-
sion with the independent investigators.“
Assessment of risk of bias in included studies
The quality of the study data was assessed in the context of the
individual patient data, study protocols, clinical study reports and
available publications. For assessment of study quality and patient
data level. Since all analyses were performed based on the inten-
tion-to-treat principle (analyzed in the allocated treatment arm);
intention-to-treat was not assessed as a quality parameter.
The following quality components, which are part of the CON-
SORT statement, were assessed based on available study protocols,
clinical study reports, publications or individual patient data:
1. Was treatment allocation sequence randomized? (as-
sessed with study documents in duplicate, JB, SK)
2. Was treatment allocation concealed? (assessed with
study documents in duplicate, JB, SK)
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3. Were clinicians / care givers blinded (masked) to the
allocated treatment? (assessed with study documents in
duplicate, JB, SK)
4. Were patients blinded (masked) to the allocated treat-
ment? (assessed with study documents in duplicate, JB,
SK)
5. Were outcome assessors blinded (masked) to the allo-
cated treatment? (assessed with study documents in du-
plicate, JB, SK)
6. What proportion of patients was excluded from the
analysis and what was the ratio of exclusions between
arms? This criterion has to be assessed for each endpoint
separately (assessed with IPD data set)
7. Were the number and reason of patient withdrawals,
dropouts and losses to follow-up in each group docu-
mented? (assessed with study documents, JB)
The quality assessment for the parameter 1 to 5 and 7 outlined
above refer to the quality of the studies as reported in the available
documents. These parameters therefore primarily reflect the re-
porting of these variables in the available documents. Datawere ex-
tracted in duplicate and compared. Inconsistencies were discussed
until consensus was reached. For any parameter that was “unclear”
after assessment we did not contact the sponsors/investigators for
clarification. Because of time constraints we did not send question-
naires concerning the study design to the investigators to collect
additional information as had been stated in the protocol. Specific
coding rules used to assess the outlined study quality parameter
are on file.
Measures of treatment effect
Organizational issues
Data management including data cleaning processes and deriva-
tion of new variables was done at the University of Cologne (CB).
Main outcome variables (on study mortality and overall survival)
were independently re-coded in duplicate at the Institute of Social
and Preventive Medicine (ISPM) in Bern (KS). Main statistical
analyses were done independently at the ISPM at the University of
Bern (KS), Switzerland and the Institute of Medical Biometry and
Medical Informatics (IMBI) at the University of Freiburg, Ger-
many (GS). Any discrepancies were resolved in discussion during
two meetings at the ISPM in Bern.
Results tables and graphswere provided tomembers of the Steering
Committee and theAdvisoryBoard anddiscussed duringmeetings
or telephone conferences.
It was prespecified in the protocol to provide the following mini-
mum set of tables and graphs (additional tables and graphs might
be provided):
1. Baseline table: summary of each included trial for the
variables (continuous variables are presented as means
and medians with accompanying standard deviations;
dichotomous variables are presented as proportions)
(note: on file, not provided in this review).
2. Kaplan-Meier curves: standard Kaplan-Meier curves for
each time-to-event outcomeplus the number of patients
under observation at specified time points for each trial
(note: on file, not provided in this report). Reverse Ka-
plan-Meier curves: to assess time to censoring for each
trial (note: on file, not provided in this review).
3. Event tables: for each time-to-event outcome a listing of
the number of events, the number of patients included
in the analysis, the patient-years of follow-up, and the
mean observation time all separately for each trial (note:
on file, not provided in this report).
4. Analyses tables: for each regression analysis a listing of
hazard ratios of coefficients and interaction terms, ac-
companying 95% confidence intervals (derived from
Wald test P values), and relevant P values from likeli-
hood ratio tests (separately for each step of the respec-
tive analysis)
5. Forest plots: standard forests plots for each outcome
separately
6. Funnel plots: standard funnel plots for each outcome
separately
Dealing with missing data
Analysis set, missing data and losses to follow-up
• All analyses were performed based on the intention-
to-treat principle: analyses included all randomized pa-
tients and patients were analyzed in the group they were
allocated to, regardless of the treatment received or other
protocol violations.
• In patients lost to follow up, time was censored at the
date of last official study visit according to the respective
study protocol.
• For patients censored on day one of randomization, 0.1
days was utilized as censoring time for technical reasons.
On study mortality
In the protocol we had defined on study mortality as time from
randomization until 28 days after last planned ESA/placebo dose.
In the statistical analysis plan we had specified two different meth-
ods for the generation of on study mortality:
• Administrative censoring: each patient will be censored
at a preplanned point in time, i.e. planned duration of
ESA study plus 28 days follow-up.
• Informative censoring: each patient will be censored at
the last study visit during study period plus 28 days
follow-up.
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Ad 1: due to the complexity of the ESA studies this was not feasi-
ble. One difficulty was the different study designs of the ESA stud-
ies included. In about 32 studies there was a prespecified duration
of ESA treatment. In 20 studies the duration of ESA administra-
tion was dependent on the duration of chemotherapy, i.e. ESA
was given during the duration of chemotherapy. The duration of
chemotherapy itself was variable, i.e. it was recommended to give
additional 4 to 6 cycles of chemotherapy with a cycle length of 21
to 28 days. Therefore, it was not possible to set an administrative
point of censoring based on the study information. In turn, using
the duration of chemotherapy of the individual patient depends
on the clinical course of the patient and can therefore not be re-
garded as “administrative”.
Ad 2: in the present study we analyzed the study data for on study
mortality as provided by the companies and investigators, i.e. for
each patient the companies and independent investigators had
submitted a date of “end of study”, (variable ENDSTUDDT_ in
DISPOSIT table of data set), i.e. the last official study visit of the
patient during active ESA study phase. In some of the studies, this
“end of study date” included already a follow-up of 28 days, in
other studies the date provided reflected the last visit and 28 days
of follow had to be added. (Details of the programming of “on
study mortality” on file, not provided in this review.)
Complete-case analyses
Main analyses were conducted based on complete-case analyses
i.e. on patients with all data available for the relevant analysis.
However, in the data sets received data were often not missing
scattered across trials. In contrast, there were several trials which
did not report specific variables for the entire study population.
In the protocol we had stated the following: “The imputation
of missing data (independent variables and continuous efficacy
outcomes) using multiple imputation methods will be explored
for sensitivity analyses.” Given the unbalanced pattern of missing
data across studies we preferred not to impute any data.
Assessment of heterogeneity
Between-trial heterogeneity was visually examined in forest plots
and assessed by calculating the I2 statistic, which describes the per-
centage of total variation across studies that is due to heterogeneity
rather than chance (Higgins 2002; Whitehead 2002). Standard
tests of heterogeneity were also done. We examined small study
effects in funnel plots of log hazard ratios or effect sizes against
their standard error.
Assessment of reporting biases
Asymmetry of the funnel plot was assessed by the asymmetry co-
efficient (the difference in log hazard ratio or effect size per unit
increase in standard error) (Sterne 2001) and tests for small study
biases (Sterne 2001; Egger 2001; Egger 1997).
Data synthesis
Overview of statistical approaches
All analyses took into account the original randomization in each
trial: no comparisons of patients from one trial with patients from
another trial were made. Stratified Cox analyses were conducted
in fixed-effects models. All other meta-analyses were conduced in
both fixed- and random-effect models. The fixed-effect analysis
was considered the primary analysis; the random-effects analysis
was used to examine the robustness of the results.
We used pre-specified and exploratory variables; all variables were
prespecified in the protocol for this analysis. The ‘main set’ of
variables include variables that were defined for subset analyses
in our first Cochrane Protocol in 2002 (Langensiepen 2002). We
consider these variables to be truly pre-specified because they were
documented before the first trials with detrimental effects on sur-
vival were published. All variables that were proposed later are in-
fluenced by the observations made when detrimental study results
became available. These variables were considered as ‘exploratory’,
see Appendix 2.
Twodifferent approaches for individual patient datameta-analyses
can be distinguished (Simmonds 2005). In the two-stage method
the available IPD are analyzed separately for each trial and then
combined using standard meta-analysis. The method is relatively
simple to apply in practice and well suited to assess between trial
heterogeneity caused by study level characteristics. It is, however,
less suitable to identify prognostic factors and interactions of pa-
tient level characteristics. A meta-analysis of IPD can also be seen
as a multilevel model, with essentially two levels, the first level be-
ing the patients and the second level being the studies. This frame-
work therefore allows estimating effects of interest in relation to
both study-level covariates and patient-level covariatess.
Analysis to address objective 1: effects of ESAs
Meta-analyses were based on a Cox regression analysis stratified by
trial with treatment as the only factor in the model. This approach
is a fixed-effect model which allows for different baseline hazard
functions in each trial (Smith 2007). Log rank estimates were cal-
culated for each study and meta-analyzed based on the fixed and
the random-effects models. We also calculated (log)-hazard ratios
for each trial separately using standard Cox regression analysis,
which were then combined using fixed-effects and the DerSimo-
nian-Laird random-effects model (DerSimonian 1986). The as-
sumption of proportional hazards was examined on the basis of
Schoenfeld residuals and graphically using log-log plots for each
trial included.
Baseline imbalances
We assessed whether baseline imbalances could explain any effects
seen on time-to-event outcomes. Bivariate Cox regression analysis
stratified by trial was used. The variables that were considered as
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independent variables besides treatment are listed in Appendix 2.
All variables with a corresponding P value of less then 0.10 were
included in a multivariate Cox regression analysis stratified by
trial. The following procedure was stated in the protocol: “Model
selection was based on a standard stepwise selection procedure
with 5% inclusion/exclusion criteria based on the likelihood ratio
test.” Since we had many missing data and the missing data were
not distributed evenly across trials (data were often missing for
entire studies), the selection for variables was based on P value of
the Likelihood Ratio (LR) test as stated above and number of cases
reported per variable. We also planned to explore the possibility to
implement a Cox regression model stratified by trial with random
treatment effects (Smith 2005). However, since the heterogeneity
between trials was low and the results of the log-rank based meta-
analyses for both fixed and random-effects models were model
identical, this was not considered a priority.
Methodological characteristics of trials
The following method was stated in the protocol: “Univariable
fixed-effect meta-regression based on the (log)-hazard ratios of
effect sizes of individual trials were used to examine whether
treatment effects vary by trial level characteristics. The variables
that will be considered as independent variables are listed in the
Appendix 2. All variables with a corresponding P value of less than
0.10 will be included in a multivariate fixed-effect meta-regression
analysis. For the survival analysis only variables 1 to 3 and 5 to 8
outlined in Appendix 2 will be included in the model. Random-
effects meta-regression will be used to explore the robustness of
the results.” Instead the study level parameters were assessed in the
Cox model by using interaction terms. Meta-regression analyses
were used for exploration of effect modifiers at study level (ex-
ploratory analysis).
Continuous independent variables
The following step was planned but considered to be not feasible:
“Non-linear effects of continuous variableswere examinedby com-
paring linear models with models with quadratic terms using the
Akaike InformationCriterion (Akaike 1974). Alternativemethods
of analyzing continuous variables will be explored (Boucher 1998;
Royston 1999).” The following procedure was done: continuous
variables were included in the multivariate models based on cate-
gories that had been outlined in the protocol for this analysis.
Hematological response
Analysis of hematological response and other time dependent ex-
planatory variables was postponed.
Assessment of eligible studies not included in the present
analysis
To assess the impact of eligible studies with no available individual
patient data, these studies were included in the analyses based on
the aggregated results reported in the literature or provided by the
investigators, see ’Results’ section.
Numbers needed to treat
We calculated numbers needed to treat for one additional harmful
outcome (NNTH) (Altman 1999; Altman 1998).
Sample size considerations
The sample size was determined by the number and size of tri-
als for which individual patient data were available as well as the
event rates in these trials. We had previously updated the litera-
ture based Cochrane Review (including studies up to end of June
2007) and identified 53 studies including 12353 patients that did
fulfill the eligibility criteria outlined above. These studies reported
approximately 4400 deaths from all causes. These numbers were
preliminary estimates. Based on these estimates we assumed that
the combined data set was to provide sufficient statistical power
to detect clinically relevant adverse effects of ESA treatment, al-
though power was expected to be insufficient to exclude small ef-
fects. Also, power was expected to be more limited for analyses of
interactions. For number of studies, patients and events reported
in the present analysis see ’Results’ section.
Limitations
Multiple testing
This is an exploratory study and several hypotheses tests were
performed. No adjustments for multiple testing were made and
no higher confidence levels for confidence intervals were applied.
The multiplicity of analyses, however, has to be considered when
interpreting the result.
Comparison of different drug formulations
No separate analysis by ESAs (epoetin alpha, epoetin beta and
darbepoetin alpha) nor any comparisons between the different
ESAs was made upon specific request of the companies providing
data for this study.
Organizational structure
All study centers that conducted ESA studies were invited to join
the collaborative group and submit their individual patient data.
Datawere held securely and treated confidentially. Analyses, results
and their interpretation were discussed with the collaborators.
Secretariat
The secretariat for this project was located at the Editorial Base of
the Cochrane Haematological Malignancies Group in Cologne,
Germany. The secretariat coordinated the project.
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Statistical Analyses and Data Management
All data were anonymized and sent encrypted to the data center at
the University of Cologne. Statistical analyses were done indepen-
dently at the Institute of Social and Preventive Medicine (ISPM)
at the University of Bern, Switzerland and the Institute of Medical
Biometry and Medical Informatics (IMBI) at the University of
Freiburg, Germany.
Steering Committee
The steering committee for this project consists of an interna-
tional group of experts for hematology, oncology, radiotherapy,
clinical epidemiology/biostatistics and a consumer representative.
The steering committee gave advice on strategic issues and anal-
yses. Final decisions concerning inclusion and exclusion of stud-
ies, statistical analyses and interpretation of findings were made
by the Steering Committee. The tasks of the Steering Committee
are documented in the Steering Committee Charter (on file, not
provided in this review).
Advisory Board
Trialists and pharmaceutical companies who provided data for
the analysis joined the Advisory Board. All data analyses were
presented to the Advisory Board. The Advisory Board could give
advice to the secretariat and the steering committee, but had no
decision-making authority. The tasks of the Advisory Board are
documented in the Advisory Board Charter (on file, not provided
in this review).
Protocol amendments
Protocol changes were avoided whenever possible. If nonetheless
changes became necessary they were documented in an amend-
ment. Any substantial change or addition to this protocol required
a written protocol amendment that had to be approved by the
Steering Committee and the Advisory Board. There was not sub-
stantial change to the protocol.
Subgroup analysis and investigation of heterogeneity
Analysis to address objective 2: analysis of effect
modification (treatment by covariate interaction)
The focus of this analysis was on first order multiplicative inter-
actions of independent variables with allocated treatment. The
variables that were considered as independent variables are listed
in Appendix 2. Bivariate Cox regression analyses with factor and
treatment allocation stratified by trial and including the respec-
tive factor-treatment interaction term (treatment by independent
variable) were used. Models with and without the respective in-
teraction term were compared using the likelihood ratio test. The
possibility to implement a model with multiple interaction terms
was reported in the protocol but not explored in the current analy-
sis. Methodological characteristics of the studies (e.g. concealment
of allocation, placebo controlled) were assessed using interaction
terms. In addition, the following exploratory analyses were done:
Meta-regression analyses were conducted for study level variables
with statistically significant effect modifications in the bivariate
analyses. Meta-regression was based on unadjusted and adjusted
hazard ratios of the individual studies. Differences for subgroups
generated with the meta-regression analyses were tested with the
Wald test.
Sensitivity analysis
Additional sensitivity analyses were performed to further check
the robustness of the results.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
A total of 5546 hits (including duplicates caused by an overlap
of the three data base searches outlined above) were identified
from the literature databases. Out of the 5546 references identified
447 full text publications were retrieved for assessment. Electronic
searches of ongoing studies data bases retrieved 575 hits.
Baseline characteristics overall
A total of 13933 patients were evaluated in the present analysis.
At randomization the median age was 60.6 years in the ESA and
59.8 years in the control group. Hb at baseline was on average
10.6 g/dL (IQR 9.6 to 12.1 g/dL) in the ES and 10.8 g/dL (IQR
9.6 to 12.5 g/dL) in the control group. 18.3% of patients in the
ESA and 15.9% of patients in the control group were diagnosed
with a hematological malignancy, whereas 76.6% of ESA patients
and 78.5% of control patients were diagnosed with a solid tumor.
30.9% of the entire patient population was diagnosed with breast
cancer and 22.1%with lung cancer, including SCLC andNSCLC.
63.1% of patients included in the current analysis were female.
For details of the patient population see Figure 1, Figure 2 and
Figure 3.
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Figure 1. Baseline characteristics, a)
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Figure 2. Baseline characteristics b)
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Figure 3. Baseline characteristics c)
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Included studies
Eligible studies
A total of 63 studies were eligible for inclusion into this anal-
ysis. For 10 of the 63 studies we could not retrieve individual
patient data for the present analysis (Blohmer 2003; Overgaard
2007; Bamias 2003; Watanabe 2006; Antonadou 2001; Janinis
2003; Iconomou 2003; Mystakidou 2005; Zajda 2007; Cascinu
1994). For six (Antonadou 2001; Mystakidou 2005; Cascinu
1994; Blohmer 2003; Overgaard 2007; Bamias 2003) of the ten
studies aggregated survival data were reported in the literature or
provided by the investigator and included in a sensitivity analy-
sis to assess the impact of the missing studies on overall survival.
In the other four studies survival data were not reported in the
literature (Watanabe 2006; Janinis 2003; Iconomou 2003; Zajda
2007).
Included studies
For a total of 53 eligible studies we retrieved individual patient
data, for list of included studies see ’Characteristics of studies’ ta-
ble. Fourty-eight studies were provided by one of the three compa-
nies Johnson & Johnson, Roche and Amgen. Three independent
investigators provided individual patient data by the means of the
company (Moebus 2007; Untch 2008, Machtay 2007). Two in-
dependent investigators provided the data in the requested format
directly to the collaborative group (Ray-Coquard 2006; Thomas
2008).
Included and excluded patients
We received the data sets for 56 studies including 14393 patients.
From the data set the following exclusions were made:
Total received: n=14393 patients, 56 studies
Exclusion of three studies including 187 patients, which did
not meet the inclusion criteria (MF4266, MF4252 (Rau 1998),
MF4253 (Kettelhack 1998).
n=14206 patients, 53 studies
Exclusion of patients without allocated study
arm
MF4467 (Osterborg 2002) (n=162)
MF4250 (Osterborg 1996) (n=1)
MF4421 (Boogaerts 2003) (n=1)
n=14042 patients, 53 studies
Exclusion of ineligible study stratum: study PR99-11-034/044 (
Razzouk 2006), children with acute lymphocytic leukemia, Non-
Hodgkin lymphoma (stratum 1, n=98), Hodgkin disease and solid
tumors (stratum 2), stratum 1 was excluded.
n=13944 patients, 53 studies
For studies where the date of randomization was missing for all
patients, the date of randomization was replaced with the date of
first study drug as provided by the company (variable FSTTXDT
from the data tableDISPOSIT): studyMF4421 (Boogaerts 2003).
For studies where only single patients had no date of randomiza-
tion the patients were excluded from the analysis.
EPO-INT-3 (n=1)
DE20010033 (Untch 2008) (n=4)
MF4313 (Cazzola 1995) (n=3)
N=13936 patients, 53 studies
If both date of randomization and date of first study drug were
missing in study MF4421 (Boogaerts 2003) (see above) these pa-
tients were excluded (n=3).
Total included: N=13933 patients, 53 studies
For identification of eligible trials see Figure 4.
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Figure 4. Identification of eligible trials
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Characteristics of included studies
Cancer entities
Both patients with hematological malignancies and solid cancers
were included in the evaluated studies. Some studieswere restricted
to single disease entities whereas other studies included various
tumor types. Some studies were restricted to patients with identical
stages of disease, whereas others included both early and advanced
stages.
In detail, the following cancers were explored:
Breast cancer
Seven studies evaluated patients with breast cancer only. Of
these, two studies included only patients with metastatic disease (
Aapro 2008; Leyland-Jones 2003). Two studies included only pa-
tients with non-metastatic disease (Moebus 2007; Untch 2008).
Three studies included patients with stages I to IV (Chang 2005;
O’Shaugnessy 2005; Pronzato 2002).
Lung cancer
Nine studies evaluated patients with lung cancer only. Of these,
five studies included patients with small cell lung cancer (SCLC)
only. Goss 2005 included patients with limited disease SCLC.
Pirker 2008 and EPO-GER-20 included patients with exten-
sive disease SCLC. Grote 2005 included both patients with lim-
ited and extensive SCLC. Thatcher 1999 included SCLC with-
out providing details on disease stage. Three studies included
patients with non-small cell lung cancer (NSCLC) only. Debus
2006 included NSCLC patients with inoperable stage III, Wright
2007 and Milroy 2003 included advanced stage NSCLC patients.
Vansteenkiste 2002 included patients with limited and advanced
stage SCLC and NSCLC.
Head and neck cancer
Three studies included patients with head and neck cancer only,
including stages I-IV (EPO-GBR-7) stages III and IV (Henke
2003) or nonmetastatic stages I-IV only (Machtay 2007). Patients
in these studies received radiotherapy.
Cervical cancer
Two studies included patients with cervical cancer only, both stud-
ies were restricted to patients in stages IIB to IVA (Thomas 2008;
Strauss 2008). Patients in these studies received radiochemother-
apy.
Ovarian cancer
Three studies included patients with ovarian cancer only, of these,
two studies included patients with stages I-IV (EPO-INT-1;
Wilkinson 2006). The third study included patients in stage II-
IV (Ten Bokkel Huinink 1998).
Gastric or rectal cancer
One study was restricted to patients with gastric and rectal
cancer (stages I-III) (Vadhan-Raj 2004). Patients received ra-
diochemotherapy.
Multiple myeloma
Two studies were restricted to patients with multiple myeloma (
Dammacco 2001; OBE/EPO-INT-03).
Chronic lymphocytic leukemia
Two studies included chronic lymphocytic leukemia (CLL) pa-
tients only (CC2574-P-174; Rose 1994). Patients received che-
motherapy or corticosteroids only
Mixed cancer populations
The other 24 studies included mixed cancer populations.
• Various hematological malignancies
Four studies were restricted to patients with different hemato-
logical malignancies (Hedenus 2003; Osterborg 1996; Osterborg
2002; Cazzola 1995).
• Various solid tumors
Fixe studies were restricted to patients with different solid tumors
(Kotasek 2003; Kotasek 2002; Oberhoff 1998; Savonije 2005;
Huddart 2002)
• Both solid tumors and hematological malignancies
Fifteen studies included patients with a wide range of different
tumor entities, including both patients with solid cancer and
hematological malignancies (Charu 2007; Ray-Coquard 2006;
Littlewood 2001; EPO-INT-3; Abels 1993; Henry 1995; Case
1993; Witzig 2005; Razzouk 2006; Quirt 1996; Gordon 2006;
Taylor 2005; Smith 2008; Thomas 2002; Boogaerts 2003).
Cancer treatment
In thirty eight studies patients received chemotherapy during ESA
treatment. In two of these studies (Moebus 2007; Untch 2008)
the chemotherapywas followed by radiotherapy. However, in both
studies ESA was given only during the duration of chemotherapy
and the studies were therefore categorized in the chemotherapy
population. In two studies (CC2574-P-174; Rose 1994), both
studies included CLL patients only, 40% (information taken from
clinical study report (CSR) (CC2574-P-174) and 41% (informa-
tion taken fromCSR (Rose 1994)) of the patients received no che-
motherapy during ESA treatment. These studies were categorized
as “mixed”.
Note: the investigator of these two studies (CC2574-P-174; Rose
1994) had recommended to evaluate the studies in the “chemo-
therapy” population. However, based on our predefined criteria
that 70% of a study population had to receive a planned treatment
to be categorized within that treatment group we decided not to
include these two studies in the chemotherapy population.
In three of the included studies patients received radiotherapy
only, in all of these three studies only patients with head and
neck cancer were included (EPO-GBR-7; Henke 2003; Machtay
2007). In another five studies patients were receiving a combined
chemo radiotherapy, defined as concomitant use of chemotherapy
and radiotherapy. These studies included patients with cervical
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cancer (Strauss 2008;Thomas 2008), SCLC (Goss 2005),NSCLC
(Debus 2006) and gastric and rectal cancers (Vadhan-Raj 2004),
none of these studies included patients with head and neck cancer.
In the study EPO-GER-22 (Debus 2006) chemotherapy was fol-
lowed by radiotherapy. However, since the planned interval be-
tween chemotherapy and radiotherapy was short it was decided to
classify this study as “radiochemotherapy” study. These five stud-
ies were evaluated together with the three radiotherapy studies in
the radio(chemo)therapy population. In sensitivity analyses we ex-
plored whether regrouping of these studies would influence the
results (see Appendix 3).
In five of the included studies patients did not receive concomi-
tant myelosuppressive chemotherapy and/or radiotherapy (Charu
2007; Smith 2008; Gordon 2006; Wright 2007; Abels 1993).
Apart from the two studies described above (Rose 1994; CC2574-
P-174) no other study was categorized as “mixed”, i.e. in no other
study less than 70% but more than 30% of the patients were
receiving either chemotherapy or radiotherapy or no anticancer
treatment.
Only seven of the 48 studies, where a myelosuppressive anticancer
treatment was given, had a prespecified chemotherapy or radio-
therapy protocol that targeted a homogenous cancer population
(Untch 2008; Witzig 2005; Debus 2006; Strauss 2008; Thomas
2008; Moebus 2007; Machtay 2007). For sensitivity analyses see
Appendix 3.
ESA dosages and schedules
The frequency of ESA application ranged from seven times per
week for the short lasting ESA preparations to once every four
weeks for the long lasting ESA preparations. Most often ESAs
were applied three times per week (26 studies) or once per week
(15 studies). In the ELYPSE 4 study (Ray-Coquard 2006) the
frequency was dependent on body weight of the patients, e.g. if
body weight < 45 kg patients received 2 x 10000 IU per week, if
body weight 45 to 89 kg 3 x 10000 IU per week and for patients
with body weight > 90 kg the dose was 4 x 10000 IU per week.
In the study 20010145 (Pirker 2008) the frequency changed over
time, i.e. 1 x 300 µg once per week sc weeks 1-4 then 300 µg three
times per week starting week 5 onwards.
In all but one study (Razzouk 2006) ESA was given subcuta-
neously. In the study by (Razzouk 2006) ESA was given intra-
venously.
In 19 studies ESAs were given in a fixed dose, i.e. independent
from body weight. In 27 studies the individual ESA dosage was
calculated based on the patient’s body weight. In six studies (
Ray-Coquard 2006; EPO-GBR-7;Milroy 2003;Wilkinson 2006;
Pronzato 2002; Thomas 2002) the dose was adjusted, i.e. there
were different fix dosages dependent on the weight or the age of
the patients. For example, in the study EPO-INT-50 (Thomas
2002) patients with body weight < 45 kg received 3 x 5000 IU per
week and patients with body weight > 45 kg received 3 x 10000
IU ESA per week. In the study MF4250 the ESA dose was titrated
(Osterborg 1996).
The planned weekly Epoetin (alpha or beta) dose ranged from
21000 IU up to 63000 IU. Studies were classified based on an
assumed average dose per study and not per patient. In detail:
for studies where patients were receiving weight based Epoetin
dosages the overall dose for the entire study was calculated based
on a assumed patient weight of 70 kg. For the present analysis the
doses were not calculated for the individual patient.
The planned weekly Darbepoetin dose ranged from 100 micro-
gram up to 157.5 microgram. For patients receiving weight based
Darbepoetin dosages the dose was calculated based on an assumed
patient weight of 70 kg for the entire study. For the present anal-
ysis the doses were not calculated for the individual patient.
In 19 studies patients were planned to receive on average less than
40000 IU Epoetin or less than 100 micro grams Darbepoetin
per week. In 12 studies patients were planned to receive 40000
IU Epoetin or 100 micro grams Darbepoetin per week. In eight
studies patients were planned to receive on average more than
40000 IU Epoetin or more than 100 microgramsDarbepoetin per
week. In 14 studies the planned ESA dosages depended on various
factors and we could therefore not calculate a single ESA dosage
per study.
The planned duration of ESA administration ranged from eight
weeks up to 52 weeks. In 20 studies the duration of ESA ad-
ministration was dependent on the duration of chemotherapy, i.e.
ESA was given during the duration of chemotherapy. In one study
Smith 2008 patients in the active study received ESA for 16 weeks
and could continue ESA treatment for additional 16 weeks after
the end of study period. Patients in the control group did not re-
ceive ESA. For the present analysis this study was categorized as
“ESA treatment longer than 17 weeks”.
Cross-over
In twelve studies patients in both the control arm and the ac-
tive arm were allowed to receive ESAs after a defined study pe-
riod (Charu 2007; Kotasek 2003; Kotasek 2002; CC2574-P-174;
Dammacco 2001; EPO-INT-3; Leyland-Jones 2003; Abels 1993;
Case 1993; Henry 1995; Rose 1994; Oberhoff 1998). Our aim
was to include only events and time under observation during this
defined treatment period in the analysis. Therefore, these studies
were evaluated for both the on study mortality and overall survival
analysis restricted to the active treatment phase during which con-
trol patients did not receive ESAs.
Cross-over studies were included in the analysis as follows:
Three studies provided by Amgen:
• Charu 2007, study 53081: last actual ESA dose plus
14 days (truncated before 1. drug injection during open
label phase, as provided by the investigator)
• Kotasek 2003, study 35466: last actual ESA dose days
plus 21 days (truncated before 1. drug injection during
open label phase, as provided by the investigator)
• Kotasek 2002, study 26117: last actual ESA dose days
plus 28 days (truncated before 1. drug injection during
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open label phase, as provided by the investigator)
Eight studies provided by Johnson& Johnson (studies Dammacco
2001, Leyland-Jones 2003, Case 1993, EPO-INT-3, CC2574-P-
174 , Henry 1995, Rose 1994, Abels 1993.
• All studies were truncated at termination visit plus 28
days in both arms
One study provided by Roche (Oberhoff 1998):
• The study was truncated as provided by the company;
i.e. for the control arm we received the data from the
controlled study phase only, in the ESA arm the follow-
up was apparently longer.
For the study EPO-INT-76 (Leyland-Jones 2003) it was discussed
whether there was a relevant “cross-over” after the end of the active
study phase since the study was stopped prematurely. However, in
the CSR it is reported that 641 patients continued in the open
label phase. Of those 413 did not receive ESA and 228 (placebo
134, ESA 94) patients were treated with ESA in the open label
phase. The median exposure to ESA in this population was 4.14
weeks (range 0.1; 50.1). The survival evaluation for the study
EPO-INT-76 was therefore restricted to the active study phase.
For a post hoc analysis percentages of patients receiving ESAs after
the controlled phase were recorded from either the clinical study
report or provided by the investigator and an exploratory survival
analysis was conducted, see Appendix 4.
Hb ceiling
Hb ceiling was defined as Hb value when ESA had to be stopped.
In none of the included studies the ceiling was 12 g/dL or below.
In six studies the ceilingwas 13 g/dL, in 20 studies 14 g/dL, in nine
studies 15 g/dL and in two studies the ceiling was 16 g/dL. In nine
studies the ceilings for men and women were different. In seven
of these studies the ceiling was 15 g/dL for men and 14 g/dL for
women, in two of the studies (EPO-INT-3, Machtay 2007) the
ceiling was 16 g/dL for men and 14 g/dL for women. Two studies
used different ceilings for different patients groups (MF4313 for
Multiple myeloma (MM) Hb 13 g/dL, for NHL Hb 15 g/dL)
(Cazzola 1995) or different age groups (PR99-11-034/044 for
children aged > 12 Hb >= 15 g/dL, for children aged < 12 Hb >=
14 g/dL) (Razzouk 2006). In four studies: J89-040 (Rose 1994),
CC2574-P-174, I88-036, 87-018, 87-019 (Henry 1995), I88-
037, 87-016, 87-017 (Case 1993) the ceiling was defined based
on hematocrit units: ceiling hematocrit 38% in the studies I88-
036, 87-018, 87-019 (Henry 1995), I88-037, 87-016, 87-017 (
Case 1993); in the studies J89-040 (Rose 1994) and CC2574-
P-174 there was no explicit hematocrit ceiling reported but the
Hct was to be maintained between 38% and 40%. Both studies
followed similar/identical study protocols. After discussion with
the investigator of these studies Hct 40% was used as ceiling for
these studies. To convert the Hct based ceilings into Hb based
ceilings the Hct values were multiplied with 0.34. In one study
the ceiling was not reported (Abels 1993).
For two studies the ceiling was changed during the study. For
EPO-GER-22 (Debus 2006) the initial Hb ceiling was 14 g/dL,
after 17.11.2003 the ceiling was 13 g/dL. For EPO-CAN-15 (
Goss 2005) the initial ceiling was 16 g/dL, after 1.12.2002 the
ceiling was 14 g/dL. For the present analysis we computed the
ceiling for each individual patient based on the ceiling that was
valid on the day the patient was randomized.
Since several studies had used different ceilings for different patient
populations, e.g. depending on sex, age and underlying disease, or
changed the ceiling over time, ceiling categories for the analyses
were constructed based on the patient level information.
Iron supplementation
In seven studies patients received a fixed iron supplementation. In
26 studies iron was given as needed following a specific protocol
and in 19 studies iron was given as needed by discretion of physi-
cian or institutional policy. In none of the studies it was explicitly
reported that iron should not be used. In one study (Grote 2005)
iron supplementation was coded as “other”. In this study it was re-
ported in the clinical study report howmany patients received oral
iron during study, but there was no statement if and how patients
and physicians were advised to use iron. For the present analysis
the study was evaluated in the category “iron given as needed by
discretion of physician or institutional policy”.
In seven studies iron was given only in the ESA arm (Machtay
2007; Untch 2008; Moebus 2007; Debus 2006; Savonije 2005)
or the policies for iron monitoring and supplementation were dif-
ferent in ESA and control arm (OBE/EPO-INT-03; EPO-GER-
20). In the Savonije et al 2005 (Savonije 2005) study ESA patients
had to receive iron mandatory by protocol, it is unclear from the
clinical study report whether patients in the control arm received
iron as well. In one unpublished study (OBE/EPO-INT-03) the
iron status in the ESA arm was to be monitored and if needed
supplemented. In the another unpublished study (EPO-GER-20)
patients in the ESA arm received iron fixed and patients in the
control arm received iron only if needed.
Excluded studies
see ’Characteristics of excluded studies’ table
Risk of bias in included studies
Allocation
Study level parameter
Randomization and concealment of allocation
Sixteen studies were judged independently by two reviewers (JB,
SK) to have reported an adequate randomization procedure, for
37 studies the method reported was judged to be unclear based
on the available documents, i.e. clinical study reports, study pro-
tocols and publications if available. Thirty-six studies were judged
to have reported adequate allocation concealment, for 17 stud-
ies the method reported was judged to be unclear based on the
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available documents. For ten of the 53 included studies both ran-
domization and concealment of allocation was judged to be ade-
quate. For another eleven studies both method of randomization
and concealment of allocation were judged to be unclear. For 26
studies themethod of allocation was judged to be adequate but the
method of randomization was unclear. For six studies the method
of randomization was judged to be adequate but the method of
allocation concealment was unclear.
Blinding
Placebo control
28 studies were placebo controlled and were reported to be “dou-
ble-blind”, 25 studies were open-label studies. The assessment of
the quality of the placebo control, i.e. whether patients, physicians
and outcome assessors were truly masked to the treatment, is not
included in the current report.
Follow up and exclusions
Drop outs
In all but four studies the numbers and reasons for with-
drawal/drop out were reported in the CSRs. Details for the four
studies not reporting drop outs: for three studies no clinical study
report of full text publication was available and therefore informa-
tion on number and reason for drop out was not available (Untch
2008; Quirt 1996; Thomas 2002). In the fourth study the num-
ber but not the reason for drop outs are reported in the statistical
report, a full CSR was not available (Gordon 2006).
Selective reporting
Publication
By June 26 2008, 32 of the included studies had been published
as full text, 15 had been published as abstracts only, four studies
(CC2574-P-174; EPO-GBR-7; EPO-INT-1; EPO-INT-3 had
been reported in the documents of the ODAC hearings in 2004,
2007 or 2008, two studies (EPO-GER-20 and OBE/EPO-INT-
03) were unpublished.
For details of the study characteristics see ’Characteristics of stud-
ies’ table.
Other potential sources of bias
Other design aspects
Study design (endpoint)
Five of the included studies evaluated overall survival as their pri-
mary endpoint (Pirker 2008; Aapro 2008; Leyland-Jones 2003;
Debus 2006; Untch 2008). Fifteen of the included studies evalu-
ated overall survival as secondary endpoint. In 29 studies survival
was assessed as safety or adverse event outcome. For two studies
it was not reported whether survival was assessed as an endpoint
or not (Dammacco 2001; O’Shaugnessy 2005). However, in both
studies deaths were reported in the safety analyses chapters of the
clinical study reports and the studies were therefore categorized as
“mortality assessed as adverse event only”. One study was catego-
rized as “other” (Smith 2008). In this study deaths were “reported
as AEs during the study period but they were also reported during
the long-term follow-up and these later deaths were not consid-
ered AEs since they occurred outside the AE reporting period”
(communication with investigator). This study was categorized as
“mortality assessed as adverse events only” in the analysis.
Long-term follow-up
Twenty four studies were planned for a long-term follow-up of at
least 12 months post active study phase. Twenty-nine studies did
not fulfill this definition. For two of these studies (Ray-Coquard
2006; Wright 2007) the investigator of the respective study had
indicated that the study conducted a long-term follow-up, since
the available study documents did not report that this follow-up
was planned, these studies were evaluated as “not designed for
long-term follow-up”. The effect of this potential misclassification
can be assessed in a sensitivity analysis.
Completed studies
Of the 53 included studies two studies (Moebus 2007; Untch
2008) were ongoing at the time of analysis. Fourteen of the in-
cluded studies were terminated or halted prematurely by its own
study protocol definition. Thirty-seven studies were completed by
their own study protocol definition.
Missing or not reported data
The amount of missing or not reported data for specific variables
is outlined below. The distribution of missing or not reported data
was generally not balanced across studies: several variables had not
been provided for entire studies. For example for several studies
we received no information on documented history of throm-
boembolic event, hypertension, diabetes mellitus or cardiovascu-
lar events, as well as no information of previous or current chemo-
therapy or radiotherapy. For few studies we had information of the
treatment status of the patient, i.e. untreated or in complete re-
sponse, partial response, stable disease etc, for 71% of the included
patients this information was missing. For about 80% of patients
we had no structured information on disease stage, i.e. whether
the patient had limited, advanced or metastatic disease. The in-
formation on stage at diagnosis was therefore generated based on
the free text entries per patient and the available study documents
(Table 1).
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Table 1. Missing or not reported data per variable, in order of percentage missing
Missing in
ESA arm
Missing in
control arm
Total included 7634 6299
Sex 0 0
Age 6 (0.1%) 6 (0.1%)
Tumor type* 17 (0.2%) 25 (0.4%)
Region (country) 231 (3.0%) 170 (2.7%)
Hb at baseline 252 (3.3%) 274 (4.3%)
Cancer stage at study entry (free text entry) 761 (10.0%) 732 (11.6%)
Derived variable stage
(metastatic/advanced versus not)
1036 (13.6%) 745 (11.8%)
Hct at baseline 1493 (19.6%) 1404 (22.3%)
Chemotherapy given during ESA study? 1501 (19.7%) 1252 (19.9%)
BMI baseline 1515 (19.8%) 973 (15.4%)
Documented history of cardiovascular
event
1932 (25.3%) 1679 (26.7%)
Chemotherapy given before ESA study? 1965 (25.7%) 1736 (27.6%)
Baseline ECOG performance status** 2035 (26.7%) 1786 (28.4%)
Radiotherapy given during ESA study? 2097 (27.5%) 1766 (28.0%)
Documented history of thromboembolic
events
2272 (29.8%) 2041(32.4%)
Documented history of hypertension 2272 (29.8%) 2041 (32.4%)
Radiotherapy given before esa study? 2529 (33.1%) 2216 (35.2%)
Documented history of diabetes mellitus 3335 (43.7%) 2573 (40.8%)
Baseline serum epo (mu/ml) 4371 (57.3%) 3911 (62.1%)
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Table 1. Missing or not reported data per variable, in order of percentage missing (Continued)
Cancer treatment status at study entry 5366 (70.3%) 4613 (73.2%)
Cancer stage at study entry 6123 (80.2%) 5069 (80.5%)
*For an independent study we received tumor types based on French pathology terms. To date we have not transferred these data into
the uniform coding system developed and used for the present study, the data of that study are coded as “other” for the time being.
**Baseline ECOG status: If other performance score systems such as Karnofsky scores were reported these were used for the analysis
but are counted as missing for the present table.
Baseline characteristics and baseline imbalances
Funnel plots were generated to investigate baseline imbalances
across all included trials. For continuous variables, means for each
trial arm were calculated (active and control arm) and the differ-
ences of the means for each study were plotted against the sam-
ple size of the corresponding study. For dichotomous variables,
proportions for each trial arm were calculated (active and control
arm) and the differences of the proportions for each study were
plotted against the sample size of the corresponding study. We
assessed asymmetry using random-effects meta-regression and de-
rived a corresponding P value (Sterne 2001). Funnel plots include
pseudo-95% confidence interval lines, which are drawn around
the summary fixed-effect estimate (red lines).
The following variables were assessed:
Continuous: ECOG, level of serumepo, BMI, time fromdiagnosis
of cancer to randomization, hemoglobin, hematocrit, age
Dichotomous: Sex, ECOG (low versus high), history of throm-
boembolic event, history of cardiovascular event, history of hyper-
tension, history of diabetes.
Plots are shown in Appendix 5. We found no evidence of baseline
imbalances across trials.
Proportional hazard assumption
For each study we plotted log-log plots for proportional hazard
assumption and conducted a Schoenfeld test for residuals. Note:
on file, not provided in this review. Overall, in most studies the
proportional hazard assumption was fulfilled. In one study (num-
ber 43680 (Osterborg 1996)) there was evidence that the propor-
tional hazard assumption was not met (Schoenfeld test p=0.0309).
Censoring
Reverse Kaplan-Meier curves to assess time to censoring for each
trial are on file. In addition, we calculated the hazard ratio for being
censored in the ESA arm compared to the control arm for each
study and conducted a meta-analysis based on these estimates. For
this analysis patients who were censored in the original trial were
considered as an event and patients who died in the original trial
were censored for the purpose of this analysis. The meta-analysis
was conducted with a two-stage random-effects model and the
Forest plot is shown in Figure 5. Overall, there was no evidence
for an unbalanced censoring between the ESA and the control
arm (HR for being censored when alive 0.97 (95% CI 0.91-1.03).
However, there was evidence for heterogeneity between studies: I²
65.5%, test for heterogeneity p<0.0001. In five studies (53081,
21481, 45434, 70404, 87660) the hazard for being censored was
higher in the control arm compared to the ESA arm and in two
studies (34917, 36158) patients in the ESA arm were more likely
to be censored compared to the control arm. For these studies we
compared the hazard ratio of being censored with the hazard ratio
for death (Table 2).
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Figure 5. On study mortality: censoring meta-analysis, HRs < 1,0 indicate that more patients in the control
arm had the event (”censoring“), HRs > 1,0 indicate that more patients in the ESA arm had the event
(”censoring“) compared to controls.
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Table 2. Hazard ratios for censoring and hazard ratios for on study mortality in selected studies
Study number On study censoring
ESA versus control
HR (95% CI)*
On study mortality
ESA versus control
HR (95% CI)*
53081 0.47 (95% CI 0.35, 0.64) 0.89 (95% CI 0.19, 4.17)
21481 0.57 (95% CI 0.39, 0.84) 0.94 (95% CI 0.06, 15.01)
45434 0.34 (95% CI 0.25, 0.47) 0.62 (95% CI 0.25, 1.58)
70404 0.52 (95% CI 0.32, 0.83) 0 deaths
87660 0.57 (95% CI 0.40, 0.80) 1.58 (95% CI 0.38, 6.61)
34917 1.62 (95% CI 1.15, 2.28) 1.10 (95% CI 0.45, 2.72)
36158 1.47 (95% CI 1.14, 1.90) 1.02 (95% CI 0.42, 2.45)
* based on two-stage Cox random-effects meta-analysis
In addition, we assessed whether in studies with a statistically sig-
nificant or borderline increased or decreased hazard ratio for on
study mortality, the number of censored patients was balanced
between the ESA arm and the control arm, see table below. In
conclusion, it seems unlikely that unbalanced censoring between
the ESA and the control arm has influenced the overall estimates
for ESA on mortality (Table 3).
Table 3. Hazard ratios for censoring and hazard ratios for on study mortality in selected studies
Study number On study censoring
ESA versus control
HR (95% CI)*
On study mortality
ESA versus control
HR (95% CI)*
17100 1.01 (95% CI 0.87, 1.16) 1.42 (95% CI 1.08, 1.86)
53572 0.89 (95% CI 0.37, 2.15) 1.68 (95% CI 0.95, 2.98)
67954 1.16 (95% CI 0.94, 1.44) 1.45 (95% CI 0.95, 2.21)
81215 1.00 (95% CI 0.87, 1.15) 1.37 (95% CI 1.05, 1.78)
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Table 3. Hazard ratios for censoring and hazard ratios for on study mortality in selected studies (Continued)
97413 1.00 (95% CI 0.82, 1.22) 1.38 (95% CI 0.89, 2.13)
* based on two-stage Cox random-effects meta-analysis
Effects of interventions
On study mortality in all cancer patients
Objective 1 for on study mortality in all cancer patients
Aim:What is the effect of ESAs compared to control for on study
mortality in this population and can the effect be explained by
baseline imbalances of prognostic factors at patient level?
A total of 53 studies with 13933 patients were included in the
analysis of on study mortality. All cancer patients regardless of
anticancer treatment receivedwere included in the present analysis.
Four studies did not contribute to the present results because there
were no deaths during on study period (study 22515 (Moebus
2007), 30540 (Vadhan-Raj 2004), 66960 (Untch 2008), 70404 (
Strauss 2008).
During on study phase 865 out of 7634 patients randomized to
the ESA arm and 665 out of 6299 patients randomized to the
control arm died. Median follow-up was 3.71 months (IQR 2.8-
5.1 months) in the ESA arm and 3.94 months (IQR 2.9 to 5.3
months) in the control arm. The overall hazard ratio for patients
receiving ESA compared to controls was 1.17 (95% CI 1.06-1.30)
during on study phase based on two-stage log-rank fixed-effects
meta-analysis. Based on aCoxmodel stratified for study the overall
result was 1.17 (95% CI 1.06-1.30). For results of all statistical
models applied, see Table 4.
Table 4. On study mortality for all cancer patients
Model ESA versus control
HR (95% CI)
P value* I² P value**
Two-stage log-rank fixed
effects model
1.17 (95% CI 1.06-
1.30)
0.0025 0% 0.8735
Two-stage log-rank ran-
dom effects model
1.17 (95% CI 1.06-
1.30)
0.0025 0% 0.8735
Two-stage Cox fixed ef-
fects model
1.16 (95% CI 1.05-
1.29)
0.0042 0% 0.9303
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Table 4. On study mortality for all cancer patients (Continued)
Two-stage Cox random
effects model
1.16 (95% CI 1.05-
1.29)
0.0042 0% 0.9303
Cox model stratified by
study
1.17 (95% CI 1.06-
1.30)
0.0025 0.6310
*LR test, ** for test of heterogeneity
There was no evidence for heterogeneity between the trials (I-
square 0%, p=0.8735), for Forest plot see Figure 6, for pooled Ka-
plan-Meier curve see Appendix 4. There was no evidence for small
study effects: linear regression test p=0.1371, rank correlation test
of funnel plot asymmetry p=0.9588. For Funnel plot see Figure 7.
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Figure 6. Forest plot for on study mortality in all cancer patients based on two stage log-rank fixed-effects
meta-analysis
32Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 7. Funnel plot (based on log-rank estimates) for on study mortality in all cancer patientsExplanation of terms
used:Full text: highest publication achieved is a full text publicationAbstract: highest publication achieved is an
abstract publicationODAC: highest publication achieved is reporting of study results in documents presented
at ODAC hearingsUnpublished: to date the study was not published in any of the sources mentioned
aboveDate of reference: June 26th 2008
Two studies contributed more than 10% weight to the overall
analysis (Leyland-Jones 2003; Smith 2008). In the study pub-
lished by Leyland-Jones 2003 (study number 17100) 937 patients
with metastatic cancer undergoing chemotherapy received ESA or
placebo for 52 weeks, therefore the study has a much longer on
study phase compared to other studies. In the study published by
Smith et al 2008 (study number 81215) 989 patients were treated
with ESA without concomitant myelosuppressive chemotherapy.
The impact of single studies was assessed in an influence analysis,
see Figure 8. When excluding study 17100 (Leyland-Jones 2003),
the overall HR slightly decreased and the confidence interval still
excluded 1. Exclusion of any of the other studies did not markedly
change the overall estimate.
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Figure 8. Influence analysis for on study mortality in all cancer patients
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Assessment of potential confounders for objective 1
In the next step we conducted bivariate analyses: adjusting on
study mortality based on the Cox model stratified by study for
one variable at the time. All variables assessed relate to the indi-
vidual patient data level. The results of the adjusted model were
compared with the unadjusted model using LR-Test. Results of
unadjusted and adjusted models as well as P values of LR-Test are
shown in Table 5. We included only patients with full informa-
tion for the respective variable; patients with missing, unknown or
unreported data were excluded. Data were often missing for entire
studies; therefore the overall HR might have changed because of
the omission of studies. We therefore present both unadjusted and
adjusted HRs based on the patient data set with available infor-
mation.
Table 5. Bivariate analyses for on study mortality in all cancer patients
On study mortality for
all cancer patients
N included ESA versus control
Unadjusted HR (95% CI)
ESA versus control
Adjusted HR (95% CI)
P value
LR-Test
Total 13933 1.17 (95% CI 1.06-1.30) - -
Hb at baseline (continu-
ous)
13407 1.17 (95% CI 1.06-1.30) 1.18 (95% CI 1.07-1.31) 0.0000
Hb at baseline (categori-
cal 1)
13407 1.17 (95% CI 1.06-1.30) 1.18 (95% CI 1.06-1.31) 0.0000
Hb at baseline (categori-
cal 2)
13407 1.17 (95% CI 1.06-1.30) 1.18 (95% CI 1.07-1.31) 0.0000
Tumor (categorical 1) 13891 1.17 (95% CI 1.06-1.30) 1.17 (95% CI 1.06-1.30) 0.0000
Tumor (categorical 2) 13891 1.17 (95% CI 1.06-1.30) 1.16 (95% CI 1.05-1.29) 0.0000
Sex 13933 1.17 (95% CI 1.06-1.30) 1.16 (95% CI 1.05-1.29) 0.0000
Age (continuous) 13921 1.17 (95% CI 1.06-1.30) 1.17 (95% CI 1.06-1.30) 0.0007
Age (categorical) 13921 1.17 (95% CI 1.06-1.30) 1.18 (95% CI 1.06-1.30) 0.0160
Hct (continuous) 11036 1.18 (95% CI 1.06-1.31) 1.19 (95% CI 1.07-1.32) 0.0000
Hct (categorical) 11036 1.18 (95% CI 1.06-1.31) 1.19 (95% CI 1.07-1.33) 0.0000
Baseline serum EPO
(cont.)
5651 1.11 (95% CI 0.95-1.29) 1.10 (95% CI 0.95-1.28) 0.1798
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Table 5. Bivariate analyses for on study mortality in all cancer patients (Continued)
Baseline serum EPO
(cat.)
5651 1.11 (95% CI 0.95-1.29) 1.10 (95% CI 0.95-1.28) 0.0006
ECOG (0 vs 1 vs 2 vs 3
vs 4)
10112 1.19 (95% CI 1.06-1.33) 1.17 (95% CI 1.05-1.32) 0.0000
ECOG (0,1,2 vs 3,4) 10225 1.18 (95% CI 1.06-1.33) 1.19 (95% CI 1.06-1.34) 0.0000
BMI (categorical) 11445 1.16 (95% CI 1.04-1.30) 1.17 (95% CI 1.04-1.31) 0.0000
History of thromboem-
bolic events
9620 1.20 (95% CI 1.06-1.34) 1.19 (95% CI 1.06-1.34) 0.1105
History of cardiovascular
events
10322 1.20 (95% CI 1.06-1.34) 1.19 (95% CI 1.06-1.34) 0.1002
History of hypertension 9620 1.20 (95% CI 1.06-1.34) 1.20 (95% CI 1.06-1.34) 0.8464
History of diabetes mel-
litus
8025 1.20 (95% CI 1.06-1.35) 1.20 (95% CI 1.06-1.35) 0.4497
Geographical region [re-
gion˙cat]
13532 1.17 (95% CI 1.05-1.29) 1.16 (95% CI 1.05-1.29) 0.0001
Metastatic vs non-
metastatic
12152 1.21 (95% CI 1.09-1.35) 1.21 (95% CI 1.08-1.35) 0.0000
Time from cancer diag-
nosis to randomization
4586 1.17 (95% CI 0.99-1.39) 1.18 (95% CI 1.00-1.40) 0.0000
Based on these analyses and the number of data available for each
variable, we conducted four different models, all of which are pre-
sented in Table 6. For model 1 we included the variables age, sex,
and Hb at baseline and tumor type into the model. For model 2
we used the same variables as in model 1 plus stage of underly-
ing tumor. For model 3 we used the same variables as in model 1
plus BMI and region, for model 4 we used the same variables as
in model 1 and 3 plus ECOG and hematocrit. For the variables
age, Hb, serum EPO and BMI the association between the expo-
sure and the outcome was not linear (graph not shown). There-
fore, these continuous variables were converted into prespecified
categories. Hematocrit was converted into categories as well for
the ease of interpretation. The variable “time for cancer diagnosis
to randomization” was not included in the model because of too
many missing data.
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Table 6. Multivariate analysis on study mortality in all cancer patients
On study mortality in
all cancer patients
Model 1 Model 2 Model 3 Model 4
Patients included n=13353 n=11636 n=10599 n=6547
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ESA vs control unad-
justed*
1.17 (95% CI 1.06-
1.30)
1.22 (95% CI 1.09-
1.36)
1.16 (95% CI 1.03-
1.30)
1.20 (95% CI 1.06-
1.37)
ESA vs control
adjusted**
1.17 (95% CI 1.06-
1.30)
1.21 (95% CI 1.08-
1.35)
1.16 (95% CI 1.03-
1.30)
1.23 (95% CI 1.08-
1.39)
Hb at baseline
Hb < 8 g/dL 1 1 1 1
Hb 8-10 g/dL 0.70 (95% CI 0.58-
0.85)
0.66 (95% CI 0.53-
0.81)
0.69 (95% CI 0.57-
0.85)
0.83 (95% CI 0.62-
1.10)
Hb 10-12 g/dL 0.49 (95% CI 0.40-
0.60)
0.46 (95% CI 0.37-
0.57)
0.52 (95% CI 0.42-
0.65)
0.71 (95% CI 0.51-
0.98)
Hb 12-14 g/dL 0.33 (95% CI 0.26-
0.42)
0.31 (95% CI 0.24-
0.40)
0.38 (95% CI 0.29-
0.49)
0.52 (95% CI 0.35-
0.77)
Hb > 14 g/dL 0.28 (95% CI 0.20-
0.39)
0.27 (95% CI 0.20-
0.38)
0.33 (95% CI 0.23-
0.46)
0.45 (95% CI 0.26-
0.79)
Age at randomization
18 - 35 yrs 0.90 (95% CI 0.55-
1.46)
1.04 (95% CI 0.61-
1.77)
0.88 (95% CI 0.51-
1.54)
0.79 (95% CI 0.42-
1.47)
35 - 45 yrs 1 1 1 1
45 - 55 yrs 1.09 (95% CI 0.86-
1.39)
1.08 (95% CI 0.84-
1.40)
1.15 (95% CI 0.87-
1.52)
1.03 (95% CI 0.77-
1.37)
55 - 65 yrs 1.23 (95% CI 0.97-
1.54)
1.25 (95% CI 0.98-
1.60)
1.37 (95% CI 1.05-
1.78)
1.19 (95% CI 0.90-
1.57)
65 - 75 yrs 1.30 (95% CI 1.03-
1.64)
1.28 (95% CI 0.99-
1.64)
1.51 (95% CI 1.15-
1.97)
1.33 (95% CI 1.00-
1.77)
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Table 6. Multivariate analysis on study mortality in all cancer patients (Continued)
> 75 ys 1.40 (95% CI 1.07-
1.82)
1.46 (95% CI 1.09-
1.94)
1.52 (95% CI 1.12-
2.08)
1.22 (95% CI 0.87-
1.71)
Sex
Male 1 1 1 1
Female 0.80 (95% CI 0.70-
0.91)
0.83 (95% CI 0.72-
0.96)
0.83 (95% CI 0.72-
0.96)
0.84 (95% CI 0.71-
0.99)
Tumor category
Hematological
malignancies
1 1 1 1
Breast cancer 1.55 (95% CI 1.09-
2.20)
1.39 (95% CI 0.88-
2.19)
1.60 (95% CI 1.08-
2.38)
1.72 (95% CI 1.12-
2.64)
Head and neck cancer 2.29 (95% CI 1.24-
4.22)
1.84 (95% CI 0.87-
3.86)
1.69 (95% CI 0.83-
3.44)
1.71 (95% CI 0.71-
4.12)
Lung cancer 3.15 (95% CI 2.32-
4.30)
2.61 (95% CI 1.74-
3.91)
2.97 (95% CI 2.06-
4.29)
3.49 (95% CI 2.35-
5.18)
Gastrointestinal 2.82 (95% CI 2.05-
3.88)
2.54 (95% CI 1.67-
3.87)
2.59 (95% CI 1.79-
3.77)
2.87 (95% CI 1.92-
4.30)
Gynecological 1.47 (95% CI 0.98-
2.19)
1.22 (95% CI 0.74-
2.01)
1.69 (95% CI 1.08-
2.64)
2.14 (95% CI 1.31-
3.38)
Genitourinary 2.16 (95% CI 1.54-
3.05)
1.97 (95% CI 1.28-
3.03)
2.14 (95% CI 1.44-
3.18)
2.48 (95% CI 1.63-
3.79)
Other 2.85 (95% CI 1.99-
4.07)
2.63 (95% CI 1.67-
4.16)
2.76 (95% CI 1.82-
4.18)
3.01 (95% CI 1.91-
4.74)
Tumor stage
Metastatic/advanced - 1 - -
Not
Metastatic/advanced
- 0.47 (95% CI 0.37-
0.59)
- -
Region
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Table 6. Multivariate analysis on study mortality in all cancer patients (Continued)
Northern America - - 1 1
Southern Europe - - 1.35 (95% CI 0.90-
2.02)
1.33 (95% CI 0.87-
2.04)
Australia & New
Zealand
- - 1.18 (95% CI 0.75-
1.86)
1.26 (95% CI 0.76-
2.07)
Eastern Europe - - 1.66 (95% CI 1.19-
2.31)
1.64 (95% CI 1.16-
2.31)
Northern Europe - - 1.75 (95% CI 1.20-
2.55)
1.94 (95% CI 1.31-
2.88)
Western Europe - - 1.75 (95% CI 1.21-
2.51)
1.84 (95% CI 1.25-
2.70)
Other - - 1.38 (95% CI 0.74-
2.58)
1.76 (95% CI 0.92-
3.38)
BMI
< 19 kg/m² - - 1 1
19-25 kg/m² - - 0.64 (95% CI 0.53-
0.77)
0.65 (95% CI 0.53-
0.80)
25-30 kg/m² - - 0.51 (95% CI 0.41-
0.62)
0.50 (95% CI 0.40-
0.63)
> 30 kg/m² - - 0.42 (95% CI 0.33-
0.54)
0.44 (95% CI 0.34-
0.58)
Hct at baseline
Hct < 23.5% - - - 1
Hct 23.5%-29.4% - - - 0.68 (95% CI 0.46-
1.01)
Hct 29.4%-35.3% - - - 0.52 (95% CI 0.34-
0.79)
Hct 35.3%-41.2% - - - 0.49 (95% CI 0.30-
0.79)
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Table 6. Multivariate analysis on study mortality in all cancer patients (Continued)
>Hct 41.2% - - - 0.47 (95% CI 0.26-
0.84)
Performance score
ECOG 0, 1 or 2 - - - 1
ECOG 3 or 4 - - - 4.03 (95% CI 2.83-
5.74)
*unadjusted based on the patients included in respective model, **adjusted for variables outlined in the columns
Summary points for objective 1 for on study mortality in all
cancer patients
• ESAs increased on study mortality in cancer patients by
factor 1.17 (HR 1.17; 95% CI 1.06-1.30, n =13933).
• Available evidence does not support the hypothesis that
baseline imbalances of prognostic factors analyzed in-
fluenced the overall results.
Objective 2 for on study mortality in all cancer patients
Aim: Is there a specific subgroup of patients that is at increased or
decreased risk to die when receiving ESAs compared to controls?
Are there design aspects at study level that influenced the effects
of ESA on survival?
We tested for interaction between ESA treatment and specific vari-
ables describing patient and study characteristics, results of inter-
action test are outlined in Table 7, results with estimates for sub-
groups are outlined in Appendix 6).
Table 7. Assessment of interaction for on study mortality in all cancer patients
On study mortality, all cancer patients Patients included P value for interaction*
Total included 13933 -
Patient level characteristics (subgroup
analysis)
Hb at baseline (continuous) 13407 0.8164
Hb at baseline (categorical 1) 13407 0.7479
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Table 7. Assessment of interaction for on study mortality in all cancer patients (Continued)
Hb at baseline (categorical 2) 13407 0.7917
Tumor (categorical 1) 13891 0.1623
Tumor (categorical 2) 13891 0.4697
Sex 13933 0.8607
Age (continuous) 13921 0.8677
Age (categorical) 13921 0.5002
Hct (continuous) 11036 0.5656
Hct (categorical) 11036 0.0110
Baseline serum EPO (continuous) 5651 0.2139
Baseline serum EPO (categorical) 5651 0.5436
ECOG 10112 0.6324
ECOG (0,1,2 vs 3,4) 10225 0.5600
BMI (categorical) 11445 0.7246
History of thromboembolic events 9620 0.0605
History of cardiovascular events 10322 0.6227
History of hypertension 9620 0.7626
History of diabetes mellitus 8025 0.6962
Geographical region [region˙cat] 13532 0.1707
Metastatic vs non-metastatic 12152 0.7588
Planned Hb ceiling (categorical 1) 13730 0.9777
Planned Hb ceiling (categorical 2) 13730 0.8840
Study level characteristics (subset analy-
sis)
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Table 7. Assessment of interaction for on study mortality in all cancer patients (Continued)
Placebo controlled 13933 0.3780
Randomization (adequate vs unclear) 13933 0.9848
Allocation (adequate vs unclear) 13933 0.2347
Endpoint overall survival 13933 0.4074
Year of last patient randomized into study
(categorical)
13933 0.2351
Source of data (company versus indepen-
dent)
13933 0.1281
Patient population (chemotherapy, ra-
diochemotherapy,
radiotherapy, none, mixed)
13933 0.4148
Iron category 13933 0.4784
Planned ESA treatment duration (categor-
ical)
13933 0.3338
Planned weekly ESA dosage (categorical) 13933 0.1227
Planned frequency of ESA administration
(categorical)
13933 0.0274
*P value for interaction based on LR test, patients with missing data are excluded from LR test
Three variables (planned frequency of ESA administration, his-
tory of thromboembolic events, hematocrit) showed a statistically
significant (p<0.1) interaction term in the bivariate analyses and
were included in the multivariate model (model 1). This model
included the variables, age and sex, Hb at baseline and tumor cat-
egory, for P values of LR tests see Table 8.
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Table 8. Assessment of selected interaction terms for on study mortality in all cancer patients, univariate and multivariate
analyses
On
study
mor-
tal-
ity all
can-
cer pa-
tients
Pa-
tients
total
ESA arm Control arm Bivariate analysis
ESR versus control
Multivariate analysis
ESR versus control
adjusted for age,
sex, Hb, tumor type
N n N % n N % HR 95% CI p* HR 95% CI p*
Hct at
base-
line,
cate-
gorical
<
23.5%
390 55 210 26% 24 180 13% 2.19 1.35-3.55 2.12 1.30-3.48
23.5-
29.4%
2788 199 1567 13% 191 1221 16% 0.96 0.78-1.77 0.96 0.79-1.18
29.4-
35.3%
4615 321 2692 12% 223 1923 12% 1.17 0.99-1.39 0.0110 1.15 0.97-1.37 0.0191
35.3-
41.2%
2458 176 1258 14% 130 1200 11% 1.41 1.12-1.76 1.39 1.10-1.74
>
41.2%
785 48 414 12% 40 371 11% 1.12 0.73-1.70 1.15 0.76-1.76
Miss-
ing
/ not re-
ported
2897 66 1493 4% 57 1404 4% 1.09 0.76-1.55 - omitted -
His-
tory of
throm-
boem-
bolic
events
Yes 561 40 318 13% 42 243 17% 0.80 0.52-1.23 0.77 0.50-1.19 0.0440
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Table 8. Assessment of selected interaction terms for on study mortality in all cancer patients, univariate and multivariate
analyses (Continued)
No 9059 637 5044 13% 474 4015 12% 1.23 1.09-1.39 0.0605 1.22 1.08-1.38
Miss-
ing
/ not re-
ported
4313 188 2272 8% 149 2041 7% 1.09 0.87-1.35 omitted
Planned
fre-
quency
of ESA
appli-
cation
Three
times
per
week
or
more
fre-
quent
6131 311 3458 9% 238 2673 9% 1.01 0.85-1.20 1.01 0.85-1.21
Once
per
week
3948 303 1972 15% 231 1976 12% 1.39 1.18-1.66 0.0274 1.41 1.18-1.67 0.0369
Every
second
week
or
less fre-
quent
3036 180 1795 10% 122 1241 10% 1.25 0.99-1.57 1.19 0.94-1.50
Other 818 71 409 17% 74 409 18% 0.93 0.67-1.29 0.96 0.69-1.32
*P value from LR test for interaction. Missing data were excluded when testing for interaction.
Summary points for objective 2 for on study mortality in all
cancer patients
• There was no strong evidence to support the hypothesis
that ESAs had different effects in sub-populations that
differed for any of the variables tested.
• For three variables (ESA administration frequency, his-
tory of thromboembolic events, and hematocrit) found
statistically significant (p < 0.1) in bivariate analyses
multivariate analyses suggested the following:
•
◦ Effect modification of Hct at baseline can
only to a certain extend be explained by con-
founding with other patient characteristics
(Hb, age, sex, tumor type).However, because
of large amounts of missing data uncertainty
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remains.
◦ Effect modification of history of throm-
boembolic events was robust in sensitivity
analyses for additional patient characteristics
(Hb, age, sex, tumor type); however, because
of large amounts of missing data uncertainty
remains.
◦ Effect modification for planned frequency of
ESA application is likely to be confounded
by other study design aspects, see Appendix
4.
On study mortality in chemotherapy trials
Objective 1 for on study mortality in chemotherapy trials
Aim:What is the effect of ESAs compared to control for on study
mortality in this population and can the effect be explained by
baseline imbalances of prognostic factors?
A total of 38 studies with 10441 patients were included in the
analysis of on study mortality analysis in patients undergoing che-
motherapy. In this analysis we included only studies where at least
70% of the study population had received a myelosuppressive che-
motherapy. Two studies did not contribute to the present results
because there were no deaths during on study period (study 22515
(Moebus 2007), 66960 (Untch 2008)).
During on study phase 605 out of 5676 patients randomized to
the ESA arm and 490 out of 4765 patients randomized to the
control arm died. Median follow-up was 4.1 months (IQR 3.0 to
5.6 months) in the ESA and 4.3 months (IQR 3.4 to 5.7 months)
in the control arm. The overall hazard ratio for patients receiving
ESAs compared to controls was 1.10 (95% CI 0.98-1.24) during
on study phase based on the two-stage log-rank fixed-effects meta-
analysis. Based on aCoxmodel stratified for study the overall result
was 1.10 (95% CI 0.98-1.24). For results of all statistical models
applied see Table 9. For Forest plot see Figure 9, for pooled Ka-
plan-Meier curve see Appendix 4. There was no evidence for het-
erogeneity between the trials (I-square 0%, p=0.7152). There was
no evidence for small study effects: linear regression test p=0.1743,
rank correlation test of funnel plot asymmetry p=0.7437. For Fun-
nel plot see Figure 10.
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Figure 9. Forest plot for on study mortality in chemotherapy trials based on two-stage log-rank fixed-effect
meta-analysis
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Figure 10. Funnel plot (based on log-rank estimates) for on study mortality in chemotherapy
trialsExplanation of terms used: Full text: highest publication achieved is a full text publicationAbstract:
highest publication achieved is an abstract publicationODAC: highest publication achieved is reporting of study
results in documents presented at ODAC hearingsUnpublished: to date the study was not published in any of
the sources mentioned above Date of reference: June 26th 2008
Table 9. On study mortality for all cancer patients
Model ESA versus control
HR (95% CI)
P value* I² P value**
Two-stage log-rank fixed
effect model
1.10 (95% CI 0.98-
1.24)
0.1212 0% 0.7152
Two-stage log-rank ran-
dom effects model
1.10 (95% CI 0.98-
1.24)
0.1212 0% 0.7152
Two-stage Cox fixed ef-
fect model
1.09 (95% CI 0.97-
1.23)
0.1555 0% 0.8813
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Table 9. On study mortality for all cancer patients (Continued)
Two-stage Cox random
effects model
1.09 (95% CI 0.97-
1.23)
0.1555 0% 0.8813
Cox model stratified by
study
1.10 (95% CI 0.98-
1.24)
0.121 0.4643
*LR test, ** for test of heterogeneity
One study contributed 19.9% weight to the overall analysis (
Leyland-Jones 2003). As described above, in the study pub-
lished by Leyland-Jones et al 2003 (study 17100) 937 patients
with metastatic cancer undergoing chemotherapy received ESA or
placebo for 52 weeks, therefore the study has a much longer on
study phase compared to other studies. The influence of single
studies was assessed in an influence analysis, see Figure 11. Exclud-
ing study 17100 decreased the overall HR (omitting 17100: HR
1.03 (95% CI 0.90-1.18); the margins of the confidence intervals
were not influenced by exclusion of any of the other studies.
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Figure 11. Influence analysis for on study mortality in chemotherapy trials
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Assessment of potential confounders for objective 1
In the next step we conducted bivariate analyses: adjusting on
study mortality based on the Coxmodel stratified by study for one
variable at the time. All variables assessed relate to the individual
patient data level. The results of the adjustedmodel were compared
with the unadjusted model using LR-Test. Results of unadjusted
and adjusted models as well as P values of LR-Test are shown in
Table 10. We included only patients with full information for the
respective variable; patients with missing, unknown or unreported
data were excluded. Data were often missing for entire studies;
exclusion of these studies might have affected the overall estimate.
We therefore present both unadjusted and adjusted HRs for the
full patient data set for each variable.
Table 10. Bivariate analysis for on study mortality in chemotherapy trials
On study mortality for
chemotherapy patients
N included ESA versus control
Unadjusted HR
(95% confidence interval)
ESA versus control
Adjusted HR
(95% confidence interval)
P value
LR-Test*
Total 10441 1.10 (95% CI 0.98-1.24) - -
Hb at baseline (continu-
ous)
9945 1.10 (95% CI 0.98-1.25) 1.12 (95% CI 0.99-1.26) 0.0000
Hb at baseline (categori-
cal 1)
9945 1.10 (95% CI 0.98-1.25) 1.12 (95% CI 0.99-1.26) 0.0000
Hb at baseline (categori-
cal 2)
9945 1.10 (95% CI 0.98-1.25) 1.12 (95% CI 0.99-1.26) 0.0000
Tumor (categorical 1) 10399 1.10 (95% CI 0.97-1.24) 1.10 (95% CI 0.97-1.24) 0.0049
Tumor (categorical 2) 10399 1.10 (95% CI 0.97-1.24) 1.10 (95% CI 0.97-1.24) 0.0000
Sex 10441 1.10 (95% CI 0.98-1.24) 1.10 (95% CI 0.97-1.24) 0.0000
Age (continuous) 10430 1.10 (95% CI 0.98-1.24) 1.10 (95% CI 0.98-1.24) 0.0000
Age (categorical) 10430 1.10 (95% CI 0.98-1.24) 1.10 (95% CI 0.98-1.24) 0.0002
Hct (continuous) 7849 1.11 (95% CI 0.98-1.26) 1.12 (95% CI 0.98-1.27) 0.0000
Hct (categorical) 7849 1.11 (95% CI 0.98-1.26) 1.12 (95% CI 0.98-1.27) 0.0000
Baseline serum EPO
(continuous)
3959 0.99 (95% CI 0.82-1.20) 0.99 (95% CI 0.82-1.19) 0.2936
50Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 10. Bivariate analysis for on study mortality in chemotherapy trials (Continued)
Baseline serum EPO
(categorical)
3959 0.99 (95% CI 0.82-1.20) 0.98 (95% CI 0.81-1.19) 0.0651
ECOG (0 vs 1 vs 2 vs 3
vs 4)
8057 1.12 (95% CI 0.98-1.28) 1.11 (95% CI 0.97-1.27) 0.0000
ECOG (0,1,2 vs 3,4) 8057 1.12 (95% CI 0.98-1.28) 1.12 (95% CI 0.98-1.29) 0.0000
BMI (categorical) 8882 1.08 (95% CI 0.94-1.23) 1.09 (95% CI 0.95-1.24) 0.0000
History of thromboem-
bolic events
6667 1.11 (95% CI 0.96-1.28) 1.11 (95% CI 0.96-1.28) 0.0658
History of cardiovascular
events
7369 1.11 (95% CI 0.96-1.28) 1.10 (95% CI 0.96-1.27) 0.0394
History of hypertension 6667 1.11 (95% CI 0.96-1.28) 1.11 (95% CI 0.96-1.28) 0.7143
History of diabetes mel-
litus
5579 1.09 (95% CI 0.94-1.26) 1.09 (95% CI 0.94-1.27) 0.0802
Geographical region [re-
gion˙cat]
10053 1.09 (95% CI 0.97-1.23) 1.09 (95% CI 0.97-1.24) 0.2767
Metastatic vs non-
metastatic
8956 1.16 (95% CI 1.02-1.32) 1.15 (95% CI 1.01-1.31) 0.0000
Time from cancer diag-
nosis to randomization
3114 1.06 (95% CI 0.85-1.31) 1.06 (95% CI 0.85-1.32) 0.6775
*This test compares the adjusted with the unadjusted model. It takes into account the entire model, not only the overall hazard ratio.
Based on these analyses and the number of data available for each
variable, we conducted four different models, all of which are
presented in Table 11. For model 1 we included the variables age,
sex, and Hb at baseline and tumor type into the model. For model
2 we used the same variables as in model 1 plus tumor stage. For
model 3 we used the same variables as in model 1 plus BMI and
region, for model 4 we used the same variables as in model 1 and 3
plus ECOGand hematocrit. For the continuous variables age,Hb,
serum EPO and BMI the association between the exposure and
the outcome was not linear (graph not shown). Therefore, these
continuous variables were converted into prespecified categories.
Hematocrit was converted into categories as well for the ease of
interpretation. When including history of cardiovascular events
into model 1, the overall effect was also not altered (data on file,
not shown).
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Table 11. Multivariate models for on study mortality in chemotherapy trials
On study mortality
chemotherapy trials
Model 1 Model 2 Model 3 Model 4
Patients included n=9892 n=8469 n=8030 n=5109
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ESA vs control, unad-
justed
1.10 (95% CI 0.98-
1.25)
1.16 (95% CI 1.02-
1.33)
1.07 (95% CI 0.94-
1.23)
1.13 (95% CI 0.97-
1.31)
ESA vs control, adjusted 1.12 (95% CI 0.99-
1.26)
1.17 (95% CI 1.02-
1.33)
1.08 (95% CI 0.95-
1.24)
1.16 (95% CI 0.99-
1.34)
Hb at baseline
Hb < 8 g/dL 1 1 1 1
Hb 8 - 10 g/dL 0.79 (95% CI 0.62-
1.01)
0.73 (95% CI 0.55-
0.96)
0.76 (95% CI 0.58-
1.00)
0.91 (95% CI 0.61-
1.34)
Hb 10 - 12 g/dL 0.57 (95% CI 0.44-
0.74)
0.53 (95% CI 0.39-
0.70)
0.61 (95% CI 0.46-
0.82)
0.76 (95% CI 0.50-
1.14)
Hb 12 - 14 g/dL 0.36 (95% CI 0.27-
0.49)
0.33 (95% CI 0.24-
0.46)
0.42 (95% CI 0.30-
0.57)
0.52 (95% CI 0.33-
0.82)
Hb > 14 g/dL 0.32 (95% CI 0.22-
0.47)
0.30 (95% CI 0.20-
0.46)
0.36 (95% CI 0.24-
0.54)
0.45 (95% CI 0.25-
0.83)
Age at randomization
18 - 35 yrs 0.92 (95% CI 0.54-
1.57)
1.12 (95% CI 0.62-
2.01)
0.94 (95% CI 0.51-
1.74)
0.77 (95% CI 0.38-
1.50)
35 - 45 yrs 1 1 1 1
45 - 55 yrs 1.16 (95% CI 0.88-
1.51)
1.16 (95% CI 0.86-
1.55)
1.24 (95% CI 0.91-
1.70)
1.08 (95% CI 0.78-
1.63)
55 - 65 yrs 1.27 (95% CI 0.98-
1.64)
1.31 (95% CI 0.99-
1.74)
1.46 (95% CI 1.07-
1.97)
1.19 (95% CI 0.87-
1.63)
65 - 75 yrs 1.51 (95% CI 1.16-
1.97)
1.52 (95% CI 1.14-
2.02)
1.74 (95% CI 1.28-
2.38)
1.52 (95% CI 1.10-
2.09)
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Table 11. Multivariate models for on study mortality in chemotherapy trials (Continued)
> 75 yrs 1.69 (95% CI 1.24-
2.31)
1.93 (95% CI 1.37-
2.71)
1.95 (95% CI 1.35-
2.81)
1.61 (95% CI 1.08-
2.40)
Sex
Male 1 1 1 1
Female 0.78 (95% CI 0.66-
0.92)
0.82 (95% CI 0.69-
0.99)
0.84 (95% CI 0.70-
1.00)
0.87 (95% CI 0.71-
1.07)
Tumor category
Hematological malign. 1 1 1 1
Breast cancer 1.36 (95% CI 0.88-
2.09)
1.12 (95% CI 0.60-
2.11)
1.32 (95% CI 0.81-
2.17)
1.38 (95% CI 0.78-
2.43)
Head and neck cancer 2.23 (95% CI 0.68-
7.32)
1.59 (95% CI 0.21-
12.12)
1.47 (95% CI 0.20-
11.07)
-
Lung cancer 2.78 (95% CI 1.83-
4.20)
2.06 (95% CI 1.11-
3.80)
2.86 (95% CI 1.70-
4.80)
3.83 (95% CI 2.15-
6.80)
Gastrointestinal 2.54 (95% CI 1.68-
3.83)
1.90 (95% CI 1.02-
3.52)
2.45 (95% CI 1.50-
4.01)
2.79 (95% CI 1.60-
4.85)
Gynecological 1.07 (95% CI 0.64-
1.80)
0.61 (95% CI 0.29-
1.29)
1.38 (95% CI 0.76-
2.50)
2.20 (95% CI 1.10-
4.40)
Genitourinary 1.34 (95% CI 0.73-
2.44)
0.97 (95% CI 0.42-
2.26)
1.06 (95% CI 0.47-
2.42)
1.19 (95% CI 0.41-
3.43)
Other 2.65 (95% CI 1.68-
4.17)
2.11 (95% CI 1.10-
4.02)
2.69 (95% CI 1.56-
4.62)
3.17 (95% CI 1.71-
5.87)
Tumor stage
Metastatic/advanced - 1 - -
Not
metastatic/advanced
- 0.38 (95% CI 0.28-
0.52)
- -
Region
Northern America - - 1 1
53Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 11. Multivariate models for on study mortality in chemotherapy trials (Continued)
Southern Europe - - 1.20 (95% CI 0.66-
2.17)
1.21 (95% CI 0.64-
2.31)
Australia & New
Zealand
- - 1.00 (95% CI 0.55-
1.81)
1.06 (95% CI 0.52-
2.14)
Eastern Europe - - 1.33 (95% CI 0.76-
2.30)
1.32 (95% CI 0.73-
2.40)
Northern Europe - - 1.25 (95% CI 0.70-
2.26)
1.43 (95% CI 0.75-
2.74)
Western Europe - - 1.50 (95% CI 0.86-
2.63)
1.61 (95% CI 0.88-
2.95)
Other - - 1.14 (95% CI 0.53-
2.43)
1.46 (95% CI 0.66-
3.26)
BMI
< 19 kg/m² - - 1 1
19-25 kg/m² - - 0.73 (95% CI 0.57-
0.92)
0.76 (95% CI 0.58-
1.00)
25-30 kg/m² - - 0.61 (95% CI 0.47-
0.78)
0.63 (95% CI 0.48-
0.85)
> 30 kg/m² - - 0.50 (95% CI 0.37-
0.68)
0.54 (95% CI 0.39-
0.76)
Hct at baseline
Hct 0-23.5% - - - 1
Hct 23.5%-29.4% - - - 0.71 (95% CI 0.37-
1.35)
Hct 29.4%-35.3% - - - 0.61 (95% CI 0.32-
1.16)
Hct 35.3%-41.2% - - - 0.60 (95% CI 0.31-
1.19)
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Table 11. Multivariate models for on study mortality in chemotherapy trials (Continued)
>Hct 41.2% - - - 0.58 (95% CI 0.27-
1.24)
Performance score
ECOG 0, 1 or 2 - - - 1
ECOG 3 or 4 - - - 3.08 (95% CI 1.99-
4.77)
Summary points for objective 1 for on study mortality in
chemotherapy trials
• The hazard ratio for on study mortality in the chemo-
therapy population is increased by factor 1.10 for pa-
tients receiving ESAs compared to controls (HR 1.10,
95% CI 0.98-1.24, n=10441). The evidence does not
conclusively demonstrate that ESAs increase on study
mortality but the evidence also does not conclusively
exclude a harmful effect in this population.
• Available evidence does not support the hypothesis that
baseline imbalances of prognostic factors analyzed in-
fluenced the overall results.
Objective 2 for on study mortality in chemotherapy trials
Aim: Is there a specific subgroup of patients that is at increased or
decreased risk to die when receiving ESAs compared to controls?
Are there design aspects at study level that influenced the effects
of ESA on survival?
We tested for interaction between ESA treatment and specific vari-
ables describing patient and study characteristics, results for inter-
action tests are shown in Table 12, results for effect estimates of
subgroups are outlined in Appendix 7.
Table 12. Assessment of interaction for on study mortality in chemotherapy trials
On study mortality, chemotherapy pa-
tients
N included P value for
interaction*
Total unadjusted (Cox model) 10441 (100%) -
Patient level characteristics
Hb at baseline (continuous) 9945 0.8689
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Table 12. Assessment of interaction for on study mortality in chemotherapy trials (Continued)
Hb at baseline (categorical 1) 9945 0.9035
Hb at baseline (categorical 2) 9945 0.9881
Tumor (categorical 1) 10399 0.1846
Tumor (categorical 2) 10399 0.1509
Sex 10441 0.1395
Age (continuous) 10430 0.5684
Age (categorical) 10430 0.3442
Hct (continuous) 7849 0.5722
Hct (categorical) 7849 0.2189
Baseline serum EPO (continuous) 3959 0.9051
Baseline serum EPO (categorical) 3959 0.2047
ECOG 8057 0.5776
ECOG (0,1,2 vs 3,4) 8057 0.9970
BMI (categorical) 8882 0.6333
History of thromboembolic events 6667 0.1421
History of cardiovascular events 7369 0.9285
History of hypertension 6667 0.6079
History of diabetes mellitus 5579 0.7429
Geographical region [region˙cat] 10053 0.3543
Metastatic vs non-metastatic 8956 0.6083
Planned Hb ceiling (categorical 1) 10362 0.2834
Planned Hb ceiling (categorical 2) 10362 0.3788
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Table 12. Assessment of interaction for on study mortality in chemotherapy trials (Continued)
Study level characteristics
Placebo controlled 10441 0.5349
Randomization (adequate vs unclear) 10441 0.8789
Allocation (adequate vs unclear) 10441 0.0722
Endpoint overall survival 10441 0.1117
Year of last patient randomized into study
(categorical)
10441 0.1568
Source of data (company versus indepen-
dent)
10441 0.1842
Iron category 10441 0.5201
Planned ESA treatment duration (categor-
ical)
10441 0.2020
Planned weekly ESA dosage (categorical) 10441 0.2940
Planned frequency ESA administration
(categorical)
10441 0.0544
*P value for interaction based on LR test, patients with missing data are excluded from LR test
Two variables (concealment of allocation, planned frequency of
ESA administration) showed a statistically significant (p<0.1) in-
teraction term in the bivariate analysis and were included in the
multivariate model (model 1). This model (model 1) included the
variables, age and sex, Hb at baseline and tumor category, see Table
13. Adjusting for these parameters did not markedly influence the
effect estimates and the P values for interaction.
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Table 13. Interaction for on study mortality in chemotherapy trials
On study mor-
tal-
ity chemother-
apy patients
Bivariate
ESA versus control
Multivariate
ESA versus control
Interaction
term
ESA* variable ESA* variable
Model adjusted
for
- age, sex, Hb, tumor type
Patients
included
n = 10441 n = 9892
HR 95% CI P value
LR test
HR 95% CI P value
LR test
Study level characteristics
Planned frequency of ESA application
Three times per
week or more
frequent
0.97 0.81-1.17 0.0544 0.97 0.81-1.18 0.0453
Once per week 1.35 1.12-1.64 1.38 1.14-1.68
Every sec-
ond week or less
frequent
0.92 0.51-1.68 0.92 0.51-1.68
Other 0.93 0.67-1.29 0.95 0.67-1.32
Overall,
unadjusted
1.10 0.98-1.24 - 1.10 0.98-1.25 -
Concealment of allocation
Adequate 1.15 1.01-1.30 0.0722 1.17 1.02-1.33 0.0608
Unclear 0.81 0.57-1.16 0.81 0.57-1.16
Overall,
unadjusted
1.10 0.98-1.24 - 1.10 0.98-1.25 -
Summary points for objective 2 for on study mortality in
chemotherapy trials
• For two variables (ESA administration frequency, con-
cealment of allocation) found statistically significant (p
< 0.1) in bivariate analyses multivariate adjustments did
not markedly effect the estimates and the correspond-
ing P values for interaction.
• For both variables statistical tests for interaction had
borderline significance only in both bivariate and mul-
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tivariate analyses.
• Overall, there is no strong evidence to support the hy-
pothesis that ESAs had different effects in sub-popula-
tions that differed for the variables tested in the chemo-
therapy population.
Overall survival in all cancer patients
Objective 1 for overall survival in all cancer patients
Aim: What is the effect of ESAs compared to control on overall
survival in this population and can the effect be explained by
baseline imbalances of prognostic factors at patient level?
53 studies with 13933 patients were included in the analysis of
overall survival for all cancer patients. 2643 out of 7634 patients
randomized to ESA and 2350 out of 6299 patients randomized to
control died during longest follow-up available. Median follow-
up was 6.2 months (IQR 3.2 to 15.4 months) in the ESA and 8.3
months (IQR 3.7 to 19.6 months) in the control arm. The overall
hazard ratio for patients receiving ESA compared to controls was
1.06 (95% CI 1.00-1.12) for longest follow-up available based on
the two-stage log-rank fixed-effects model meta-analysis. Based on
a Cox model stratified for study the overall result was 1.06 (95%
CI 1.00-1.12). For results of all statistical models applied see Table
14. There was no evidence for heterogeneity between the trials (I-
square 7.1%, p=0.3288). For Forest plot see Figure 12, for pooled
Kaplan-Meier curve see Appendix 4. There was no evidence for
small study effects: linear regression test p=0.7567, rank correla-
tion test of funnel plot asymmetry p=0.602. For Funnel plot see
Figure 13.
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Figure 12. Forest plot for overall survival in all cancer patients based on two-stage log-rank fixed effect
meta-analysis
60Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 13. Funnel plot (based on log-rank estimates) for overall survival in all cancer patientsExplanation of terms
used: Full text: highest publication achieved is a full text publicationAbstract: highest publication achieved is an
abstract publicationODAC: highest publication achieved is reporting of study results in documents presented
at ODAC hearingsUnpublished: to date the study was not published in any of the sources mentioned above
Date of reference: June 26th 2008
Table 14. Overall survival for all cancer patients
Model ESA versus control
HR (95% CI)
P value* I² P value**
Two-stage log-rank fixed
effect model
1.06 (95% CI 1.00-
1.12)
0.0464 7.1% 0.3288
Two-stage log-rank ran-
dom effects model
1.06 (95% CI 1.00-
1.13)
0.0611 7.1% 0.3288
Two-stage Cox fixed ef-
fect model
1.06 (95% CI 1.00-
1.12)
0.0561 0% 0.6129
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Table 14. Overall survival for all cancer patients (Continued)
Two-stage Cox random
effects model
1.06 (95% CI 1.00-
1.12)
0.0561 0% 0.6129
Cox model stratified by
study
1.06 (95% CI 1.00-
1.12)
0.0462 0.2072
*LR test, ** for test of heterogeneity
Overall, 24 of the 53 included trials were designed for long-term
follow-up, defined as planned follow-up of at least 12 months
after end of treatment phase. 14 of the 53 included studies (all
of which were designed for long-term follow-up) had a median
follow-up of at least 12 months. Tables providing median follow-
up for both on study mortality and overall survival per study are
on file. Results for studies designed for long-term follow-up as well
as other sensitivity analyses are provided in Appendix 3.
Two studies contributed 9.5% and 10.1% weight to the overall
analysis (Pirker 2008), (Smith 2008). In the study published by
Smith 2008) (study number 81215) 989 patients were treatedwith
ESA or placebo without concomitant myelosuppressive chemo-
therapy. In the study published by (Pirker 2008) (study number
89335) 600 patients with untreated, extensive SCLC underwent
chemotherapy and were randomized to receive ESA or placebo.
The influence of single studies was assessed; see Figure 14, exclu-
sion of single studies at a time did not influence the overall result.
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Figure 14. Influence analysis for overall survival in all cancer patients
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Assessment of potential confounders for objective 1
In the next step we conducted bivariate analyses: adjusting overall
survival based on theCoxmodel stratified by study for one variable
at the time. All variables assessed relate to the individual patient
data level. The results of the adjusted model were compared with
the unadjustedmodel using LR-Test. Number of patients included
per variable and P values of LR-Test are shown in Table 15. We
included only patients with full information for the respective
variable; patients with missing, unknown or unreported data were
excluded. Data were often missing for entire studies; therefore the
overall HRmight have changed because of the omission of studies.
We therefore present both unadjusted and adjusted HRs based on
the patient data set with available information.
Table 15. Bivariate analysis for overall survival in all cancer patients
Overall survival all can-
cer patients
Patients included ESA versus control
Unadjusted hazard ratio
(95% CI)
ESA versus control
Adjusted hazard ratio
(95% CI)
P value LR-Test*
Total 13933 1.06 (95% CI 1.00-1.12) - -
Hb at baseline (continu-
ous)
13407 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Hb at baseline (categori-
cal 1)
13407 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Hb at baseline (categori-
cal 2)
13407 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.13) 0.0000
Tumor (categorical 1) 13891 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Tumor (categorical 2) 13891 1.06 (95% CI 1.00-1.12) 1.05 (95% CI 1.00-1.11) 0.0000
Sex 13933 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Age (continuous) 13921 1.06 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Age (categorical) 13921 1.06 (95% CI 1.01-1.12) 1.06 (95% CI 1.01-1.12) 0.0000
Hct (continuous) 11036 1.06 (95% CI 0.99-1.12) 1.06 (95% CI 1.00-1.13) 0.0000
Hct (categorical) 11036 1.06 (95% CI 0.99-1.12) 1.06 (95% CI 1.00-1.13) 0.0000
Baseline serum EPO
(continuous)
5651 1.03 (95% CI 0.94-1.12) 1.03 (95% CI 0.94-1.12) 0.1678
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Table 15. Bivariate analysis for overall survival in all cancer patients (Continued)
Baseline serum EPO
(categorical)
5651 1.03 (95% CI 0.94-1.12) 1.03 (95% CI 0.94-1.12) 0.0000
ECOG (0 vs 1 vs 2 vs 3
vs 4)
10112 1.08 (95% CI 1.01-1.15) 1.07 (95% CI 1.00-1.14) 0.0000
ECOG (0,1,2 vs 3,4) 10225 1.08 (95% CI 1.01-1.15) 1.08 (95% CI 1.01-1.16) 0.0000
BMI (categorical) 11445 1.05 (95% CI 0.99-1.12) 1.05 (95% CI 0.99-1.12) 0.0000
History of thromboem-
bolic events
9620 1.05 (95% CI 0.98-1.12) 1.05 (95% CI 0.98-1.12) 0.0218
History of cardiovascular
events
10322 1.05 (95% CI 0.99-1.13) 1.05 (95% CI 0.98-1.13) 0.0011
History of hypertension 9620 1.05 (95% CI 0.98-1.12) 1.05 (95% CI 0.98-1.12) 0.2436
History of diabetes mel-
litus
8025 1.06 (95% CI 0.99-1.14) 1.06 (95% CI 0.98-1.14) 0.0577
Geographical region
(categorical 1)
13532 1.05 (95% CI 1.00-1.12) 1.06 (95% CI 1.00-1.12) 0.0000
Metastatic vs non-
metastatic
12152 1.06 (95% CI 1.00-1.13) 1.05 (95% CI 0.99-1.12) 0.0000
Time from cancer diag-
nosis to randomization
4586 1.06 (95% CI 0.97-1.17) 1.06 (95% CI 0.97-1.16) 0.0000
*The LR test compares the adjusted with the unadjusted model. It takes into account the entire model, not only the overall hazard
ratio.
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Based on these analyses and the number of data available for each
variable, we conducted four different models, all of which are
presented in Table 16. For model 1 we included the variables age,
sex, Hb at baseline and tumor type into the model. For model 2
we used the same variables as in model 1 plus tumor stage. For
model 3 we used the same variables as in model 1 plus BMI and
region, for model 4 we used the same variables as in model 1 and 3
plus ECOGand hematocrit. For the continuous variables age,Hb,
serum EPO and BMI the association between the exposure and
the outcome was not linear (graph not shown). Therefore, these
continuous variables were converted into prespecified categories.
Hematocrit was converted into categories as well for the ease of
interpretation. The variables serum EPO and time from cancer
diagnosis to randomization were excluded because too many data
weremissing.When history of thromboembolic events and history
of cardiovascular events were included in model 1 (each at a time),
the overall results were also not changed (data on file).
Table 16. Multivariate analyses for overall survival in all cancer patients
Overall survival all can-
cer patients
Model 1 Model 2 Model 3 Model 4
Patients included n=13353 n=11636 n=10599 n=6547
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ESA vs ctrl unadjusted* 1.06 (95% CI 1.00-
1.12)
1.06 (95% CI 1.00-
1.13)
1.04 (95% CI 0.98-
1.11)
1.07 (95% CI 0.99-
1.15)
ESA vs ctrl adjusted** 1.06 (95% CI 1.00-
1.12)
1.05 (95% CI 1.00-
1.12)
1.04 (95% CI 0.98-
1.11)
1.09 (95% CI 1.01-
1.17)
Hb at baseline
Hb < 8 g/dL 1 1 1 1
Hb 8-10 g/dL 0.77 (95% CI 0.68-
0.87)
0.72 (95% CI 0.63-
0.83)
0.78 (95% CI 0.68-
0.90)
0.86 (95% CI 0.70-
1.04)
Hb 10-12 g/dL 0.60 (95% CI 0.52-
0.68)
0.56 (95% CI 0.48-
0.64)
0.62 (95% CI 0.54-
0.71)
0.74 (95% CI 0.60-
0.92)
Hb 12-14 g/dL 0.48 (95% CI 0.41-
0.56)
0.45 (95% CI 0.38-
0.53)
0.52 (95% CI 0.44-
0.61)
0.71 (95% CI 0.55-
0.93)
Hb > 14 g/dL 0.40 (95% CI 0.33-
0.48)
0.39 (95% CI 0.32-
0.47)
0.44 (95% CI 0.36-
0.54)
0.69 (95% CI 0.48-
0.99)
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Table 16. Multivariate analyses for overall survival in all cancer patients (Continued)
Age at randomization
18 - 35 yrs 0.82 (95% CI 0.62-
1.07)
0.91 (95% CI 0.68-
1.22)
0.84 (95% CI 0.62-
1.13)
0.65 (95% CI 0.42-
1.00)
35 - 45 yrs 1 1 1 1
45 - 55 yrs 1.06 (95% CI 0.93-
1.21)
1.05 (95% CI 0.91-
1.20)
1.10 (95% CI 0.95-
1.28)
1.16 (95% CI 0.96-
1.40)
55 - 65 yrs 1.13 (95% CI 1.00-
1.28)
1.15 (95% CI 1.01-
1.31)
1.25 (95% CI 1.08-
1.44)
1.32 (95% CI 1.09-
1.58)
65 - 75 yrs 1.23 (95% CI 1.08-
1.39)
1.22 (95% CI 1.07-
1.40)
1.34 (95% CI 1.16-
1.55)
1.34 (95% CI 1.11-
1.62)
> 75 ys 1.32 (95% CI 1.14-
1.53)
1.40 (95% CI 1.19-
1.63)
1.39 (95% CI 1.17-
1.65)
1.31 (95% CI 1.06-
1.63)
Sex
Male 1 1 1 1
Female 0.79 (95% CI 0.73-
0.84)
0.81 (95% CI 0.75-
0.88)
0.80 (95% CI 0.74-
0.86)
0.77 (95% CI 0.70-
0.84)
Tumor category
Hematological malign. 1 1 1 1
Breast cancer 1.91 (95% CI 1.54-
2.37)
1.57 (95% CI 1.15-
2.13)
1.93 (95% CI 1.51-
2.46)
2.05 (95% CI 1.59-
2.65)
Head and neck cancer 2.57 (95% CI 1.87-
3.53)
2.31 (95% CI 1.56-
3.41)
2.56 (95% CI 1.79-
3.65)
3.38 (95% CI 1.96-
5.83)
Lung cancer 4.06 (95% CI 3.31-
4.99)
3.06 (95% CI 2.30-
4.07)
3.79 (95% CI 2.96-
4.86)
3.98 (95% CI 3.07-
5.16)
Gastrointestinal 3.08 (95% CI 2.49-
3.82)
2.90 (95% CI 2.15-
3.90)
3.11 (95% CI 2.42-
4.01)
3.27 (95% CI 2.51-
4.26)
Gynecological 2.19 (95% CI 1.70-
2.82)
1.67 (95% CI 1.20-
2.32)
2.33 (95% CI 1.74-
3.12)
2.86 (95% CI 2.11-
3.88)
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Table 16. Multivariate analyses for overall survival in all cancer patients (Continued)
Genitourinary 2.76 (95% CI 2.17-
3.50)
2.36 (95% CI 1.72-
3.22)
2.69 (95% CI 2.04-
3.55)
2.90 (95% CI 2.18-
3.87)
Other 3.21 (95% CI 2.55-
4.04)
2.94 (95% CI 2.15-
4.01)
3.24 (95% CI 2.48-
4.24)
3.35 (95% CI 2.52-
4.47)
Tumor stage
Metastatic or advanced - 1 - -
Not
metastatic/advanced
- 0.51 (95% CI 0.46-
0.57)
- -
Region
Northern America - - 1 1
Southern Europe - - 1.33 (95% CI 1.06-
1.68)
1.27 (95% CI 1.00-
1.61)
Australia & New
Zealand
- - 0.97 (95% CI 0.72-
1.31)
0.97 (95% CI 0.71-
1.32)
Eastern Europe - - 1.50 (95% CI 1.23-
1.82)
1.50 (95% CI 1.22-
1.83)
Northern Europe - - 1.59 (95% CI 1.29-
1.97)
1.61 (95% CI 1.29-
2.01)
Western Europe - - 1.47 (95% CI 1.19-
1.82)
1.47 (95% CI 1.18-
1.83)
Other - - 1.23 (95% CI 0.85-
1.77)
1.51 (95% CI 0.96-
2.37)
BMI
< 19 kg/m² - - 1 1
19-25 kg/m² - - 0.79 (95% CI 0.70-
0.88)
0.82 (95% CI 0.71-
0.94)
25-30 kg/m² - - 0.69 (95% CI 0.61-
0.77)
0.70 (95% CI 0.60-
0.81)
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Table 16. Multivariate analyses for overall survival in all cancer patients (Continued)
> 30 kg/m² - - 0.61 (95% CI 0.53-
0.71)
0.61 (95% CI 0.51-
0.72)
Hct at baseline
Hct <23.5% - - - 1
Hct 23.5%-29.4% - - - 0.84 (95% CI 0.63-
1.12)
Hct 29.4%-35.3% - - - 0.71 (95% CI 0.53-
0.96)
Hct 35.3%-41.2% - - - 0.61 (95% CI 0.44-
0.85)
>Hct 41.2% - - - 0.48 (95% CI 0.32-
0.72)
Performance score
ECOG 0, 1 or 2 - - - 1
*unadjusted HR based on the number of patients included in the respective model
**HR adjusted for the variables outlined in the respective columns
Summary points for objective 1:
• Across all cancer patients analyzed, ESAs increase the
risk for mortality over longest available follow-up when
compared with controls (HR 1.06, 95% CI 1.00-1.12,
n=13933).
• Available evidence does not support the hypothesis that
baseline imbalances of prognostic factors analyzed in-
fluenced the overall results.
Objective 2 for overall survival in all cancer patients
Aim: Is there a specific subgroup of patients that is at increased or
decreased risk to die when receiving ESAs compared to controls?
Are there design aspects at study level that influenced the effects
of ESA on survival?
We tested for interaction between ESA treatment and specific vari-
ables describing patient and study characteristics, results are out-
lined in Table 17, results with subgroup effects are outlined in
Appendix 8.
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Table 17. Assessment of interaction, overall survival in all cancer patients
Overall survival, all cancer patients Patients included P value for interaction
Total 13933
Patient level characteristics
Hb at baseline (continuous) 13407 0.7547
Hb at baseline (categorical 1) 13407 0.6326
Hb at baseline (categorical 2) 13407 0.8292
Tumor (categorical 1) 13891 0.2315
Tumor (categorical 2) 13891 0.2122
Sex plus 13933 0.1480
Age (continuous) 13921 0.3758
Age (categorical) 13921 0.2610
Hct (continuous) 11036 0.8998
Hct (categorical) 11036 0.0330
Baseline serum EPO (continuous) 5651 0.1424
Baseline serum EPO (categorical) 5651 0.8116
ECOG 10112 0.4115
ECOG (0,1,2 vs 3,4) 10225 0.4980
BMI (categorical) 11445 0.7189
History of thromboembolic events 9620 0.8964
History of cardiovascular events 10322 0.6886
History of hypertension 9620 0.5700
History of diabetes mellitus 8025 0.9435
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Table 17. Assessment of interaction, overall survival in all cancer patients (Continued)
Geographical region [region˙cat] 13532 0.9000
Metastatic vs non-metastatic 12152 0.8573
Planned Hb ceiling (categorical 1) 13730 0.3973
Planned Hb ceiling (categorical 2) 13730 0.5976
Study level characteristics
Placebo controlled 13933 0.2932
Randomization (adequate vs unclear) 13933 0.8042
Allocation (adequate vs unclear) 13933 0.4945
Endpoint overall survival 13933 0.3866
Designed for long term follow up (binary) 13933 0.6423
Year of last patient randomized into study
(categorical)
13933 0.1285
Source of data (company versus indepen-
dent)
13933 0.5736
Patient population (chemotherapy, radio-
chemo- therapy, none, mixed)
13933 0.1133
Iron category 13933 0.4786
Planned ESA treatment duration (categor-
ical)
13933 0.7393
Planned weekly ESA dosage (categorical) 13933 0.8780
Planned frequency of ESA administration
(categorical)
13933 0.0748
*P value for interaction based on LR test, patients with missing data are excluded from LR test
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Two variables (planned frequency,Hct at baseline) showed a statis-
tically significant (p<0.1) interaction term in the bivariate analysis
and was included in themultivariate model (model 1). This model
(model 1) included the variables, age and sex, Hb at baseline and
tumor category; for P values of LR test see Table 18.
Table 18. Overall survival in all cancer patient trials, test for interaction, univariate and multivariate models
Overall survival
in all cancer pa-
tients
Bivariate
ESA versus control
Multivariate
ESA versus control
Interaction
term
ESA*variable ESA*variable
Adjusted for - age, sex, Hb, tumor type
HR 95% CI P* HR 95% CI P*
Patient level
characteristics
Hct categorical 0.0330 0.1343
Patients
included
n = 11036 n = 10972
< 23.5% 1.66 1.18-2.34 1.54 1.09-2.18
23.5-29.4% 0.94 0.83-1.07 0.96 0.84-1.09
29.4-35.3% 1.10 0.99-1.21 1.08 0.98-1.19
35.3-41.2% 1.07 0.95-1.21 1.07 0.95-1.21
> 41.2% 1.02 0.82-1.26 1.04 0.84-1.29
Missing 1.08 0.93-1.24 - omitted omitted -
Overall,
unadjusted
1.06 0.99-1.12 - 1.06 0.99-1.12 -
Study level
characteristics
Planned fre-
quency of ESA
application
0.0748 0.1949
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Table 18. Overall survival in all cancer patient trials, test for interaction, univariate and multivariate models (Continued)
Patients
included
n = 13933 n = 13353
Three times per
week or more
frequent
1.07 0.98-1.18 1.07 0.97-1.15
Once per week 1.06 0.97-1.17 1.08 0.87-1.18
Every sec-
ond week or less
frequent
1.20 1.02-1.40 1.14 0.97-1.34
Other 0.90 0.77-1.05 - 0.91 0.78-1.06 -
Overall,
unadjusted
1.06 1.00-1.39 - 1.06 1.00-1.30 -
*P value LR test
Summary points for objective 2 for overall survival in all
cancer patients
• Two variables (ESA administration frequency, Hct at
baseline) were found to be statistically significant (p <
0.1) in bivariate analyses. Multivariate adjustments did
not markedly effect the estimates; however, correspond-
ing P values for interaction did not reach conventional
levels of significance.”
• Overall, available evidence does not support the hypoth-
esis that ESAs had different effects in sub-populations
that differed for any of the variables tested for overall
survival in all cancer patients.
Objective 1 for overall survival in chemotherapy trials
Aim: What is the effect of ESAs compared to control on overall
survival in this population and can the effect be explained by
baseline imbalances of prognostic factors?
A total of 38 studies with 10441 patients were included in the
overall survival analysis of patients undergoing chemotherapy. In
this analysis we included only studies where at least 70% of the
study population had received a myelosuppressive chemotherapy.
1888 out of 5676 patients randomized to ESA and 1667 out of
4765 patients randomized to controls died during on study phase
and subsequent follow-up. Median follow-up was 6.7 months
(IQR 3.4 to 15.7 months) in the ESA and 8.4 months (IQR 3.7
to 19.1 months) in the control arm. The hazard ratio for over-
all survival in chemotherapy patients receiving ESA compared to
controls was 1.04 (95% CI 0.97-1.11) based on the two-stage
log-rank fixed-effects meta-analysis. Based on a Cox model strat-
ified for study the overall result was 1.04 (95% CI 0.97-1.11).
For results of all statistical models applied see Table 19. For Forest
plot see Figure 15, for pooled Kaplan-Meier curve see Appendix
4. There was no evidence for heterogeneity between the trials (I-
square 5.3%, p=0.3775). There was no evidence for small study
effects: linear regression test p=0.7008, rank correlation test of
funnel plot asymmetry p=0.6782. For Funnel plot see Figure 16.
One study contributed about 14% weight to the overall analysis
(Pirker 2008). In this study (Pirker 2008) (study number 89335)
600 patients with untreated, extensive SCLC underwent chemo-
therapy and were randomized to receive ESA or placebo. Exclu-
sion of single studies at a time did only marginally influence the
overall results, see influence analysis Figure 17.
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Figure 15. Forest plot for overall survival in chemotherapy trials based on two-stage log-rank fixed-effect
meta-analysis
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Figure 16. Funnel plot (based on log-rank estimates) for overall survival in chemotherapy trials (subset
analysis)Explanation of terms used: Full text: highest publication achieved is a full text publicationAbstract:
highest publication achieved is an abstract publicationODAC: highest publication achieved is reporting of study
results in documents presented at ODAC hearingsUnpublished: to date the study was not published in any of
the sources mentioned above Date of reference: June 26th 2008
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Figure 17. Influence analysis for overall survival in chemotherapy trials
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Table 19. Overall survival for chemotherapy trials
Model ESA versus control
HR (95% CI)
P value* I² P value**
Two-stage log-rank
fixed-effect model
1.04 (95% CI 0.97-
1.11)
0.2634 5.3% 0.3775
Two-stage log-rank ran-
dom-effect model
1.04 (95% CI 0.97-
1.12)
0.2774 5.3% 0.3775
Two-stage Cox fixed-ef-
fect model
1.04 (95% CI 0.97-
1.11)
0.3081 0% 0.6828
Two-stage Cox random-
effects model
1.04 (95% CI 0.97-
1.11)
0.3081 0% 0.6828
Cox model stratified by
study
1.04 (95% CI 0.97-
1.11)
0.263 - 0.2359
*LR test, ** for test of heterogeneity
Assessment of potential confounders for objective 1
In the next step we conducted bivariate analyses: adjusting overall
survival based on the Cox model stratified by study for one vari-
able at the time. All variables assessed relate to the individual pa-
tient data level. The results of the adjusted model were compared
with the unadjusted model using LR-Test. Results of unadjusted
and adjusted models as well as P values of LR-Test are shown in
Table 20. We included only patients with full information for the
respective variable; patients with missing, unknown or unreported
data were excluded. Data were often missing for entire studies;
therefore the overall HR might change because of the omission
of specific studies. We therefore present both unadjusted and ad-
justedHRs based on the patient data set available for each variable.
Table 20. Bivariate analysis for overall survival in chemotherapy trials
Overall survival for
chemotherapy patients
Patients included ESA versus control
Unadjusted hazard ratio
(95% CI)
ESA versus control
Adjusted hazard ratio
(95% CI)
P value LR-Test*
Total 10441 1.04 (95% CI 0.97-1.11) - -
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Table 20. Bivariate analysis for overall survival in chemotherapy trials (Continued)
Hb at baseline (continu-
ous)
9945 1.04 (95% CI 0.97-1.11) 1.05 (95% CI 0.98-1.12) 0.0000
Hb at baseline (categori-
cal 1)
9945 1.04 (95% CI 0.97-1.11) 1.05 (95% CI 0.98-1.12) 0.0000
Hb at baseline (categori-
cal 2)
9945 1.04 (95% CI 0.97-1.11) 1.05 (95% CI 0.98-1.12) 0.0000
Tumor (categorical 1) 10399 1.04 (95% CI 0.97-1.11) 1.04 (95% CI 0.97-1.11) 0.0000
Tumor (categorical 2) 10399 1.04 (95% CI 0.97-1.11) 1.03 (95% CI 0.97-1.11) 0.0000
Sex 10441 1.04 (95% CI 0.97-1.11) 1.04 (95% CI 0.97-1.11) 0.0000
Age (continuous) 10430 1.04 (95% CI 0.97-1.11) 1.04 (95% CI 0.97-1.11) 0.0000
Age (categorical) 10430 1.04 (95% CI 0.97-1.11) 1.04 (95% CI 0.97-1.11) 0.0000
Hct (continuous) 7849 1.03 (95% CI 0.96-1.11) 1.04 (95% CI 0.97-1.12) 0.0000
Hct (categorical) 7849 1.03 (95% CI 0.96-1.11) 1.04 (95% CI 0.97-1.12) 0.0000
Baseline serum EPO
(continuous)
3959 0.97 (95% CI 0.88-1.07) 0.97 (95% CI 0.88-1.07) 0.1538
Baseline serum EPO
(categorical)
3959 0.97 (95% CI 0.88-1.07) 0.97 (95% CI 0.88-1.07) 0.0000
ECOG (0 vs 1 vs 2 vs 3
vs 4)
8057 1.04 (95% CI 0.97-1.12) 1.04 (95% CI 0.96-1.12) 0.0000
ECOG (0,1,2 vs 3,4) 8057 1.04 (95% CI 0.97-1.12) 1.04 (95% CI 0.97-1.12) 0.0000
BMI (categorical) 8882 1.02 (95% CI 0.95-1.10) 1.03 (95% CI 0.95-1.10) 0.0000
History of thromboem-
bolic events
6667 1.04 (95% CI 0.95-1.13) 1.03 (95% CI 0.95-1.12) 0.0194
History of cardiovascular
events
7369 1.04 (95% CI 0.96-1.13) 1.04 (95% CI 0.96-1.13) 0.0033
History of hypertension 6667 1.04 (95% CI 0.95-1.13) 1.03 (95% CI 0.95-1.12) 0.5565
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Table 20. Bivariate analysis for overall survival in chemotherapy trials (Continued)
History of diabetes mel-
litus
5579 1.04 (95% CI 0.95-1.14) 1.05 (95% CI 0.95-1.15) 0.0253
Geographical region [re-
gion˙cat]
10053 1.03 (95% CI 0.97-1.10) 1.03 (95% CI 0.97-1.11) 0.1689
Metastatic vs non-
metastatic
8956 1.06 (95% CI 0.98-1.13) 1.04 (95% CI 0.97-1.12) 0.0000
Time from cancer diag-
nosis to randomization
3114 1.01 (95% CI 0.91-1.13) 1.01 (95% CI 0.91-1.13) 0.7895
*This test compares the adjusted with the unadjusted model. It takes into account the entire model, not only the overall hazard ratio.
Based on these analyses and the number of data available for each
variable, we conducted four different models, all of which are pre-
sented in Table 21. For model 1 we included the variables age, sex,
and Hb at baseline and tumor type into the model. For model 2
we used the same variables as in model 1 plus tumor stage. For
model 3 we used the same variables as in model 1 plus BMI and
region, for model 4 we used the same variables as in model 1 and
3 plus ECOG and hematocrit. For the continuous variables age,
Hb, serum EPO and BMI the association between the exposure
and the outcome was not linear (graph not shown). Therefore,
these continuous variables were converted into prespecified cate-
gories. Hematocrit was converted into categories as well for the
ease of interpretation. When history of thromboembolic events,
history of cardiovascular events and history of diabetes mellitus
were included in model 1 (each at a time) the overall results were
also not altered (data on file).
Table 21. Multivariate models for overall survival in chemotherapy trials
Overall survival, che-
motherapy trials
Model 1 Model 2 Model 3 Model 4
Patients included n=9892 n=8469 n=8030 n=5109
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
ESA vs ctrl unadjusted* 1.04 (95% CI 0.97-
1.11)
1.05 (95% CI 0.98-
1.13)
1.01 (95% CI 0.94-
1.09)
1.02 (95% CI 0.94-
1.11)
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Table 21. Multivariate models for overall survival in chemotherapy trials (Continued)
ESA vs ctrl adjusted** 1.05 (95% CI 0.98-
1.12)
1.05 (95% CI 0.98-
1.13)
1.02 (95% CI 0.94-
1.10)
1.04 (95% CI 0.96-
1.14)
Hb at baseline
Hb < 8 g/dL 1 1 1 1
Hb 8-10 g/dL 0.85 (95% CI 0.73-
0.99)
0.79 (95% CI 0.66-
0.94)
0.87 (95% CI 0.74-
1.03)
0.97 (95% CI 0.76-
1.23)
Hb 10-12 g/dL 0.67 (95% CI 0.57-
0.79)
0.62 (95% CI 0.51-
0.74)
0.72 (95% CI 0.60-
0.86)
0.83 (95% CI 0.64-
1.07)
Hb 12-14 g/dL 0.53 (95% CI 0.44-
0.64)
0.49 (95% CI 0.40-
0.60)
0.59 (95% CI 0.48-
0.72)
0.78 (95% CI 0.58-
1.05)
Hb > 14 g/dL 0.44 (95% CI 0.35-
0.56)
0.41 (95% CI 0.32-
0.53)
0.48 (95% CI 0.37-
0.62)
0.76 (95% CI 0.51-
1.13)
Age at randomization
18 - 35 yrs 0.79 (95% CI 0.59-
1.07)
0.89 (95% CI 0.65-
1.22)
0.83 (95% CI 0.59-
1.15)
0.56 (95% CI 0.34-
0.91)
35 - 45 yrs 1 1 1 1
45 - 55 yrs 1.09 (95% CI 0.94-
1.26)
1.07 (95% CI 0.91-
1.25)
1.15 (95% CI 0.97-
1.36)
1.19 (95% CI 0.96-
1.46)
55 - 65 yrs 1.16 (95% CI 1.01-
1.33)
1.18 (95% CI 1.02-
1.37)
1.32 (95% CI 1.11-
1.55)
1.33 (95% CI 1.08-
1.63)
65 - 75 yrs 1.29 (95% CI 1.11-
1.49)
1.28 (95% CI 1.09-
1.49)
1.42 (95% CI 1.20-
1.69)
1.41 (95% CI 1.14-
1.73)
> 75 ys 1.43 (95% CI 1.20-
1.70)
1.54 (95% CI 1.27-
1.86)
1.57 (95% CI 1.28-
1.93)
1.56 (95% CI 1.22-
2.00)
Sex
Male 1 1 1 1
Female 0.74 (95% CI 0.68-
0.80)
0.76 (95% CI 0.69-
0.83)
0.76 (95% CI 0.70-
0.83)
0.76 (95% CI 0.68-
0.84)
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Table 21. Multivariate models for overall survival in chemotherapy trials (Continued)
Tumor category
Hematological
malignancies
1 1 1 1
Breast cancer 1.88 (95% CI 1.46-
2.42)
1.50 (95% CI 0.98-
2.29)
1.87 (95% CI 1.39-
2.51)
1.98 (95% CI 1.44-
2.71)
Head and neck cancer 1.84 (95% CI 0.80-
4.23)
1.71 (95% CI 0.23-
12.7)
2.03 (95% CI 0.28-
14.97)
0.00
Lung cancer 4.15 (95% CI 3.19-
5.39)
2.99 (95% CI 1.92-
4.64)
4.37 (95% CI 3.09-
6.18)
5.02 (95% CI 3.47-
7.26)
Gastrointestinal 2.82 (95% CI 2.17-
3.67)
2.58 (95% CI 1.66-
3.99)
3.22 (95% CI 2.32-
4.46)
3.58 (95% CI 2.53-
5.07)
Gynecological 1.82 (95% CI 1.32-
2.51)
1.08 (95% CI 0.66-
1.76)
2.03 (95% CI 1.36-
3.01)
2.89 (95% CI 1.89-
4.44)
Genitourinary 2.29 (95% CI 1.54-
3.41)
1.86 (95% CI 0.97-
3.57)
1.91 (95% CI 1.05-
3.47)
2.37 (95% CI 1.21-
4.63)
Other 3.08 (95% CI 2.32-
4.09)
2.57 (95% CI 1.63-
4.03)
3.42 (95% CI 2.42-
4.83)
4.00 (95% CI 2.77-
5.77)
Tumor stage
Metastatic/advanced - 1 - -
Not
metastatic/advanced
- 0.48 (95% CI 0.41-
0.55)
- -
Region
Northern America - - 1 1
Southern Europe - - 0.87 (95% CI 0.63-
1.21)
0.82 (95% CI 0.58-
1.14)
Australia & New
Zealand
- - 0.73 (95% CI 0.50-
1.09)
0.69 (95% CI 0.46-
1.05)
Eastern Europe - - 0.97 (95% CI 0.71-
1.31)
0.96 (95% CI 0.70-
1.31)
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Table 21. Multivariate models for overall survival in chemotherapy trials (Continued)
Northern Europe - - 1.02 (95% CI 0.75-
1.40)
1.03 (95% CI 0.75-
1.43)
Western Europe - - 1.02 (95% CI 0.75-
1.39)
1.01 (95% CI 0.73-
1.38)
Other - - 0.80 (95% CI 0.52-
1.25)
0.97 (95% CI 0.58-
1.61)
BMI
< 19 kg/m² - - 1 1
19-25 kg/m² - - 0.83 (95% CI 0.72-
0.97)
0.87 (95% CI 0.74-
1.03)
25-30 kg/m² - - 0.75 (95% CI 0.64-
0.87)
0.78 (95% CI 0.66-
0.92)
> 30 kg/m² - - 0.64 (95% CI 0.54-
0.77)
0.63 (95% CI 0.52-
0.77)
Hct at baseline
Hct 0-23.5% - - - 1
Hct 23.5%-29.4% - - - 0.90 (95% CI 0.60-
1.34)
Hct 29.4%-35.3% - - - 0.81 (95% CI 0.54-
1.21)
Hct 35.3%-41.2% - - - 0.70 (95% CI 0.46-
1.07)
>Hct 41.2% - - - 0.55 (95% CI 0.34-
0.90)
Performance score
ECOG 0, 1 or 2 - - - 1
ECOG 3 or 4 - - - 2.24 (95% CI 1.70-
2.96)
*unadjusted HR based on the number of patients included in the respective model
** HR adjusted for the variables outlined in the columns
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Summary points for objective 1 overall survival in
chemotherapy trials
• Across studies with >70% of patients receiving chemo-
therapy, ESA treatment appeared to slightly increase the
risk of mortality over longest available follow-up (HR
1.04, 95% CI 0.97-1.11, n=10441).
• Available evidence does not support the hypothesis that
baseline imbalances of prognostic factors analyzed in-
fluenced the overall results.
Objective 2 for overall survival in chemotherapy trials
Aim: Is there a specific subgroup of patients that is at increased or
decreased risk to die when receiving ESAs compared to controls?
Are there design aspects at study level that influenced the effects
of ESA on survival?
We conducted subgroup analyses for each patient and study char-
acteristic variable at the time and tested for interaction between
ESA treatment and specific variables describing patient and study
characteristics. Results of tests for interactions are outlined inTable
22, results for subgroup estimates are outlined in Appendix 9.
Table 22. Assessment of interaction for overall survival in chemotherapy trials
Overall survival, chemotherapy patients Patients included P value for interaction
Total included 10441 (100%)
Patient level characteristics
Hb at baseline (continuous) 9945 0.4909
Hb at baseline (categorical 1) 9945 0.8848
Hb at baseline (categorical 2) 9945 0.9844
Tumor (categorical 1) 10399 0.3301
Tumor (categorical 2 10399 0.3287
Sex 10441 0.0370
Age (continuous) 10430 0.4055
Age (categorical) 10430 0.4024
Hct (continuous) 7849 0.2527
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Table 22. Assessment of interaction for overall survival in chemotherapy trials (Continued)
Hct (categorical 7849 0.2445
Baseline serum EPO (continuous) 3959 0.9996
Baseline serum EPO (categorical) 3959 0.4910
ECOG 8057 0.3408
ECOG (0,1,2 vs 3,4) 8057 0.9230
BMI (categorical) 8882 0.5227
History of thromboembolic events 6667 0.6838
History of cardiovascular events 7369 0.7809
History of hypertension 6667 0.9079
History of diabetes mellitus 5579 0.6186
Geographical region [region˙cat] 10053 0.9283
Metastatic vs non-metastatic 8956 0.6040
Planned Hb ceiling (categorical 1) 10362 0.5706
Planned Hb ceiling (categorical 2) 10362 0.7743
Study level characteristics
Placebo controlled 10441 0.7668
Randomization (adequate vs unclear) 10441 0.9035
Allocation (adequate vs unclear) 10441 0.2609
Endpoint overall survival 10441 0.5819
Designed for long term follow up (binary) 10441 0.4744
Year of last patient randomized into study
(categorical)
10441 0.1793
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Table 22. Assessment of interaction for overall survival in chemotherapy trials (Continued)
Source of data (company versus indepen-
dent)
10441 0.5404
Iron category 10441 0.4098
Planned ESA treatment duration (categor-
ical)
10441 0.7156
Planned weekly ESA dosage (categorical) 10441 0.3738
Planned frequency of ESA administration
(categorical)
10441 0.1562
*P value for interaction based on LR test, patients with missing data are excluded from LR test
Only one variable (sex) showed a statistically significant interaction
term in the bivariate analysis. Women were at increased risk to die
when receiving ESAs (HR 1.10, 95% CI 1.01-1.21) compared
to men (HR 0.96, 95% CI 0.87-1.06, P value for interaction:
0.0370). When adjusting in addition for age, Hb at baseline and
tumor category, the modifying effect for sex remained (P value for
interaction 0.0362) (Table 23). For additional exploratory analyses
see Appendix 4.
Table 23. Overall survival in chemotherapy trials, tests for interaction, univariate and multivariate models
Overall survival
in
chemotherapy
trials
Bivariate
ESA versus control
Multivariate
ESA versus control
Interaction
term
ESA*sex ESA*sex
Adjusted for - age, sex, Hb, tumor type
Patients
excluded
- -
Patients
included
n = 10441 n = 9892
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Table 23. Overall survival in chemotherapy trials, tests for interaction, univariate and multivariate models (Continued)
ESA versus con-
trol
HR 95% CI P* HR 95% CI P*
Sex
Male 0.96 0.87-1.06 0.0370 0.97 0.87-1.07 0.0362
Female 1.10 1.01-1.21 1.12 1.02-1.22
Overall result,
unadjusted
1.04 0.97-1.11 - 1.04 0.97-1.11 -
*P value LR test comparing model with and without interaction term
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Summary points for objective 2 for overall survival in
chemotherapy patients
• Within the chemotherapy population there was no con-
vincing evidence to support the hypothesis that ESAs
had different effects in sub-populations that differed for
any of the variables tested.
• However, effectmodification of sex cannot be explained
by confounding with other patient characteristics (Hb,
age, sex, tumor type), see also Appendix 4.
Survival at predefined time points
In addition to the endpoints “on study mortality” and “overall
survival”, we specifically examined the following prespecified time
points: survival at 4, 8, 12, 24, 36 and 60months after randomiza-
tion. We conducted these analyses in two different data sets: one
analysis was based on the “on study mortality” data set. In this data
set all patients were censored after the end of active treatment plus
a follow-up window of 28 days. In contrast in the overall survival
analysis patients were followed up after the end of active study
treatment phase (exception: studies with “cross-over” after end of
study period). When comparing the numbers of death at specific
time points, the number of patients who died was higher in the
overall survival data set compared to the on study mortality data
set at 4, 8 and 12 months. The point estimates for HRs of overall
survival appear smaller, but confidence intervals are wide, with
substantial overlap. Several reasons might explain this observation:
patients in both active and control arm might have received ESAs
after end of study period, the underlying disease might dominate
the picture after the end of ESA treatment and there might be
losses to follow-up since not all studies were designed for a long-
term active follow-up.We conducted a sensitivity analysis for stud-
ies, which had an active follow-up after the end of ESA treatment
period at least additional 12 months, see Appendix 3.
Survival at predefined time points: including all studies
see Table 24, Table 25, Table 26, and Table 27
Table 24. Survival at predefined time points for all cancer patients*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 1193 1.13 (95% CI
1.01-1.27)
0.036 1419 1.12 (95% CI 1.01-1.24) 0.038
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Table 24. Survival at predefined time points for all cancer patients* (Continued)
At 8 months 1425 1.16 (95% CI
1.04-1.29)
0.006 2678 1.06 (95% CI 0.98-1.14) 0.140
At 12 months 1507 1.17 (95% CI
1.06-1.30)
0.002 3561 1.06 (95% CI 0.99-1.14) 0.071
At 24 months - - - 4537 1.06 (95% CI 1.00-1.13) 0.042
At 36 months - - - 4833 1.05 (95% CI 0.99-1.12) 0.075
At 60 months - - - 4977 1.06 (95% CI 1.00-1.12) 0.043
*13933 patients from all treatment populations were under observation.
**based on Cox fixed-effects model stratified by study
Table 25. Survival at predefined time points for all chemotherapy trials*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 792 1.03 (95% CI
0.89-1.18)
0.705 948 1.06 (95% CI 0.93-1.21) 0.383
At 8 months 992 1.08 (95% CI
0.95-1.23)
0.225 1870 0.99 (95% CI 0.91-1.09) 0.886
At 12 months 1072 1.10 (95% CI
0.98-1.25)
0.117 2552 1.01 (95% CI 0.93-1.09) 0.797
At 24 months - - - 3246 1.04 (95% CI 0.97-1.11) 0.312
At 36 months - - - 3452 1.03 (95% CI 0.96-1.10) 0.368
At 60 months - - - 3544 1.04 (95% CI 0.97-1.11) 0.257
*10441 patients from the chemotherapy treatment population were under observation.
**based on Cox fixed-effects model stratified by study
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Table 26. Survival at predefined time points for radiotherapy and radiochemotherapy trials*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths Overall survival
HR (95% CI)*
P value
At 4 months 74 1.40 (95% CI
0.88-2.23)
0.152 114 1.16 (95% CI 0.80-1.67) 0.440
At 8 months 82 1.51 (95% CI
0.97-2.35)
0.067 300 1.20 (95% CI 0.95-1.50) 0.119
At 12 months 82 1.51 (95% CI
0.97-2.35)
0.067 442 1.12 (95% CI 0.93-1.35) 0.235
At 24 months - - - 686 1.05 (95% CI 0.91-1.22) 0.498
At 36 months - - - 774 1.02 (95% CI 0.89-1.18) 0.753
At 60 months - - - 826 1.03 (95% CI 0.90-1.18) 0.653
*1536 patients from the radiotherapy and radiochemotherapy treatment population were under observation.
**based on Cox fixed-effects model stratified by study
Table 27. Survival at predefined time points for patients from the “mixed” treatment group*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths HR (95% CI)**
ESA versus con-
trol
On study mortal-
ity
data set
P value Deaths HR (95% CI)*
Overall survival
data set
P value
At 4 months 24 1.53 (95% CI
0.63-3.69)
0.335 24 1.53 (95% CI 0.63-3.69) 0.335
*266 patients from two studies under observation, both studies included CLL patients only, patients received either chemotherapy or
corticosteroids only. Since follow up in these studies was short data are provided at 4 months only.
**based on Cox fixed-effects model stratified by study
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Sensitivity analysis: survival at predefined time points
including only studies with long-term follow-up
The outputs of Table 28, Table 29, Table 30, Table 31, Table 32,
and Table 33 were restricted to studies that were designed for long-
term follow-up. Long-term follow-up was defined as follow-up of
at least 12 months after end of treatment phase.
Table 28. Survival at predefined time points in trials without concomitant radiotherapy and/or chemotherapy*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 303 1.35 (95% CI
1.07-1.71)
0.010 333 1.27 (95% CI 1.02-1.58) 0.035
At 8 months 327 1.32 (95% CI
1.06-1.65)
0.013 484 1.24 (95% CI 1.03-1.48) 0.021
At 12 months 329 1.33 (95% CI
1.06-1.66)
0.012 543 1.28 (95% CI 1.08-1.52) 0.005
At 24 months - - - 581 1.22 (95% CI 1.04-1.44) 0.017
At 36 months - - - 583 1.22 (95% CI 1.04-1.44) 0.017
*1690 patients were under observation, patients were mainly not receiving chemotherapy or radiotherapy, table truncated after end of
follow up.
**based on Cox fixed-effects model stratified by study
Table 29. Survival at predefined time points for all cancer patients, long term follow up studies only*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 790 1.22 (95% CI
1.06-1.41)
0.005 965 1.17 (95% CI 1.03-1.33) 0.015
At 8 months 970 1.25 (95% CI
1.10-1.42)
0.001 2023 1.08 (95% CI 0.99-1.18) 0.097
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Table 29. Survival at predefined time points for all cancer patients, long term follow up studies only* (Continued)
At 12 months 1050 1.26 (95% CI
1.11-1.42)
<0.001 2823 1.08 (95% CI 1.00-1.16) 0.046
At 24 months - - - 3743 1.07 (95% CI 1.01-1.15) 0.032
At 36 months - - - 4028 1.06 (95% CI 0.99-1.13) 0.077
At 60 months - - - 4169 1.07 (95% CI 1.00-1.13) 0.041
*8974 patients from all treatment populations stemming from trials designed for long term follow up were under observation.
**based on Cox fixed-effects model stratified by study
Table 30. Survival at predefined time points in chemotherapy trials, long term follow up studies only*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 499 1.14 (95% CI
0.95-1.36)
0.153 604 1.14 (95% CI 0.97-1.34) 0.119
At 8 months 658 1.18 (95% CI
1.01-1.37)
0.040 1346 1.01 (95% CI 0.91-1.13) 0.842
At 12 months 738 1.20 (95% CI
1.03-1.39)
0.016 1952 1.03 (95% CI 0.94-1.13) 0.527
At 24 months - - - 2594 1.05 (95% CI 0.97-1.14) 0.191
At 36 months - - - 2789 1.04 (95% CI 0.97-1.12) 0.290
At 60 months - - - 2878 1.05 (95% CI 0.98-1.13) 0.182
*6509 patients from the chemotherapy treatment population stemming from trials that were designed for long term follow up were
under observation.
** Based on Cox fixed-effects model stratified by study
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Table 31. Survival at predefined time points in radiotherapy and radiochemotherapy trials, long term follow up studies only*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 74 1.40 (95% CI
0.88-2.23)
0.152 114 1.16 (95% CI 0.80-1.67) 0.440
At 8 months 82 1.51 (95% CI
0.97-2.35)
0.067 299 1.21 (95% CI 0.96-1.51) 0.107
At 12 months 82 1.51 (95% CI
0.97-2.35)
0.067 441 1.12 (95% CI 0.93-1.36) 0.219
At 24 months - - - 685 1.06 (95% CI 0.91-1.22) 0.477
At 36 months - - - 773 1.03 (95% CI 0.89-1.18) 0.729
At 60 months - - - 825 1.03 (95% CI 0.90-1.19) 0.631
*1476 patients from the radiotherapy and radiochemotherapy treatment population stemming from trials designed for long term follow
up were under observation.
**based on Cox fixed-effects model stratified by study
Table 32. Survival at predefined time points for patients from the “mixed” treatment group, long term follow up studies only*
Time after date
of
randomization
Deaths On study mortal-
ity
data set
P value Deaths Overall survival
data set
P value
At 4 months - - - - - -
*266 patients from two studies under observation, both studies included CLL patients only, patients received either chemotherapy
or corticosteroids only. Both studies were not designed for long term follow-up and are therefore not reported for this sensitivity
analysis.
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Table 33. Survival at predefined time points in trials without concomitant radiotherapy and/or chemotherapy, long term
follow up studies only*
On study mortality data set Overall survival data set
Time after date
of
randomization
Deaths ESA versus con-
trol
HR (95% CI)**
P value Deaths ESA versus control
HR (95% CI)*
P value
At 4 months 217 1.38 (95% CI
1.05-1.81)
0.018 247 1.26 (95% CI 0.98-1.62) 0.070
At 8 months 230 1.37 (95% CI
1.05-1.78)
0.018 378 1.23 (95% CI 1.00-1.51) 0.045
At 12 months 230 1.37 (95% CI
1.06-1.78)
0.018 430 1.27 (95% CI 1.05-1.54) 0.013
At 24 months - - - 464 1.22 (95% CI 1.02-1.47) 0.032
At 36 months - - - 466 1.22 (95% CI 1.02-1.47) 0.032
*989 patients were under observation, patients were mainly not receiving chemotherapy or radiotherapy, table truncated after end of
follow up, only patients stemming from studies with long term follow up were included. For the no treatment population this was
actually only one study.
**based on Cox fixed-effects model stratified by study
Sensitivity analyses
see Appendix 3
Exploratory analyses
see Appendix 4
Clinical relevance
To calculate the number needed to treat for an additional harmful
outcome (NNTH) we applied the overall estimate for on study
mortality for all cancer patients (HR 1.17; 95% CI 1.06 to 1.30)
to different hypothetical cancer populations (Altman 1999).With
an underlying survival probability of 95% at one year it is expected
that one additional person may die for every 121 participants
randomized to receive ESAs (NNTH 121, 95% CI 69 to 343).
With an underlying survival probability of 80% the NNTH is
34 (95% CI 19 to 94) and 24 (95% CI 14 to 67) for a survival
probability of 70%, see Table 34.
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Table 34. Clinical relevance for overall estimate of on study mortality applied to hypothetical populations
Underlying survival probability ESA versus control HR (95% CI) Number needed to treat (95% CI)
On study mortality, all cancer patients
95% 1.17 (95% CI 1.06-1.30) NNTH 121 (NNTH 69 to NNTH 343)
80% NNTH 34 (NNTH 19 to NNTH 94)
70% NNTH 24 (NNTH 14 to NNTH 67)
On study mortality, chemotherapy trials
95% 1.10 (95% CI 0.98-1.24) NNTH 206 (NNTH 86 to to NNTB 1026)
80% NNTH 57 (NNTH 24 to to NNTB 279)
70% NNTH 41 (NNTH 17 to to NNTB 200)
We also calculated the number needed to treat for an additional
harmful outcome (NNTH) for the on study mortality estimate
from chemotherapy trials. Note: the confidence intervals for this
estimate include 1.0which requires special considerationwhen cal-
culating confidence intervals for numbers needed to treat (Altman
1998).We applied the overall estimate for on studymortality from
chemotherapy trials (HR 1.10; 95% CI 0.98 to 1.24) to different
hypothetical cancer populations (Altman 1999). With an under-
lying survival probability of 95% at one year it is expected that one
additional person may die for every 206 participants randomized
to receive ESAs (95% CI NNTH 86 to to NNTB 1026). With
an underlying survival probability of 80% the NNTH is 57 (95%
CI NNTH 24 to to NNTB 279) and 41 (95% CI NNTH 17 to
to NNTB 200) for a survival probability of 70%, see also Table
34.
D I S C U S S I O N
Summary of main results
This individual patient data meta-analysis of 53 randomized clin-
ical trials in cancer patients found that ESAs caused an estimated
17% increase in mortality relative to control during the study pe-
riod and a relative increase of 6% when the longest available fol-
low-up was considered. The increase in mortality was less pro-
nounced in patients receiving chemotherapy, but this difference is
likely to be the product of chance.
Overall completeness and applicability of
evidence
Our analysis has a number of strengths. It was based on individual
patient data from 13933 patients who were enrolled in trials con-
ducted by manufacturers and independent investigators. We had
access to the study protocols and clinical study reports. All analy-
ses were based on the intention-to-treat principle, i.e. all patients
were evaluated in the treatment groups assigned at randomization;
analyses were conducted in duplicate by two independent, expe-
rienced groups. Only factors known before the onset of treatment
were considered as candidate effect modifiers. A striking finding
was that although the studies included clinically diverse popula-
tions, and different ESA regimens, we detected very little, if any
heterogeneity between trials. Sensitivity analyses confirmed the
robustness of the overall results.
Potential biases in the review process
Data were not available for some trials, in particular RCTs with
radiotherapy or radiochemotherapy (Overgaard 2007; Blohmer
2003; Antonadou 2001).However, inclusionof these studies based
on the results published in the literature did not change the overall
estimates. An important finding of this study is the absence of
strong modifiers of the effect of ESAs on mortality. Given the
large data set analyzed it seems unlikely that larger differences were
missed. However, uncertainty remains since smaller differences in
effects cannot be excluded with confidence.
Agreements and disagreements with other
studies or reviews
While most literature-based meta-analyses are limited by access to
aggregated data at study level only, our IPD meta-analysis con-
tained data on prognostic factors at patient level. Therefore, sub-
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group analyses based on the information for the individual patient
and statistical tests for modification of results by patient and study
characteristics could be analyzed across almost 14000 patients.
Another advantage is the harmonized definition and analysis of
different survival endpoints. I.e. we differentiated on study mor-
tality and overall survival, which included the longest follow-up
available. While overall survival aims to detect long-term effects,
confounders occurring after the end of active study phase cannot
be excluded. I.e. control patients may start ESA treatment, pro-
gression of the underlying malignancy may dominate the course
of disease and follow-up might be less rigorous leading to losses
to follow-up; all of these factors may dilute the overall effect. In-
deed, the overall survival estimates in our analyses were lower com-
pared to the on study mortality estimates. For the latter we re-
stricted follow-up to the study phase when patients were under
close and active observation and control of both ESA medication
and events. Thus, on study mortality presents the most reliable
information with respect to unconfounded assessment of the ef-
fects of ESAs during treatment period. This clear definition of
separate endpoints at different periods under observation distin-
guishes our IPD meta-analysis from literature based meta-analy-
ses, which must rely on the results as reported in the literature.
However, survival is often not reported or reported incompletely.
For example, in the reports identified for the 51 published studies
analyzed here, five studies did not report any survival data, 19 re-
ported on study mortality, 14 overall survival and only 13 reported
both endpoints; two studies were unpublished. Given the paucity
of published data previous literature-based meta-analyses (Bohlius
2006; Bennett 2008; Seidenfeld 2006) combined on study mor-
tality and overall survival data into one analysis, which led to an
underestimation of the effect size of ESAs on mortality.
Previous analyses hypothesized that poor study designs may have
produced biased results. In particular, some argued that baseline
imbalances favoring the control groups might partially explain
the increased mortality (Henke 2003; Leyland-Jones 2003; Smith
2008). Our analysis found no evidence that imbalances at baseline
in prognostic factors influenced the overall results. However, base-
line imbalances for prognostic factors not included in the present
analysis cannot be excluded. For the analysis of on study mortality
in chemotherapy we observed that studies with adequate report-
ing of concealment of allocation reported worse effect estimates
compared to studies with inadequate reporting of allocation pro-
cedures. In general, studies with adequate reporting of allocation
concealment are considered to indicate studies of higher quality.
Patients who were censored at a given point were often followed
for only four weeks after the last drug application but not until
the end of the planned treatment duration.
Epo receptors have been identified on the cell surface of numerous
cancer entities. Consequently, endogenously produced or exoge-
nously administered erythropoietins may stimulate proliferation
of cancer cells expressing these receptors (Arcasoy 2003; Arcasoy
2005; Dagnon 2005; McBroom 2005; Leo 2006). However, con-
troversy about the functionality of these receptors in tumor tissues
remains (Jelkmann 2008; Sinclair 2008). Data on Epo receptor
status of tumor tissues were not systematically collected in the in-
cluded trials and were therefore not available for the present study.
It was also hypothesized that the increase in hemoglobin levels as-
sociated with ESAs, particularly to beyond 15 g/dL, might impair
tumor control. Radiobiological data suggest that tumor hypoxia
is associated with an increased resistance to radiation induced tu-
mor cell kill due to lower production of cytotoxic free radicals (
Vaupel 2001). Thus, tumor hypoxia caused either by anemia or
excessively high hemoglobin levels and increased viscous resistance
may result in worse treatment outcomes (Vaupel 2002). Similarly,
it was argued, that high hemoglobin levels might increase the risk
for fatal thromboembolic and cardiovascular events. Trials directly
comparing different Hb targets in patients with renal impairment
found increased mortality in patients treated to higher Hb targets
(13.5 g/dL versus 11.3 g/dL)who had received higher ESA dosages
(mean 11215 units per week versus 6276 IU per week) (Singh
2006; Besarab 1998). Of note, ESA dosages applied in cancer pa-
tients are on average three to four times higher than the high ESA
doses reported in the study by Singh et al. We found no robust
evidence for an interaction between ESA treatment hemoglobin
ceilings, planned ESA dosages and mortality. However, our anal-
ysis was based on indirect comparisons only.
Other hypotheses relate to the effects of erythropoietins on the vas-
cular system and tumor tissues. There is increasing evidence that
ESAs might influence the vascular system including hematocrit-
independent hypertension, increased endothelin production and
stimulation of endothelial and vascular smooth muscle cell prolif-
eration which may contribute to an increased risk of thromboem-
bolic and cardiovascular events independent of Hb levels (Vaziri
1999; Fisher 2003; Stohlawetz 2000; Wun 2003). Intriguingly,
in our analysis patients with a history of thromboembolic events
were less likely to die when receiving ESAs compared to patients
without a history of thromboembolic events. One potential expla-
nation for the observed effect is the possibility that patients with
a history of thromboembolic events may have received better an-
ticoagulation precautions during cancer therapy and this measure
may have protected against the thrombogenic effects of ESAs. This
is in line with a finding from a randomized trial in critically ill pa-
tients indicating that patients receiving heparin were less likely to
develop thromboembolic events when receiving ESAs compared
to patients not receiving heparin (Corwin 2007). However, for
31% of our entire study population history of thromboembolic
events was not reported; thus, a selection bias cannot be excluded.
In conclusion, the evidence reported here is too weak to establish
a robust association between history of thromboembolic events
and effects of ESA on mortality during study in cancer patients.
There was some evidence that women were at increased risk to die
when receiving ESAs compared to men. This effect modification
was only observed for overall survival in chemotherapy patients,
however, for all other endpoints the risk for women to die when
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receiving ESAs ranged between HR 1.10 and HR 1.17, although
not statistically significant. The observed estimates were attenu-
ated when excluding patients with breast cancer and other cancers
that occur in women or men only. Further investigation is needed
to clarify this observation.
We also observed a modifying effect of baseline Hct on mortal-
ity during active study phase and long-term follow-up. Patients
with low hematocrit at baseline (< 23.5%) were more likely to die
when receiving ESAs compared to patients with higher hematocrit
values. This observed effect was robust when adjusting for other
prognostic factors such as tumor stage and ECOG performance
status. Similarly, patients with baseline Hb below 8 g/dL were at
increased risk to die compared to others, although this effect was
not statistically significant in any of the analyses. This observation
may indicate that low hematocrit values are a surrogate for poor
risk patients and that these patients might be more vulnerable to
harm from ESAs. However, data for 21% of patients were missing
leaving uncertainty to the validity of this finding.
Patients receiving ESAs three times per week or more frequently
were not at increased risk to die compared to patients who received
ESAs only once per week. This was observed for on studymortality
analyses but not for the overall survival analyses. However, the data
did not show a dose response relationship and the observed effect
was confounded by other study design aspects such as planned
dose of ESA, year of study conduct and primary endpoint of the
study. The effect was not observed for the overall survival analysis.
Of particular interest is the possibility that ESAs have less poten-
tial harm in patients receiving chemotherapy compared to patients
receiving radiochemotherapy, radiotherapy or no anticancer treat-
ment. Mortality was increased in patients from chemotherapy tri-
als by 10% (HR 1.10, 95% CI 0.98 to 1.24). From a statistical
point of view the estimated increase in mortality from the chemo-
therapy trials is compatible with that obtained from other treat-
ment group (including radiochemotherapy, radiotherapy, none
and other, p=0.42 for difference). From a clinical point of view, pa-
tients not receiving myelosuppressive anticancer treatment might
be more likely to experience higher hemoglobin levels leading to
thromboembolic events and impaired tumor control, as discussed
above. However, in the present analysis we found little evidence
to support this notion.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In conclusion, this large scale individual patient data meta-anal-
ysis found that ESAs increase mortality in cancer patients, and
such an increase is also likely in patients receiving chemotherapy.
Most randomized studies and previous meta-analyses have shown
that ESAs increase hemoglobin levels, decrease the need for red
blood cell transfusions and spare some patients from transfusions
(Seidenfeld 2001; Bohlius 2005). A recent meta-analysis also sug-
gested that ESAsmay effectively reduce fatigue (Minton 2008). In
clinical practice the increased risks of death and thromboembolic
events (Bohlius 2006; Bennett 2008) must be balanced against the
possible benefits of ESAs on quality of life, taking into account the
clinical circumstances and preferences of the individual patient.
Implications for research
More data are needed on ESAs effect on quality of life and an
individual patient data meta-analysis project similar to this will be
needed to address this question.
Further research is also needed to clarify mechanisms and path-
ways of ESAs effects at the cellular and molecular levels for both
potential tumor growth stimulation and thrombogenic effects of
ESAs.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aapro 2008
Methods randomized controlled trial, not placebo-controlled
Participants n = 463, breast cancer (M1); concomitant treatment: chemotherapy
Interventions drug = Epoetin beta
dose = 30000 IU sc weekly
hb-target = 13-15 d/dL
planned ESA duration = 24 weeks
Outcomes Primary: overall survival; secondary: progression free survival, tumor response rate, QoL
Notes study number = 97413
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Abels 1993
Methods randomized controlled trial, placebo-controlled
Participants n = 124, hematological malignancies, genitourinary, gastrointestinal, other cancer; no anticancer
therapy
Interventions drug = Epoetin alpha
dose = 100 IU/kg sc TIW
hb-target = not reported
planned ESA duration = 8 weeks
Outcomes Primary: transfusion, Hct; secondary: QoL, safety
Notes study number = 98906
Risk of bias
Item Authors’ judgement Description
113Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Abels 1993 (Continued)
Adequate sequence generation? Yes computer-generated
Allocation concealment? Unclear each patient was assigned a random identification number and was assigned
to a treatment group by a computerized randomization schedule
Boogaerts 2003
Methods randomized controlled trial, not placebo-controlled
Participants n = 259, multiple myeloma, Non-Hodgkin lymphoma, chronic lymphocytic leukemia, Hodgkin
disease, ovarian, bone, gastrointestinal, respiratory, other cancer; concomitant treatment: chemo-
therapy
Interventions drug = Epoetin beta
dose = 150 IU/kg sc TIW
hb-target = 12-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: QoL; secondary: direct and indirect costs
Notes study number = 36158
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Case 1993
Methods randomized controlled trial, placebo-controlled
Participants n = 157, hematological malignancies, breast, lung, gynecological, gastrointestinal, other cancer;
concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = Hct 38%-40%
planned ESA duration = 12 weeks
Outcomes Transfusion, Hct, QoL, safety
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Case 1993 (Continued)
Notes study number = 34917
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated
Allocation concealment? Unclear description is unclear
Cazzola 1995
Methods randomized controlled trial, not placebo-controlled
Participants n = 143, multiple myeloma, Non-Hodgkin lymphoma; concomitant treatment: chemotherapy
Interventions drug = Epoetin beta
dose = a: 1000 IU sc 7x/week, b: 2000 IU sc 7x/week; c: 5000 IU sc 7x/ week; d: 10000 IU sc
7x/week
hb-target = 11-13 g/dL (MM), 11-15 g/dL (NHL)
planned ESA duration = 8 weeks
Outcomes Primary: Hb response; secondary: Hb, Hct, reticulocytes, iron, ferritin, safety
Notes study number = 37653
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization list
Allocation concealment? Yes central randomization
CC2574-P-174
Methods randomized controlled trial, placebo-controlled
Participants n = 45, chronic lymphocytic leukemia (any stage); concomitant therapy: other
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CC2574-P-174 (Continued)
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = Hct 38%-40%
planned ESA duration = 12 weeks
Outcomes Primary: Hct; secondary: Hb, transfusion, QoL, safety
Notes study number = 60584
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Unclear no description
Chang 2005
Methods randomized controlled trial, not placebo-controlled
Participants n = 354, breast cancer (stage I-IV); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: QoL; secondary: maintain Hb above 12 g/dL, tumor response, overall survival
Notes study number = 99137
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
116Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Charu 2007
Methods randomized controlled trial, not placebo-controlled
Participants n = 287, lymphoma, breast, lung, gastrointestinal, genitourinary, gynecologic, other cancer; no
anticancer therapy
Interventions drug = Darbepoetin alpha
dose = 3.0 µg/kg sc Q2W
hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: hospitalization days; secondary: costs, QoL, transfusion, Hb, safety
Notes study number = 53081
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Dammacco 2001
Methods randomized controlled trial, placebo-controlled
Participants n = 145, multiple myeloma; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 12-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: transfusion; secondary: Hb, Hct, reticulocytes, serum erythropoietin levels, QoL
Notes study number = 11220
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization schedule prepared by RWJPRI
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Dammacco 2001 (Continued)
Allocation concealment? Unclear two randomization lists (patients previously transfused or not), when pa-
tient enters the study the next number was to be assigned
Debus 2006
Methods randomized controlled trial, not placebo-controlled
Participants n = 385, non-small cell lung cancer (stage III, primarily inoperable); concomitant treatment:
radiochemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12-14 g/dL, in 11/2003 reduced to 12-13 g/dL
planned ESA duration = during chemotherapy and radiotherapy
Outcomes Primary: 2-year-survival rate; secondary: tumor response, QoL, tolerance to epoetin alpha, Hb
change, transfusion, safety
Notes study number = 83322
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization code provided by OrthoBiothech
Allocation concealment? Unclear assigned envelopes, sequentially numbered, but it is unclear whether they
were sealed and opaque
EPO-GBR-7
Methods randomized controlled trial, not placebo-controlled
Participants n = 300, head and neck cancer (stage I-IV); concomitant treatment: radiotherapy
Interventions drug = Epoetin alpha
dose = if Hb < 12.5 10000 IU sc TIW; if Hb > 12.5 4000 IU sc TIW
hb-target = 12.5-15 g/dL
planned ESA duration = during radiotherapy
Outcomes Primary: local disease free survival; secondary: overall survival, QoL, safety
Notes study number = 81645
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EPO-GBR-7 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear central randomization schedule stratified by the study site was generated
by the sponsor
Allocation concealment? Unclear no description
EPO-GER-20
Methods randomized controlled trial, not placebo-controlled
Participants n = 93, small cell lung cancer (extensive stage); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 10000 IU sc TIW
hb-target = 12-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: rate of patients with anemia; secondary:QoL, tolerability of ESA, transfusion, effectiveness
of chemotherapy
Notes study number = 31678
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were assigned with a randomization code provided by Janssen-
Cilag
Allocation concealment? Unclear assigned envelopes, sequentially numbered, but it is unclear whether they
were sealed and opaque
EPO-INT-1
Methods randomized controlled trial, placebo-controlled
Participants n = 246, ovarian cancer (stage I-IV); concomitant treatment: chemotherapy
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EPO-INT-1 (Continued)
Interventions drug = Epoetin alpha
dose = a: 150 IU/kg sc TIW; b: 300 IU/kg sc TIW
hb-target = 12.5 to 14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: transfusion; secondary: Hb change, Hct, QoL
Notes study number = 53915
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Unclear no description
EPO-INT-3
Methods randomized controlled trial, placebo-controlled
Participants n = 200, breast, Non-Hodgkin lymphoma, multiple myeloma, ovarian, small cell lung cancer, other
cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 12-14 g/dL (women), 14-16 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: Transfusion; secondary: Hb, QoL
Notes study number = 36274
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear according to randomization schedule prepared by RWJPRI
Allocation concealment? Yes central randomization
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Gordon 2006
Methods randomized controlled trial, placebo-controlled
Participants n = 220, breast, non-myeloid hematological malignancies, gastrointestinal, genitourinary, lung,
gynecological, other cancer (stage I-IV); no anticancer therapy
Interventions drug = Darbepoetin alpha
dose = 6.75 µg/kg sc Q4W
hb-target = 12-13 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: Hb response; secondary: transfusion, Hb change, QoL, safety
Notes study number = 65772
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization list will be centrally generated by Amgen
Allocation concealment? Yes central randomization
Goss 2005
Methods randomized controlled trial, placebo-controlled
Participants n = 104, small cell lung cancer (limited disease); concomitant treatment: radiochemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 14-16 g/dL, in 10/2002 reduced to 13-14 g/dL
planned ESA duration = during chemotherapy and radiotherapy
Outcomes Disease progression free survival, tumor response, overall survival, local disease progression, Hb,
transfusion, QoL
Notes study number = 55703
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
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Goss 2005 (Continued)
Allocation concealment? Yes central randomization
Grote 2005
Methods randomized controlled trial, placebo-controlled
Participants n = 224, small cell lung cancer (limited and extensive disease); concomitant treatment: chemother-
apy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 14-16 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: assess possible stimulatory effects of ESA on solid tumor growth, tumor response; sec-
ondary: overall survival, Hb, transfusion, safety
Notes study number = 73807
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated
Allocation concealment? Unclear description is unclear
Hedenus 2003
Methods randomized controlled trial, placebo-controlled
Participants n = 349, Hodgkin disease, Non-Hodgkin lymphoma, multiple myeloma, chronic lymphocytic
leukemia, Waldenstrom´ s disease; concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = 2.25 µg/kg sc weekly
hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: Hb response; secondary: transfusion, Hb change, QoL, safety
Notes study number = 63455
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Hedenus 2003 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear based on a schedule specified by Amgen before the start of the study
Allocation concealment? Yes central randomization
Henke 2003
Methods randomized controlled trial, placebo-controlled
Participants n = 351, head and neck cancer (advanced, stage III, IV); concomitant treatment: radiotherapy
Interventions drug = Epoetin beta
dose = 300 IU/kg sc TIW
hb-target = 12-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = during radiotherapy
Outcomes Primary: efficacy of radiotherapy, measured as local progression free survival; secondary: survival,
progression free survival, Hb, safety, tolerability
Notes study number = 58106
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Each center had numbered packages per stratum, once randomized the
lowest number had to be assigned. There was a randomization list only the
statistics center had access to. In addition, there were sealed envelopes for
emergencies.
Allocation concealment? Yes coded drug packs of identical appearance
Henry 1995
Methods randomized controlled trial, placebo-controlled
Participants n = 132, lung, gynecological, gastrointestinal, hematological malignancies, other cancer; concomi-
tant treatment: chemotherapy
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Henry 1995 (Continued)
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = Hct 38%-40%
planned ESA duration = 12 weeks
Outcomes Primary: Hct, transfusion; secondary: correction of anemia, response, QoL, safety
Notes study number = 70332
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Unclear Medication boxes were used, but without identical appearance
Huddart 2002
Methods randomized controlled trial, not placebo-controlled
Participants n = 95, lung, gynecological, genitourinary, other cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 10000 IU sc TIW
hb-target = 12-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Hb response, reticulocyte, survival, QoL, safety
Notes study number = 88443
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Unclear no description
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Kotasek 2002
Methods randomized controlled trial, placebo-controlled
Participants n = 161, lung, breast, gastrointestinal, genitourinary, gynecological, other cancer (stage I-IV);
concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = a: 9 µg/kg sc Q4W, b: 12 µg/kg sc Q4W, c: 15 µg/kg sc Q4W, d: 18 µg/kg sc Q4W
hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: safety; secondary: determine effective dose, effect of ESA, QoL feasibility
Notes study number = 26117
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Kotasek 2003
Methods randomized controlled trial, placebo-controlled
Participants n = 259, breast, gynecological, gastrointestinal, lung, genitourinary, other cancer (stage I-IV, most
patients advanced); concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = a: 4.5 µg/kg sc Q3W, b: 6.75 µg/kg sc Q3W, c: 9 µg/kg sc Q3W, d: 12 µg/kg sc Q3W, e:
13.5 µg/kg sc Q3W, f: 15 µg/kg sc Q3W
hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: safety; secondary: determine effective dose, effect of ESA, QoL feasibility
Notes study number = 35466
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
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Kotasek 2003 (Continued)
Allocation concealment? Yes central randomization
Leyland-Jones 2003
Methods randomized controlled trial, placebo-controlled
Participants n = 939, breast cancer (stage IV, M1); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12-14 g/dL
planned ESA duration = 52 weeks
Outcomes Primary: overall survival; secondary: Hb, transfusion, tumor control, QoL, time to progression
Notes study number = 17100
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated
Allocation concealment? Yes central randomization
Littlewood 2001
Methods randomized controlled trial, placebo-controlled
Participants n = 375, breast, Non-Hodgkin lymphoma, multiple myeloma, Hodgkin disease, chronic lympho-
cytic leukemia, gastrointestinal, other cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 12-15 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: transfusion; secondary:Hb,Hct, reticulocytes, predictors for response,QoL, after protocol
amendment also survival
Notes study number = 17123
Risk of bias
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Littlewood 2001 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated randomization schedule prepared by RWJPRI
Allocation concealment? Yes coded drug packs of identical appearance
Machtay 2007
Methods randomized controlled trial, not placebo-controlled
Participants n = 148, head and neck cancer (stage I-IV); concomitant treatment: radiotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12.5-14 g/dL (women), 13.5-16 g/dL (men)
planned ESA duration = 8 weeks
Outcomes Primary: local regional control tumor response; secondary: overall survival, patterns of failure, local-
regional progression-free survival, Hb, toxicity, QoL
Notes study number = 87660
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Milroy 2003
Methods randomized controlled trial, not placebo-controlled
Participants n = 424, non-small cell lung cancer (stage IIIb or IV, advanced); concomitant treatment: chemo-
therapy
Interventions drug = Epoetin alpha
dose = if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW
hb-target = 12.5-14 g/dL (women), 13.5-15 g/dL (men)
planned ESA duration = during chemotherapy
Outcomes Primary: QoL; secondary: Hb, tumor response, survival, transfusion
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Milroy 2003 (Continued)
Notes study number = 67954
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Moebus 2007
Methods randomized controlled trial, not placebo-controlled
Participants n = 643, breast cancer (high risk, stage II/IIIA; M0); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 13-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: transfusion, Hb; secondary: recurrence free survival, overall survival, relapse, QoL
Notes study number = 22515
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes central randomization
O’Shaugnessy 2005
Methods randomized controlled trial, placebo-controlled
Participants n = 100, breast cancer (stage I, II, IIIB); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 13-15 g/dL
planned ESA duration = during chemotherapy
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O’Shaugnessy 2005 (Continued)
Outcomes Primary: cognitive function, fatigue; secondary: QoL
Notes study number = 40730
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes coded drug packs of identical appearance
OBE/EPO-INT-03
Methods randomized controlled trial, not placebo-controlled
Participants n = 72, multiple myeloma; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12-13 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: Hb change; secondary: QoL, Hb response, transfusion, safety
Notes study number = 92503
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Oberhoff 1998
Methods randomized controlled trial, not placebo-controlled
Participants n = 227, ovarian, breast, lung, genitourinary, gastrointestinal, other cancer; concomitant treatment:
chemotherapy
129Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Oberhoff 1998 (Continued)
Interventions drug = Epoetin beta
dose = 5000 IU sc 7x per week
hb-target = 11-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: transfusion ; secondary: Hb response, safety
Notes study number = 45434
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Osterborg 1996
Methods randomized controlled trial, not placebo-controlled
Participants n = 148, multiple myeloma, Non-Hodgkin lymphoma, chronic lymphocytic lymphoma; concomi-
tant treatment: chemotherapy
Interventions drug = Epoetin beta
dose = a: 10000 IU sc 7x/week, b: titration
hb-target = 10-14 g/dL (women), 10-13 g/dL (men)
planned ESA duration = 24 weeks
Outcomes Primary: transfusion; secondary: safety, Hb
Notes study number = 43680
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
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Osterborg 2002
Methods randomized controlled trial, placebo-controlled
Participants n = 349, multiple myeloma, Non-Hodgkin lymphoma, chronic lymphocytic lymphoma; concomi-
tant treatment: chemotherapy
Interventions drug = Epoetin beta
dose = 150 IU/kg sc TIW
hb-target = 13-14 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: transfusion free survival; secondary: Hb response, time to response, number of blood
transfusions, QoL, safety
Notes study number = 77914
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization program
Allocation concealment? Yes central randomization
Pirker 2008
Methods randomized controlled trial, placebo-controlled
Participants n = 600, small cell lung cancer (untreated, extensive stage); concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = 300 µg sc weekly for weeks 1-4 then 300 µg Q3W starting week 5 onwards
hb-target = 13-14 g/dL
planned ESA duration = 19 weeks
Outcomes Primary: Hb change, survival; secondary: QoL, progression-free-survival, tumor response, time to
progression, transfusion
Notes study number = 89335
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
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Pirker 2008 (Continued)
Allocation concealment? Unclear central randomization
Pronzato 2002
Methods randomized controlled trial, not placebo-controlled
Participants n = 223, breast cancer (stage I-IV); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = if body weight > 45 kg 10000 IU sc TIW, if < 45 kg 5000 IU sc TIW
hb-target = 12-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: QoL; secondary: Hb change, tumor response
Notes study number = 22233
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Quirt 1996
Methods randomized controlled trial, placebo-controlled
Participants n = 56, lung, gynecological, hematological malignancies, other cancer; concomitant treatment:
chemotherapy
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = 12.5-14 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: transfusion; secondary: QoL, costs from societal perspective, tumor response
Notes study number = 80214
Risk of bias
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Quirt 1996 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Unclear no description
Ray-Coquard 2006
Methods randomized controlled trial,
Participants n = 218, breast, sarcoma, lung, ovarian, other solid cancer and hematological malignancies; concomitant treatment:
chemotherapy
Interventions drug = Epoetin alpha
dose = if body weight < 45 kg 10000 IU sc 2x/week, if body weight 45 kg to < 89 kg 10000 IU sc TIW, if body
weight > 89 kg 10000 IU sc 4x/week
hb-target = 12-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: transfusion dependent anemia; secondary: QoL, Hb response predictors, Hb, toxicity, survival, costs
Notes study number = 37491
Razzouk 2006
Methods randomized controlled trial, placebo-controlled
Participants n = 126, solid tumors, Hodgkin disease, Non-Hodgkin lymphoma (patients excluded from the
present meta-analysis), acute lymphocytic leukemia (patients excluded from the present meta-
analysis); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 600 IU/kg iv weekly
hb-target = 13-15 g/dL (age > 12 years), 13-14 g/dL (age <12 years)
planned ESA duration = 16 weeks
Outcomes Primary: QoL; secondary: Hb, transfusion
Notes study number = 80515
Risk of bias
Item Authors’ judgement Description
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Razzouk 2006 (Continued)
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes central randomization and coded drug packs of identical appearance
Rose 1994
Methods randomized controlled trial, placebo-controlled
Participants n = 221, chronic lymphocytic leukemia (stage III, IV); concomitant therapy: other
Interventions drug = Epoetin alpha
dose = 150 IU/kg sc TIW
hb-target = Hct 38%-40%
planned ESA duration = 12 weeks
Outcomes Primary: Hct; secondary: transfusion, QoL, safety
Notes study number = 98358
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer-generated
Allocation concealment? Unclear no description
Savonije 2005
Methods randomized controlled trial, not placebo-controlled
Participants n = 315, non-small cell lung cancer, gastrointestinal, gynecological, colorectal, small cell lung cancer,
other cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = 10000 IU sc TIW
hb-target = 13-14 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: transfusion; secondary: Hb, tumor response, QoL, survival
Notes study number = 70724
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Savonije 2005 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear randomization center generates a list of subject numbers and randomly
allocate numbers to the two treatment groups using a block size of six
Allocation concealment? Yes central randomization
Smith 2008
Methods randomized controlled trial, placebo-controlled
Participants n = 989, lung, hematological malignancies, breast, gastrointestinal, genitourinary, other cancer
(stage III-IV); no anticancer therapy
Interventions drug = Darbepoetin alpha
dose = 6.75 µg/kg sc Q4W
hb-target = 12-13 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: transfusion; secondary: Hb, QoL, safety
Notes study number = 81215
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear based on a schedule specified by Amgen prior to the start of the study
Allocation concealment? Yes central randomization
Strauss 2008
Methods randomized controlled trial, not placebo-controlled
Participants n = 74, cervical cancer (stage IIB-IVA); concomitant treatment: radiochemotherapy
Interventions drug = Epoetin beta
dose = 150 IU/kg sc TIW
hb-target = 14-15 g/dL
planned ESA duration = 12 weeks
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Strauss 2008 (Continued)
Outcomes Primary: tumor control failures; secondary: progression-free survival, overall response rate, re-
lapses/metastases, overall survival, Hb change, QoL, safety
Notes study number = 70404
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear patient randomization number will be generated by Roche
Allocation concealment? Unclear patient randomization numbers are to be allocated sequentially in the order
in which the patients are enrolled
Taylor 2005
Methods randomized controlled trial, placebo-controlled
Participants n = 391, non-myeloid hematological malignancies, breast, lung, gastrointestinal, genitourinary,
gynecological, other cancer (stage I-IV); concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = 300 µg sc Q3W
hb-target = 12-13 g/dL
planned ESA duration = 15 weeks
Outcomes Primary: transfusion; secondary: Hb target achieved, number of transfusions, safety, QoL
Notes study number = 37476
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
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Ten Bokkel Huinink 1998
Methods randomized controlled trial, not placebo-controlled
Participants n = 120, ovarian cancer (stage II-IV); concomitant treatment: chemotherapy
Interventions drug = Epoetin beta
dose = a: 150 IU/kg sc TIW, b: 300 IU/kg sc TIW
hb-target = 14-15 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: transfusion; secondary: Hb, reticulocytes, Hct, safety
Notes study number = 47852
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Thatcher 1999
Methods randomized controlled trial, not placebo-controlled
Participants n = 130, small cell lung cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = a: 150 IU/kg sc TIW, b: 300 IU/kg sc TIW
hb-target = 13-15 g/dL
planned ESA duration = 26 weeks
Outcomes Efficacy, safety, QoL
Notes study number = 65529
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear upon study entry each patient was assigned a sequential identification num-
ber which had been randomly assigned to chemotherapy with or without
ESA, blocks of 6, each investigator had to treat at least 6 patients, but
preferably 12 patients
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Thatcher 1999 (Continued)
Allocation concealment? Unclear see randomization
Thomas 2002
Methods randomized controlled trial, not placebo-controlled
Participants n = 130, breast, gastrointestinal, gynecological, other cancer; concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = if body weight > 45 kg 10000 IU sc TIW, if body weight < 45 kg 5000 IU sc TIW
hb-target = 12-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: Hb response; secondary: QoL, tumor response, survival, safety
Notes study number = 84090
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Thomas 2008
Methods randomized controlled trial, not placebo-controlled
Participants n = 114, cervical cancer (stage IIB - IV A, M0); concomitant treatment: radiochemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 13-14 g/dL
planned ESA duration = during chemotherapy and radiotherapy
Outcomes Primary: progression-free survival; secondary: overall survival, local control, distant recurrences,
thromboembolic events
Notes study number = 21481
Risk of bias
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Thomas 2008 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Yes central randomization
Untch 2008
Methods randomized controlled trial, not placebo-controlled
Participants n = 729, breast cancer (M0); concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = 4.5 µg/kg sc Q2W
hb-target = 13 g/dL
planned ESA duration = during chemotherapy
Outcomes Primary: relapse free survival time, overall survival; secondary: tumor control, safety and tolerability,
transfusion, Hb level, QoL
Notes study number = 66960
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear no description
Allocation concealment? Unclear description is unclear
Vadhan-Raj 2004
Methods randomized controlled trial, placebo-controlled
Participants n = 60, gastric or rectal cancer (stage I-III); concomitant treatment: radiochemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 14-15 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: transfusions; secondary: maintain Hb levels, QoL, tumor response, safety
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Vadhan-Raj 2004 (Continued)
Notes study number = 30540
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes coded drug packs of identical appearance
Vansteenkiste 2002
Methods randomized controlled trial, placebo-controlled
Participants n = 320, small cell lung cancer (limited and extensive), and non-small lung cancer (stage I-IV);
concomitant treatment: chemotherapy
Interventions drug = Darbepoetin alpha
dose = 2.25 mg/kg sc weekly
hb-target = 13-14 g/dL (women), 13-15 g/dL (men)
planned ESA duration = 12 weeks
Outcomes Primary: transfusion; secondary: Hb response, Hb, transfusion timing and quantity, QoL
Notes study number = 49684
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear based on a schedule specified by Amgen before the start of the study
Allocation concealment? Yes central randomization
Wilkinson 2006
Methods randomized controlled trial, not placebo-controlled
Participants n = 182, ovarian cancer (stage I-IV); concomitant treatment: chemotherapy
Interventions drug = Epoetin alpha
dose = if body weight > 45 kg 10000 IU sc TIW, if < 45 kg 5000 IU sc TIW
hb-target = 12-14 g/dL
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Wilkinson 2006 (Continued)
planned ESA duration = during chemotherapy
Outcomes Primary: Hb response; secondary: QoL, transfusion, tumor response
Notes study number = 75688
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear a prospective randomization procedure will be employed
Allocation concealment? Unclear assigned envelopes, sealed, but it is unclear whether they were opaque and
sequentially numbered
Witzig 2005
Methods randomized controlled trial, placebo-controlled
Participants n = 344, lung, breast, other cancer (active incurable advanced stage); concomitant treatment:
chemotherapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 13-15 g/dL
planned ESA duration = 16 weeks
Outcomes Primary: transfusion; secondary: Hb change, haemoglobin over time, predictors for response, inci-
dence of nephrotoxicity, overall survival, tumor response, QoL
Notes study number = 36512
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes central randomization and coded drug packs of identical appearance
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Wright 2007
Methods randomized controlled trial, placebo-controlled
Participants n = 70, non-small lung cancer (advanced stage IIIA, B and IV, recurrent disease); no anticancer
therapy
Interventions drug = Epoetin alpha
dose = 40000 IU sc weekly
hb-target = 12-14 g/dL
planned ESA duration = 12 weeks
Outcomes Primary: QoL; secondary: Hb, Hct, transfusion, safety
Notes study number = 53572
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes computer generated
Allocation concealment? Yes central randomization
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Characteristics of excluded studies [ordered by study ID]
Abdelrazik 2007 ineligible patient characteristics (e.g. with MDS or SAA)
Alexopoulos 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Antonadou 2001 no access to the individual patient data
Aravantinos 2003 too small for inclusion
Auerbach 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Aziz 2001 too small for inclusion
Bamias 2003 no access to the individual patient data
Beggs 2003 too small for inclusion
Bessho 1997 ineligible patient characteristics (e.g. with MDS or SAA)
Bindi 2004 too small for inclusion
Blayney 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Blohmer 2003 no access to the individual patient data
Candelaria 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Canon 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Carabantes 1999 too small for inclusion
Casadevall 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Cascinu 1994 no access to the individual patient data
Cazzola 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Chan 1995 too small for inclusion
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(Continued)
Charu 2007a ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Christodoulakis 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Crawford 1997 too small for inclusion
Crawford 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Crawford 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Daneryd 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Dannemann 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Del Mastro 1997 too small for inclusion
Dunphy 1999 too small for inclusion
Elsaid 2001 too small for inclusion
Freeman 2006 too small for inclusion
Garton 1995 too small for inclusion
Gebbia 1992 too small for inclusion
Glaspy 2002 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glaspy 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glaspy 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glaspy 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
144Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Glimelius 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Glossmann 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Granetto 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Hedenus 2002 too small for inclusion
Hedenus 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Hellström Lindberg 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henke 1999 too small for inclusion
Henry 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henry 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henry 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Henze 2002 ineligible patient characteristics (e.g. with MDS or SAA)
Hesketh 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Iconomou 2003 no access to the individual patient data
Italian 1998 ineligible patient characteristics (e.g. with MDS or SAA)
Janinis 2003 no access to the individual patient data
Jitnuyanont 2001 too small for inclusion
Johansson 2001 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
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(Continued)
Justice 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Kettelhack 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Kosmadakis 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Kotasek 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Kotasek 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Kunikane 2001 too small for inclusion
Kurz 1997 too small for inclusion
Mangiameli 2002 too small for inclusion
Marinaccio 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Merlano 2001 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
MF4266 ineligible patient characteristics (e.g. with MDS or SAA)
Miller 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Morishima 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Mystakidou 2005 no access to the individual patient data
Olsson 2002 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Overgaard 2007 no access to the individual patient data
Pierelli 1999 too small for inclusion
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(Continued)
Policarpo 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Porter 1996 too small for inclusion
Rau 1998 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Rearden 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Reed 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Rosen 2003 too small for inclusion
Rosenzweig 2004 too small for inclusion
Rubio-Martinez 2003 too small for inclusion
Sakai 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Schwartzberg 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Schwartzberg 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Schwartzberg 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Scott 2002 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Senecal 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Shi 2007 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Silvestris 1995 too small for inclusion
Smith 2003 too small for inclusion
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(Continued)
Spicka 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Steensma 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Stein 1991 ineligible patient characteristics (e.g. with MDS or SAA)
Straus 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Sweeney 1998 too small for inclusion
Thompson 2000 ineligible patient characteristics (e.g. with MDS or SAA)
Throuvalas 2000 too small for inclusion
Tsukuda 1998 too small for inclusion
Varan 1999 too small for inclusion
Wagner 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Waltzman 2005 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Watanabe 2006 no access to the individual patient data
Welch 1995 too small for inclusion
Wurnig 1996 too small for inclusion
Yilmaz 2004 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Zagari 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
Zajda 2007 no access to the individual patient data
Zhang 2003 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
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Zhou 2006 ESAs were given in context with surgery, stem cell transplantation, compared different ESA dosages or
ESA products (epoetin versus darbepoetin), or trials were not randomised
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategies
Search strategies for IPD meta-analysis update
Database: Ovid MEDLINE(R)
--------------------------------------------------------------------------------
1 exp ERYTHROPOIETIN/
2 exp ERYTHROPOIETIN, RECOMBINANT/
3 erythropoietin.mp.
4 erythropoiesis.mp.
5 exp EPOETIN ALFA/
6 epoetin.mp.
7 epo.mp.
8 epoetin alfa.mp.
9 epoetin beta.mp.
10 eprex.mp.
11 neorecormon.mp.
12 aranesp.mp.
13 procrit.mp.
14 recombinant erythropoietin.mp.
15 darbepoetin alfa.mp.
16 darbepoetin.mp.
17 RECEPTORS, ERYTHROPOIETIN/
18 CERA.mp.
19 or/1-18
20 exp ANEMIA/dt, th [Drug Therapy, Therapy]
21 anaemia.mp.
22 anemia.mp.
23 (anemi$ adj3 cancer).mp.
24 (anaemi$ adj3 cancer).mp.
25 or/20-24
26 exp Neoplasms/
27 malignan$.mp.
28 cancer$.mp.
29 oncolog$.tw.
30 myelodysplas$.tw.
31 chemotherapy.mp.
32 tumo?r$.mp.
33 carcinom$.mp.
34 or/26-33
35 19 and 25
36 34 and 25
37 randomized controlled trial.pt.
38 controlled clinical trial.pt.
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39 randomized controlled trials/
40 random allocation/
41 double blind method/
42 single blind method/
43 or/37-42
44 (ANIMALS not HUMANS).sh.
45 43 not 44
46 clinical trial.pt.
47 exp clinical trials/
48 (clin$ adj25 trial$).ti,ab.
49 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.
50 placebos/
51 placebo$.ti,ab.
52 random$.ti,ab.
53 research design/
54 or/46-53
55 54 not 44
56 55 not 45
57 comparative study/
58 exp evaluation studies/
59 follow up studies/
60 prospective studies/
61 (control$ or prospectiv$ or volunteer$).ti,ab.
62 or/57-61
63 62 not 44
64 63 not (45 or 56)
65 45 or 56 or 64
66 36 and 65
Database: Ovid (Embase)
Database: Ovid (Embase)
1 erythropoietin.mp.
2 exp ERYTHROPOIETIN/
3 exp RECOMBINANT ERYTHROPOIETIN/
4 epoetin.mp
5 epo.mp.
6 eprex.mp
7 neorecormon.mp
8 procrit.mp
9 recombinant erythropoietin.mp.
10 darbepoetin alfa.mp.
11 exp NOVEL ERYTHROPOIESIS STIMULATING PROTEIN/
12 aranesp.mp.
13 nesp.mp
14 exp darbepoetin/
15 exp darbepoietin alfa/
16 exp CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR
17 CERA.mp
18 Or/1-17
19 exp ANEMIA/
20 anemia.mp.
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21 anaemi$.tw.
22 anemi$.mp.
23 (anemi$ adj3 cancer$).mp.
24 (anaemi$ adj3 cancer$).mp.
25 Or/19-24
26 malignan$.mp.
27 cancer$.mp.
28 exp CANCER/
29 exp NEOPLASM/
30 neoplasm$.mp.
31 oncology.mp.
32 exp ONCOLOGY/
33 exp MYELODYSPLASIA/
34 myelodysplas$.tw.
35 chemotherapy.mp.
36 exp CHEMOTHERAPY/
37 exp TUMOR/
38 tumo?r$.mp.
39 carcinom$.mp.
40 Or/26-40
41 randomized controlled trial/
42 exp clinical trial/
43 exp controlled study/
44 double blind procedure/
45 randomization/
46 placebo/
47 single blind procedure/
48 (control$ adj (trial$ or stud$ or evaluation$ or experiment$)).mp.
49 ((singl$ or doubl$ or trebl$ or tripl$) adj5 (blind$ or mask$)).mp.
50 (placebo$ or matched communities or matched schools or matched populations).mp.
51 (comparison group$ or control group$).mp.
52 (clinical trial$ or random$).mp.
53 (quasiexperimental or quasi experimental or pseudo experimental).mp.
54 matched pairs.mp.
55 or/41-54
56 18 and 25
57 55 and 40
58 57 and 56
CENTRAL
ID Search
#1 (erythropoietin)
#2 MeSH descriptor Erythropoietin explode all trees
#3 epoetin
#4 epo
#5 (epoetin next alfa)
#6 (epoetin next beta)
#7 (darbepoetin next alfa)
#8 eprex
#9 neorecormon
#10 aranesp
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#11 procrit
#12 (recombinant near erythropoietin)
#13 “continuous erythropoietin receptor activation”
#14 “continuous erythropoietin receptor activator”
#15 CERA
#16 C.E.R.A.
#17 erythropoiesis
#18 darbepoetin
#19 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18)
#20 anemia
#21 anaemia
#22 MeSH descriptor Anemia explode all trees
#23 (anemi* near cancer)
#24 (anaemi* near cancer)
#25 (#20 OR #21 OR #22 OR #23 OR #24)
#26 (#19 AND #25)
Appendix 2. List of variables evaluated
1. Variables to assess baseline imbalances
The following list provides pre-specified and exploratory variables that were used to assess baseline imbalances. MAIN variables, i.e.
variables that were pre-specified in advance (Langensiepen 2002) are highlighted in BOLD. All other variables are considered to be
exploratory. All variables refer to patient level data, unless otherwise specified. The technical name of the variable is given in [brackets].
PATIENT
1. Hemoglobin at baseline (randomization): continuous and categorical
a. (Hb ≤ 8 g/dL versus 8 g/dL < Hb ≤ 10 g/dL versus 10 g/dL < Hb ≤ 12 g/dL versus 12 g/dL < Hb ≤ 14 g/dL versus Hb > 14
g/dL) [hgb_cat1]
b. by 1 g/dL increments, i.e. 8 g/dL < Hb ≤ 9 g/dL versus 9 g/dL < Hb ≤ 10 g/dL versus 10 g/dL < Hb ≤ 11 g/dL versus 11 g/dL <
Hb ≤ 12 g/dL versus 12 g/dL < Hb ≤ 13 g/dL versus 13 g/dL < Hb ≤ 14 g/dL versus > 14 g/dL [hgb_cat2]
2. Hematocrit at baseline (randomization): continuous and categorical (Hct ≤ 23.5% versus 23.5% < Hct ≤ 29.4% versus 29.4% <
Hct ≤ 35.3% versus 35.3% < Hct ≤ 41.2% versus Hct > 41.2%) [hct_cat]
Note: use hematocrit values only if measurements was made, mathematical conversions from hemoglobin to hematocrit are not allowed
3. Serum EPO level at baseline before first study drug: continuous and categorical (< 25 mU/ml versus 25 -< 100 mU/ml versus 100 -
< 200 mU/ml versus≥ 200 mU/ml) (Littlewood 2003). Note: two categories were added: “200 - < 500 mU/ml versus≥ 500 mU/ml”)
[serepo]
4. Gender: dichotomous (male versus female) [sex]
5. Age at randomization: continuous and categorical (< 18 years versus 18 to < 35 years versus 35 to < 45 years versus 45 to < 55 years
versus 55 to < 65 years versus 65 to < 75 years versus ≥ 75 years) [age_cat]
6. Body mass index (BMI): continuous and categorical (BMI < 19 kg/m2 versus 19 ≤ BMI < 25 kg/m2 versus 25 ≤ BMI < 30 kg/m2
versus BMI ≥ 30 kg/m2) [bmi_cat]
7. ECOG performance score: categorical
a. each score value (0 versus 1 versus 2 versus 3 versus 4) [ecog_b]
b. 0, 1 or 2 versus 3 or 4 [ecog_cat]
8. History of thromboembolic event EXCLUDING central line associated thrombosis? Categorical (yes versus no) [hxthrom]
9. History of cardiovascular disease including coronary artery disease, myocardial infarction, atrial fibrillation or congestive heart disease?
Categorical (yes versus no) [hxcardio]
10. History of hypertension? Categorical (yes versus no) [hxhyper]
11. History of diabetes mellitus? Categorical (yes versus no) [hxdiab]
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12. Geographical region: categorical (Northern America versus Northern, Western, Southern Europe versus Australia/New Zealand
versus Eastern Europe
versus Americas versus other) [region_cat]
TUMOR
13. Tumor type with different categorizations
a. few categories (solid tumors versus hematological malignancies; note: chronic lymphocytic leukemia will be coded as lym-
phoma)
[tumor_cat1]
b. more categories (hematological versus breast cancer versus head and neck versus lung cancer versus other cancer). Note: the catego-
rization was
changed as follows: hematological versus breast cancer versus head and neck versus lung cancer versus gastrointestinal versus gyneco-
logical
versus genitourinary versus other cancer [tumor_cat2]
c. many categories (each cancer entity will be kept as separate category). Note: category c was not applied in the analysis
14. Disease stage at ESA study entry: categorical (limited disease versus locally advanced versus extensive/metastatic disease versus
other). Note: data
quality did only permit to dichotomize the data into metastatic or advanced versus not metastatic or not advanced. [stagem_cat1]
15. Disease status at ESA study entry: categorical (untreated versus complete response versus partial response or stable disease versus
progression
or progressive disease or relapsed versus not evaluable versus not evaluated). Note: data quality did not permit to use this variable.
16. Time from tumor diagnosis to randomization [cancertime]
TUMOR TREATMENT
17. Cancer treatment modality (note this replaces the analysis for chemotherapy induced anemia versus anemia of cancer):
a. Categorical at patient level (non-platinum chemotherapy/combined modality treatment versus platinum chemotherapy/combined
modality treatment
versus radiotherapy versus radiochemotherapy versus none versus unclear/mixed versus other). Note: radiotherapy and radiochemother-
apy were
kept as separate categories [popchmg], for a sensitivity analyses both categories were collapsed into one category [popispm_cat]
2. Variables to assess study design
The following list provides pre-specified and exploratory variables that were used to assess the study design of the included trials.
MAIN variables, i.e. variables that were pre-specified in advance (Langensiepen 2002) are highlighted in BOLD. All other variables
are considered to be exploratory. All variables refer to the study level, unless otherwise specified.
1. Randomization: categorical (adequate versus unclear versus inadequate) [randomisation]
2. Concealment of allocation: categorical (adequate versus unclear versus inadequate) [allocation]
3. Placebo controlled: dichotomous (yes versus no/unclear) [placebo]
4. Blinded outcome assessment: dichotomous (yes, no/unclear; this assessment may vary between outcomes)
a. PFS: Was there independent and blinded adjudication of events and cause of deaths?
b. TEE: Was there independent and blinded adjudication of events?
5. IPD submitted by pharmaceutical company or independent investigators: categorical (pharmaceutical company versus independent
investigators versus
other) [source]
6. Was the outcome of interest assessed as an endpoint (primary or secondary) or as an adverse event only? dichotomous (yes (endpoint)
versus no
(adverse event only)) and categorical (primary versus secondary versus an adverse event only) [endpoint]. Note: this variable was only
assessed
categorical, not dichotomous
7. Was the study designed to assess long-term follow-up? dichotomous versus (yes versus no) [longfu], note: assessed in sensitivity
analysis, long-term follow-up was defined as planned follow-up of at least 12 months after end of active treatment period
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8. Calendar year of last patient randomized per study (to be calculated based on the individual patient data): continuous [calyear] and
categorical
(calendar time split in 5 years period) [calyear_cat]
9. Were less than 10% of subjects within each study arm excluded from the analysis and was the ratio of exclusions between
arms less
than a 2:1?
10. Actual study size: continuous and dichotomous (small (n overall < 200) versus large (n overall ≥ 200)), note: not assessed
11. Prematurely terminated or halted study or completed by own study protocol: dichotomous (terminated/halted versus completed)
[stop], note: assessed in sensitivity analysis
12. Median time from randomization to censoring per study, separate for each outcome (to be calculated based on the individual patient
data): continuous, note: not assessed
3. Variables to assess effect modification
The following list provides pre-specified and exploratory variables that were examined in analyses of effectmodification.MAIN variables,
i.e. variables that were pre-specified in advance (Langensiepen 2002) are highlighted in BOLD. All other variables were considered
to be exploratory. All variables refer to patient level data, unless otherwise specified. The technical name of the variable is given in
[brackets].
PATIENT
1. Hemoglobin at baseline (randomization): continuous and categorical
a. (Hb ≤ 8 g/dL versus 8 g/dL < Hb ≤ 10 g/dL versus 10 g/dL < Hb ≤ 12 g/dL versus 12 g/dL < Hb ≤ 14 g/dL versus Hb > 14
g/dL) [hgb_cat1]
b. by 1 g/dL increments, i.e. 8 g/dL < Hb ≤ 9 g/dL versus 9 g/dL < Hb ≤ 10 g/dL versus 10 g/dL < Hb ≤ 11 g/dL versus 11 g/dL <
Hb ≤ 12 g/dL versus
12 g/dL < Hb ≤ 13 g/dL versus 13 g/dL < Hb ≤ 14 g/dL versus > 14 g/dL [hgb_cat2]
2. Hematocrit at baseline (randomization): continuous and categorical (Hct ≤ 23.5% versus 23.5% < Hct ≤ 29.4% versus 29.4% <
Hct ≤ 35.3% versus
35.3% < Hct ≤ 41.2% versus Hct > 41.2%) [hct_cat]
Note: Use hematocrit values only if measurements was made,mathematical conversions from hemoglobin to hematocrit are not allowed.
3. Serum EPO level at baseline before first study drug: continuous and categorical (< 25 mU/ml versus 25 -< 100 mU/ml versus 100 -
< 200 mU/ml versus
≥ 200 mU/ml) (Littlewood 2003). Note: two categories were added: “200 - < 500 mU/ml versus ≥ 500 mU/ml”) [serepo]
4. Gender: dichotomous (male versus female) [sex]
5. Age at randomization: continuous and categorical (< 18 years versus 18 to < 35 years versus 35 to < 45 years versus 45 to < 55 years
versus 55 to <
65 years versus 65 to < 75 years versus ≥ 75 years) [age_cat]
6. Body mass index (BMI): continuous and categorical (BMI < 19 kg/m2 versus 19 ≤ BMI < 25 kg/m2 versus 25 ≤ BMI < 30 kg/m2
versus BMI ≥ 30 kg/m2)
[bmi_cat]
7. ECOG performance score: categorical
a. each score value (0 versus 1 versus 2 versus 3 versus 4) [ecog_b]
b. 0, 1 or 2 versus 3 or 4 [ecog_cat]
8. History of thromboembolic event EXCLUDING central line associated thrombosis? Categorical (yes versus no) [hxthrom]
9. History of cardiovascular disease including coronary artery disease, myocardial infarction, atrial fibrillation or congestive heart disease?
(yes versus no) [hxcardio]
10. History of hypertension? Categorical (yes versus no) [hxhyper]
11. History of diabetes mellitus? Categorical (yes versus no) [hxdiab]
12. Geographical region: categorical (Northern America versus Northern, Western, Southern Europe versus Australia/New Zealand
versus Eastern Europe
versus Americas versus other) [region_cat]
TUMOR
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13. Tumor type with different categorizations
a. few categories (solid tumors versus hematological malignancies; note: chronic lymphocytic leukemia will be coded as lym-
phoma)
[tumor_cat1]
b. more categories (hematological versus breast cancer versus head and neck versus lung cancer versus other cancer). Note: the catego-
rization was
changed as follows: hematological versus breast cancer versus head and neck versus lung cancer versus gastrointestinal versus gyneco-
logical
versus genitourinary versus other cancer [tumor_cat2]
c. many categories (each cancer entity will be kept as separate category). Note: category c was not applied in the analysis
14. Disease stage at ESA study entry: categorical (limited disease versus locally advanced versus extensive/metastatic disease versus
other).
Note: data quality did only permit to dichotomize the data into metastatic or advanced versus not metastatic or not advanced. [stagem_
cat1]
15. Disease status at ESA study entry: categorical (untreated versus complete response versus partial response or stable disease versus
progression or
progressive disease or relapsed versus not evaluable versus not evaluated). Note: data quality did not permit to use this variable.
16. Time from tumor diagnosis to randomization [cancertime]
TUMOR TREATMENT
17. Cancer treatment modality (note this replaces the analysis for chemotherapy induced anemia versus anemia of cancer):
a. Categorical at patient level (non-platinum chemotherapy/combined modality treatment versus platinum chemotherapy/combined
modality treatment
versus radiotherapy versus radiochemotherapy versus none versus unclear/mixed versus other). Note: data quality did not allow to
differentiate
platinum containing versus non platinum chemotherapy.
b. Categorical at study level (mainly chemotherapy/combined modality treatment (both platinum containing and platinum
free) versus mainly radiotherapy/radiochemotherapy versus none versus unclear/mixed versus other). Note: radiotherapy and
radiochemotherapy
were kept as separate categories [popchmg], for a sensitivity analyses both categories were collapsed into one category [popispm_cat]
ESA TREATMENT
18. Iron supplementation policy as per study protocol (study level information): categorical (fixed versus as needed by study
protocol or by discretion of physician versus no iron versus no statement). [iron_cat]Note: the category “by discretion of physician”
was amended to “by discretion of physician or institutional policy”.
19. Planned duration of ESA treatment as per study protocol (study level information): continuous and categorical (up to 8
weeks versus 9 to 16 weeks versus > 17 weeks versus not applicable) [plandur_cat].
Note: studies that did not indicate a specific number of weeks for ESA treatment durationwere categorized as “until end of chemotherapy
or
radiotherapy”, if indicated.
20. Planned weekly ESA dosage as defined in the study protocol (starting dose, study level information): continuous and categorical
(EPO < 40,000
IU/week or darbepoetin <100 µg/week versus EPO =40,000 IU/week or darbepo = 100 µg /week versus EPO > 40,000 IU/week or
darbepoetin > 100 µg /week) [weekesa_cat]
21. Planned frequency of ESA applications as defined in the study protocol (study level information): categorical (TIW or more often
versus QW versus
Q2W versus Q3W versus Q4W). Note: the categorization was simplified to (TIW or more often versus QW versus Q2W or more
often). [planfreq_cat]
22. Planned hemoglobin ceiling target i.e. when ESA had to be stopped according to the study protocol (study level information):
continuous and categorical
a. Hb ≤ 11 versus 11 g/dL < Hb ≤ 13 g/dL versus 13 g/dL < Hb ≤ 15 g/dL versus > Hb > 15 g/dL [ceiling_cat1]
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b. by 1 g/dL increments, i.e. 8 g/dL < Hb ≤ 9 g/dL versus 9 g/dL < Hb ≤ 10 g/dL versus 10 g/dL < Hb ≤ 11 g/dL versus 11 g/dL <
Hb ≤ 12 g/dL versus
12 g/dL < Hb ≤ 13 g/dL versus 13 g/dL < Hb ≤ 14 g/dL versus 14 g/dL < Hb ≤ 15 g/dL versus 15 g/dL < Hb ≤ 16 g/dL versus 16
g/dL < Hb ≤ 17 g/dL
versus 17 g/dL < Hb ≤ 18 g/dL versus > 18 g/dL [ceiling_cat2]
23. Maximal hemoglobin within 4 weeks before event or end of study: continuous and categorical (Hb ≤ 8 g/dL versus 8 g/dL < Hb
≤ 10 g/dL versus 10 g/dL < Hb ≤ 12 g/dL versus 12 g/dL < Hb ≤ 14 g/dL versus 14 g/dL < Hb ≤ 16 g/dL versus 16 g/dL < Hb ≤
18 g/dL versus Hb > 18 g/dL), TIME DEPENDENT VARIABLE. Note: this variable has not been applied in the analysis.
24. Maximal hematocrit within 4 weeks before event or end of study: continuous and categorical (Hct hct ≤ 23.5% versus 23.5%
< hct ≤ 29.4% versus 29.4% < hct ≤ 35.3% versus 35.3% < hct ≤ 41.2% versus 41.2% < hct ≤ 47.1% versus hct >53%), TIME
DEPENDENT VARIABLE. Note: this variable has not been applied in the analysis.
4. Other protocol amendments
The variable FIX (not listed above) was amended with one category: “adjusted” for patients who received a fix dose of drug depending
on their age or weight category. This category was added to differentiate between a truly weight based dosing scheme.
Appendix 3. Sensitivity analyses
Sensitivity analyses for studies with aggregated survival data
Ten studies were eligible for the IPDmeta-analysis but individual patient data could not be retrieved. For six of these studies (Antonadou
2001; Bamias 2003; Blohmer 2003; Mystakidou 2005; Overgaard 2007) results for survival were either reported in the literature or
provided by the investigator. Overall, the inclusion of these results in the meta-analyses did not lead to important changes.
Table 1: Sensitivity analyses for effect of missing studies, on study mortality
Two-stage log-rank fixed-effect meta-
analysis
Results based on IPD analysis Including additional literature based data
ESA versus control HR (95% CI) HR (95% CI)
On study mortality, all cancer patients* 1.17 (1.06-1.30) 1.17 (1.06-1.30)
On study mortality, chemotherapy trials 1.10 (0.98-1.24) 1.11 (0.98-1.25)
*Not included: Overgaard 2007, no on study mortality data reported
Table 2: Sensitivity analyses for effect of missing studies, overall survival
Two-stage log-rank fixed-effect meta-
analysis
Results based on IPD analysis Including additional literature based data
ESA versus control HR (95% CI) HR (95% CI)
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Overall survival, all cancer patients 1.06 (1.00-1.12) 1.06 (1.00-1.11)
Overall survival, chemotherapy trials 1.04 (0.97-1.11) 1.04 (0.97-1.11)
Sensitivity analyses for on study mortality in all cancer patients
Classification of studies into different treatment populations
In study 83322 (Debus 2006) patients with non-resectable NSCLC received chemotherapy which was followed by radiotherapy. ESA
was given during the treatment of chemotherapy and radiotherapy. However, only patients who achieved CR, PR or stable disease were
subsequently treated with radiotherapy (39.5% of the ESA patients and 44.2% of the control patients did not receive radiotherapy,
information taken from CSR). Since the chemotherapy was followed by radiotherapy after a short interval, the study was classified as
“radiochemotherapy”. However, it could also be argued that the study should be classified as “combined modality treatment” because
radiotherapy was given after chemotherapy or as “mixed” population, because less then 70% of the treatment population actually
received radiotherapy. Both options were tested in a sensitivity analysis, results for on study mortality for the various treatment subsets
and LR test for difference between subsets of studies did not change, see below.
Table 3: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis
based on random- effects Cox
model
Study
83322 in radiochemotherapy
treatment group
Study 83322 in mixed treat-
ment group
Study 83322 in chemother-
apy treatment group
ESA versus control HR (95% CI) HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.09 ( 0.97-1.23) 1.10 (0.98-1.24)
Radiochemotherapy 1.47 (0.83-2.59) 2.34 (0.42-13.03) 2.34 (0.42-13.03)
Radiotherapy 1.51 (0.73-3.12) 1.51 (0.73-3.12) 1.51 (0.73-3.12)
Mixed 1.50 (0.62-3.66) 1.42 (0.86-2.34) 1.50 (0.62-3.66)
None 1.32 (1.06-1.65) 1.32 (1.06-1.65) 1.32 (1.06-1.65)
Overall 1.16 (1.05-1.29) 1.16 (1.05-1.29) 1.16 (1.05-1.29)
LR test 0.4234 0.3607 0.4290
Sensitivity analysis for on study mortality: mixed treatment group
In two studies with CLL patients (Rose 1994; CC2574-P-174 about 40% of the patients received corticosteroids and 60% of patients
received chemotherapy during study. Since the definition for treatment populations was set at 70% (i.e. 70% of a trial population had
to have received the planned anticancer treatment) these two studies were classified and analyzed in the “mixed” treatment population.
In a sensitivity analysis we included these two studies in the “chemotherapy” population, for results see below. Overall, the results did
not change.
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Table 4: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis based on ran-
dom-effects Cox model
Mixed treatment group separate subset Mixed treatment group merged to che-
motherapy treatment group
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.10 (0.97-1.24)
Radiochemotherapy 1.47 (0.83-2.59) 1.47 (0.83-2.59)
Radiotherapy 1.51 (0.73-3.12) 1.51 (0.73-3.12)
Mixed 1.50 (0.62-3.66) -
None 1.32 (1.06-1.65) 1.32 (1.06-1.65)
Overall 1.16 (1.05-1.29) 1.16 (1.05-1.29)
LR test 0.4234 0.3382
Sensitivity analyses for on study mortality: radiochemotherapy treatment population
In five studies patients received both radiotherapy and chemotherapy. Since patients in these studies received chemotherapy, a myelo-
suppressive effect of the chemotherapy cannot be excluded and it might be argued that those studies should be evaluated in the che-
motherapy population. For a sensitivity analysis these patients were included in the chemotherapy treatment population, overall, the
results did not change, see below.
Table 5: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis based on ran-
dom-effects Cox model
Radiochemotherapy treatment group
merged to radiotherapy treatment group
Radiochemotherapy treatment group
merged to chemotherapy treatment
group
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.11 (0.98-1.25)
Radiotherapy 1.48 (0.95-2.32) 1.51 (0.73-3.12)
Mixed 1.50 (0.62-3.66) 1.50 (0.62-3.66)
None 1.32 (1.06-1.65) 1.32 (1.06-1.65)
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Overall 1.16 (1.05-1.29) 1.16 (1.05-1.29)
LR test 0.2715 0.4246
Sensitivity analysis for on study mortality: exclusion of study without date of randomization
For one study (study 36158 (Boogaerts 2003), chemotherapy population) the date of randomization was not available and was replaced
with the date of “first study drug” as provided by the investigators/sponsors of the study. For a sensitivity analysis we excluded this
study, for results see below. Overall, inclusion or exclusion of this study did not affect the overall results and the test for differences
between treatment populations did not change.
Table 6: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis based on ran-
dom-effects Cox model
Chemotherapy subset including study
36158
Chemotherapy subset without study
36158
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.09 (0.97-1.24)
Radiochemotherapy 1.47 (0.83-2.59) 1.47 (0.83-2.59)
Radiotherapy 1.51 (0.73-3.12) 1.51 (0.73-3.12)
Mixed 1.50 (0.62-3.66) 1.50 (0.62-3.66)
None 1.32 (1.06-1.65) 1.32 (1.06-1.65)
Overall 1.16 (1.05-1.29) 1.16 (1.05-1.29)
LR test 0.4234 0.4279
Sensitivity analyses for on study mortality chemotherapy patients: exclusion of studies with different
concomitant treatments in active and control arm
For two studies concomitant treatments in the active and the control arm were not identical, i.e. in one study 21481 (Thomas 2008)
the transfusion trigger in the ESA armwas 12 g/dL and in the control arm 10 g/dL. In another study 70404 (Strauss 2008) radiotherapy
for patients in the control arm started two weeks earlier compared to patients in the ESA arm. For a sensitivity analysis these studies
were excluded, for results see below. Overall, exclusion of these two studies from the radiochemotherapy population (Thomas 2008;
Strauss 2008) did not change the overall result and did also not change the differences between the treatment populations.
Table 7: Sensitivity analyses for on study mortality in all cancer patients
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Two-stage meta-analysis based on ran-
dom- effects Cox model
Radiochemotherapy subset including
studies 21481, 70404
Radiochemotherapy subset without
studies 21481, 70404
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.09 (0.97-1.23)
Radiochemotherapy 1.47 (0.83-2.59) 1.50 (0.84-2.67)
Radiotherapy 1.51 (0.73-3.12) 1.51 (0.73-3.12)
Mixed 1.50 (0.62-3.66) 1.50 (0.62-3.66)
None 1.32 (1.06-1.65) 1.32 (1.06-1.65)
Overall 1.16 (1.05-1.29) 1.16 (1.05-1.29)
LR test 0.4234 0.4063
Sensitivity analysis for on study mortality in all cancer patients: exclusion of studies with different iron policies
in active and control arm
For seven studies (Machtay 2007; Untch 2008; Moebus 2007; Debus 2006; Savonije 2005; EPO-GER-20; OBE/EPO-INT-03) the
iron policies in the active and the control arm were different, for a sensitivity analysis we excluded these studies from the analysis, for
results see below. Overall, the results did not change.
Table 8: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis based on ran-
dom-effects Cox model
Including studies with different iron
policies
Excluding studies with different iron
policies
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.11 (0.98-1.26)
Radiochemotherapy 1.47 (0.83-2.59) 4.13 (0.46-36.94)
Radiotherapy 1.51 (0.73-3.12) 1.48 (0.64-3.45)
Mixed 1.50 (0.62-3.66) 1.50 (0.62-3.66)
None 1.32 (1.06-1.65) 1.32 (1.06-1.65)
Overall 1.16 (1.05-1.29) 1.17 (1.05-1.30)
161Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
LR test 0.4234 0.3974
Sensitivity analyses for on study mortality: exclusion of studies terminated prematurely
Fourteen studies were terminated prematurely (Charu 2007; CC2574-P-174; Quirt 1996; Goss 2005; Wright 2007; EPO-GBR-7;
EPO-GER-20; Debus 2006; Thomas 2008; Leyland-Jones 2003; Grote 2005; OBE/EPO-INT-03; Vadhan-Raj 2004;Machtay 2007),
for a sensitivity analysis we excluded these studies from the analysis, for results see below. Apparently, exclusion of these studies reduced
the overall effect estimate; however, the change was small.
Table 9: Sensitivity analyses for on study mortality in all cancer patients
Two-stage meta-analysis based on ran-
dom-effects Cox model
Including prematurely stopped studies Excluding prematurely stopped studies
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.05 (0.91-1.21)
Radiotherapy/radiochemotherapy 1.48 (0.95-2.32) 1.22 (0.46-3.29)
Mixed 1.50 (0.62-3.66) 1.72 (0.67-4.41)
None 1.32 (1.06-1.65) 1.28 (1.01-1.63)
Overall 1.16 (1.05-1.29) 1.11 (0.99-1.25)
LR test 0.2715 0.4088
Sensitivity analysis for on study mortality: studies designed for long-term follow-up.
Twenty four studies (Hedenus 2003; Smith 2008; Pirker 2008; Vansteenkiste 2002; Aapro 2008; Untch 2008; Goss 2005; Chang 2005;
EPO-GBR-7; Debus 2006; Thomas 2008; Littlewood 2001; Milroy 2003; Thomas 2002; Leyland-Jones 2003; Pronzato 2002; Henke
2003; Osterborg 2002; Strauss 2008; Moebus 2007; Grote 2005; OBE/EPO-INT-03; Savonije 2005; Machtay 2007) were designed
for long-term follow-up, defined as follow-up of at least 12 months after treatment period. For a sensitivity analysis we restricted the
on study mortality analysis to these studies, for results see below. There is an apparent change in the chemotherapy group; however,
the confidence intervals are widely overlapping.
Table 10: Sensitivity analyses for on study mortality in all cancer patients at study level
Two-stage meta-analysis based on ran-
dom-effects Cox model
Including all studies Including only studies designed for long-term follow-up
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ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.09 (0.97-1.23) 1.19 (1.03-1.37)
Radiochemotherapy 1.47 (0.83-2.59) 1.47 (0.83-2.59)
Radiotherapy 1.51 (0.73-3.12) 1.51 (0.72-3.12)
Mixed 1.50 (0.62-3.66) -
None 1.32 (1.06-1.65) 1.37 (1.05-1.78)
Overall 1.16 (1.05-1.29) 1.24 (1.10-1.41)
LR test 0.4234 0.6638
Sensitivity analysis for on study mortality chemotherapy population
Sensitivity analysis for on study mortality chemotherapy population patients truly receiving chemotherapy at individual
patient level
We analyzed whether the mortality signal seen in the chemotherapy population can be explained by patients in these studies not
receiving chemotherapy. For this analysis we included all patients from the chemotherapy trials and restricted the analysis to those
patients who did receive chemotherapy as reported in the data set provided. Patients who did not receive chemotherapy and patients
without reported data whether or not they received chemotherapy were excluded from the analysis. In the next step we restricted
the analysis to patients who truly received chemotherapy and received at least one dose of ESA in the active arm and zero doses of
ESA in the control arm, for results see table below. We then included stepwise patients from the treatment populations “mixed” and
“radiochemotherapy” and restricted the analyses stepwise as outlined above, for results see below.
Table 11: Sensitivity analyses for on study mortality in chemotherapy patients
Two-stage meta-analysis
based on random-effects Cox
model
ESA versus control
HR (95% CI)
P value N included
Chemotherapy trials
Analysis restricted to studies re-
porting chemotherapy status of
each patient during ESA study
1.08 (0.95-1.24) 0.242 8732
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Analysis restricted to patients
who actually received chemo-
therapy (subsets included: “che-
motherapy”)
1.10 (0.96-1.27) 0.172 8481
Analysis restricted to patients
who actually received chemo-
therapyANDESA in active arm
AND no ESA in control arm
(subsets included: “chemother-
apy”)
1.09 (0.94-1.26) 0.257 8114
Chemotherapy and mixed trials
Analysis restricted to studies re-
porting chemotherapy status of
each patient during ESA study
1.09 (0.96-1.25) 0.199 8998
Analysis restricted to patients
who actually received chemo-
therapy (subsets included: “che-
motherapy” and “mixed”)
1.12 (0.97-1.28) 0.112 8651
Analysis restricted to patients
who actually received chemo-
therapyANDESA in active arm
AND no ESA in control arm
(subsets included: “chemother-
apy” and “mixed”)
1.10 (0.96-1.27) 0.173 8284
Chemotherapy, mixed and radiochemotherapy trials
Analysis restricted to studies re-
porting chemotherapy status of
each patient during ESA study
1.11 (0.96-1.27) 0.153 9661
Analysis restricted to patients
who actually received che-
motherapy (subsets: “chemo-
therapy”, “mixed” and “ra-
diochemotherapy”)
1.14 (1.00-1.30) 0.051 9307
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Analysis restricted to patients
who actually received chemo-
therapy AND ESA in active
arm AND no ESA in con-
trol arm (subsets included:
“chemotherapy”, “mixed” “ra-
diochemotherapy”)
1.12 (0.98-1.28) 0.101 8919
Overall the effect of ESA on patients receiving chemotherapy did not change, i.e. the effect estimate did not decrease. Therefore it is
unlikely that the observed effect of ESA in the subset chemotherapy treatment population can be explained by events in patients who
did not receive chemotherapy.
Studies with prespecified chemotherapy protocols at study level
Of the 38 studies classified as chemotherapy trial, in three studies (Untch 2008; Moebus 2007; EPO-GER-20) a detailed protocol that
specified the substance, dosage, timing and frequency of chemotherapy was part of the ESA study. We compared the results of these
studies with chemotherapy studies where the chemotherapy modalities were not specified in detail, for results see below. Of note: in
two (Untch 2008; Moebus 2007) of the studies with prespecified chemotherapy protocols, no patient died during on study treatment
phase. Overall, there was no evidence for a difference between studies with and without prespecified study protocol.
Table 12: Sensitivity analysis for on study mortality in chemotherapy patients
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Chemotherapy with prespecified chemotherapy protocol* 0.61 (0.211.76)
Chemotherapy without prespecified chemotherapy protocol 1.10 (0.97-1.24)
Overall 1.09 (0.97-1.23)
LR test 0.2702
*Only one study included (EPO-GER-20)
Table 13: Sensitivity analysis for overall survival in chemotherapy patients
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Chemotherapy with prespecified chemotherapy protocol* 1.11 (0.861.45)
Chemotherapy without prespecified chemotherapy protocol 1.03 (0.96-1.10)
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Overall 1.04 (0.97-1.11)
LR test 0.5937
*Three studies included (Untch 2008; Moebus 2007; EPO-GER-20)
Sensitivity analyses for radiotherapy population
Studies with prespecified radiotherapy protocols at study level
Of the eight studies classified as radiotherapy and radiochemotherapy population, in one radiotherapy study (Machtay 2007) and in
three radiochemotherapy studies (Thomas 2008; Debus 2006; Strauss 2008) a detailed anti-cancer treatment protocol was part of the
ESA study. We compared the results of these studies with radiotherapy/radiochemotherapy studies where the treatment modalities were
not specified in detail. There was no evidence for a difference between these two subsets of studies, for results see below.
Table 14: Sensitivity analysis for on study mortality in radiotherapy patients at study level
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Radiotherapy/radiochemotherapy with prespecified treatment
protocol
1.39 (0.812.40)
Radiotherapy/radiochemotherapy without prespecified treatment
protocol
1.69 (0.773.73)
Overall 1.48 (0.95-2.32)
LR test 0.6233
Table 15: Sensitivity analysis for overall survival in radiotherapy patients at study level
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Radiotherapy/radiochemotherapy with prespecified treatment
protocol
1.05 (0.751.46)
Radiotherapy/radiochemotherapy without prespecified treatment
protocol
1.16 (0.951.41)
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Overall 1.06 (0.90-1.26)
LR test 0.1051
Sensitivity analyses for overall survival
Sensitivity analysis for overall survival: studies designed for long-term follow-up.
Twenty four studies (Hedenus 2003; Smith 2008; Pirker 2008; Vansteenkiste 2002; Aapro 2008; Untch 2008; Goss 2005; Chang 2005;
EPO-GBR-7; Debus 2006; Thomas 2008; Littlewood 2001; Milroy 2003; Thomas 2002; Leyland-Jones 2003; Pronzato 2002; Henke
2003; Osterborg 2002; Strauss 2008; Moebus 2007; Grote 2005; OBE/EPO-INT-03; Savonije 2005; Machtay 2007) were designed
for long-term follow-up, defined as follow-up of at least 12 months after treatment period. For a sensitivity analysis we restricted overall
survival to these studies, for results see below. Overall, the results did not change.
Table 16: Sensitivity analysis for overall survival in all cancer patients: studies designed for long-term follow-up
Two-stage meta-analysis based on ran-
dom-effects Cox model
Including all studies Including only studies designed for long-term follow-up
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.04 (0.97-1.11) 1.06 (0.97-1.15)
Radiochemotherapy 0.98 (0.75-1.27) 1.02 (0.74-1.41)
Radiotherapy 1.17 (0.96-1.42) 1.17 (0.96-1.42)
Mixed 1.50 (0.62-3.66) -
None 1.22 (1.04-1.44) 1.22 (1.02-1.47)
Overall 1.06 (1.00-1.12) 1.07 (0.99-1.15)
LR test 0.11 0.1240
Sensitivity analysis for overall survival: exclusion of studies terminated prematurely
Fourteen studies were terminated prematurely (Charu 2007; CC2574-P-174; Quirt 1996; Goss 2005; Wright 2007; EPO-GBR-7 ;
EPO-GER-20; Debus 2006; Thomas 2008; Leyland-Jones 2003; Grote 2005; OBE/EPO-INT-03; Vadhan-Raj 2004;Machtay 2007),
for a sensitivity analysis we excluded these studies from the analysis, for results see below. Exclusion of these studies did not affect the
overall effect estimate.
Table 17: Sensitivity analysis for overall survival in all cancer patients
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Two-stage meta-analysis based on ran-
dom-effects Cox model
Including prematurely stopped studies Excluding prematurely stopped studies
ESA versus control HR (95% CI) HR (95% CI)
Chemotherapy 1.04 (0.97-1.11) 1.01 (0.94-1.08)
Radiochemotherapy 0.98 (0.75-1.27) 2.00 (0.65-6.15)
Radiotherapy 1.17 (0.96-1.42) 1.27 (0.96-1.69)
Mixed 1.50 (0.62-3.66) 1.72 (0.67-4.41)
None 1.22 (1.04-1.44) 1.19 (1.00-1.42)
Overall 1.06 (1.00-1.12) 1.05 (0.98-1.42)
LR test 0.11 0.1128
Appendix 4. Exploratory analyses
Analyses that were not planned at the protocol stage are listed in this section.
Characteristics of studies included: changes over time
We evaluated changes over time of the characteristics of the included studies based on the year when the last patient was randomized
into the respective study. Cut off for this binary comparison was last patient randomized before (early studies) or after 2000 (later
studies). Patients in early studies were more likely to have Hb baseline < 10 g/dL (63% versus 25%) and less likely to have solid tumors
(46% versus 85%). None of the early studies evaluated survival as primary endpoint and none included a stringent anticancer therapy
protocol. All (100%) of the early studies applied ESA three times per week or more often compared to 31% of the more recent studies.
Early studies used more likely to use chemotherapies (83% versus 66%) and no radiotherapy (0% versus 9%). Reporting of the study
methods changed over time: while reporting of concealment of allocation improved over time (42% adequate in the early and 76%
adequate in the late studies); reporting of randomization procedures did not improve (adequate in 42% of the early studies and 27%
in the late studies). Although the study designs changed over time, the observed hazard ratios for on study mortality did not change,
i.e. the percentage of studies reporting increased mortality (HR => 1.0) was identical in the early and the more recent studies (50%
versus 51%), see Figure 18.
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Figure 18. Comparing studies with last patient randomized before 2000 or after 2000
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Exploratory analysis: Kaplan-Meier curves for all endpoints
Kaplan-Meier survival curves for all four outcomes are presented below. For these curves patient data were pooled without stratification
for study, see Figure 19, Figure 20, Figure 21 and Figure 22.
Figure 19. Pooled Kaplan Meier plot for on study mortality in all cancer patients
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Figure 20. Pooled Kaplan Meier plot for on study mortality in chemotherapy patients
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Figure 21. Pooled Kaplan Meier plot for overall survival in all cancer trials
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Figure 22. Pooled Kaplan Meier plot for overall survival in chemotherapy trials (subset analysis)
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Exploratory analyses of interaction terms for on study mortality, all cancer patients
History of thromboembolic events
In the analysis of on study mortality in all cancer patients, patients with a history of thromboembolic events were less likely to die
when receiving ESAs (HR 0.80, 95% CI 0.52-1.23) compared to patients without a previous thromboembolic event and receiving
ESAs (HR 1.23, 95% CI 1.09-1.39, test for interaction: 0.0605. The effect remained after adjusting for sex, age, Hb at baseline and
tumor type (P value for interaction = 0.0440), see table below. History of thromboembolic events was more often recorded in more
recent studies (46% missing in studies with last patient randomized before 2000 versus 27% in the more recent studies). Patients with
a history of thromboembolic events had more often a poor ECOG performance status (12% versus 6%) and high serum EPO levels
(7% versus 3% serum EPO > 500) compared to patients without a positive history of thromboembolic events. There was no difference
with respect to percentage of patients with metastatic disease. When adjusting for age, sex, Hb at baseline, tumor type and in addition
ECOG and serum EPO level the observed effect became more pronounced, see table below. However, only 7999 out of 13933 (57%)
and 4281 (31%) of patients were included in these analyses; others were excluded because of missing data. Therefore, a selection bias
cannot be excluded.
Table 1: Assessment of history of thromboembolic events and effect modification, on study mortality in all cancer patients
On
study
mortal-
ity
all can-
cer pa-
tients
Bivariate
ESA versus control
Multivariate
ESA versus control
Multivariate
ESA versus control
Multivariate
ESA versus control
Inter-
action
term
ESA*HTX ESA*HTX ESA*HTX ESA*HTX
Model
ad-
justed
for
- age, sex, Hb, tumor type age, sex, Hb, tumor type
and ECOG
age, sex, Hb, tumor type and
serum EPO
Pa-
tients
in-
cluded
n = 9620 n = 9467 n = 7999 n = 4281
HR 95% CI P* HR 95% CI P* HR 95% CI P* HR 95% CI P*
History of thromboembolic events (HTX)
Yes 0.80 0.52-
1.23
0.0605 0.77 0.50-
1.19
0.0440 0.75 0.48-
1.18
0.0338 0.48 0.25-
0.93
0.0129
No 1.23 1.09-
1.39
1.22 1.08-
1.38
1.25 1.10-
1.42
1.13 0.94-
1.34
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(Continued)
Miss-
ing / not
reported
1.09 0.87-
1.35
- omitted omitted - omitted omitted - omitted omitted -
Over-
all, un-
ad-
justed
1.20 1.07-
1.34
- 1.20 1.07-
1.34
- 1.21 1.07-
1.36
- 1.10 0.93-
1.30
-
*P value from LR test, patients with missing values were excluded from tests for interactions
Hematocrit at baseline
In the analysis of on study mortality in all cancer patients, there was some evidence that patients with a very low hematocrit at baseline
(< 23.5%) had an increased risk to die compared to patients with higher hematocrit levels at baseline. Compared to patients with Hct
above 23.5% at baseline, patients with low Hct had more often metastatic disease (89% versus 79%), were more often aged > 65 years
(44% versus 40%) and had more often a poor ECOG performance status (4.7% versus 1.7%). Patients with low Hct values at baseline
had also low Hb values and there was a correlation between Hct and Hb at baseline (correlation coefficient 0.8335). Hct data were
missing for 21% of patients of the total population. In studies which recruited until 2000 (year last patient randomized) data were
missing for only 8% of patients whereas for 24% of patients in the more recent studies Hct at baseline was not recorded.
After adjusting for age, sex, Hb at baseline and tumor type the effect remained, see table below. When in addition tumor stage was
included in the multivariate model the effect of Hct on mortality was attenuated and the interaction test was not statistically significant.
When ECOG performance status was included the effect of low Hct increased and the test for interaction was statistically significant.
However, since only 9714 (70%) and 7686 (55%) of the total patient population was included in these analyses, the power for statistical
tests was reduced and a selection bias cannot be excluded. For results see table below.
Table 2: Assessment of additional factors for hematocrit and interaction, on study mortality all cancer patients
On
study
mortal-
ity
all can-
cer pa-
tients
Bivariate
ESA versus control
HCT*ESA
Multivariate
ESA versus control
HCT*ESA
Multivariate
ESA versus control
HCT*ESA
Multivariate
ESA versus control
HCT*ESA
Ad-
justed
for
- age, sex, Hb, tumor type age, sex, Hb, tumor type
and tumor stage
age, sex, Hb, tumor type and
ECOG
Pa-
tients
in-
cluded
n = 11036 n = 10972 n = 9714 n = 7686
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HR 95% CI P* HR 95% CI P* HR 95% CI P* HR 95% CI P*
Hct at baseline
<
23.5%
2.19 1.35-
3.55
0.0110 2.13 1.30-
3.48
0.0191 1.92 1.13-
3.24
0.1220 2.85 1.47-5.53 0.0254
23.5-
29.4%
0.96 0.78-
1.17
0.96 0.79-
1.18
1.00 0.80-
1.24
1.00 0.80-1.26
29.4-
35.3%
1.17 0.99-
1.39
1.15 0.97-
1.37
1.23 1.02-
1.48
1.17 0.96-1.42
35.3-
41.2%
1.41 1.12-
1.76
1.39 1.10-
1.74
1.37 1.08-
1.72
1.39 1.07-1.79
>
41.2%
1.12 0.73-
1.70
1.15 0.76-
1.76
1.15 0.75-
1.75
1.15 0.71-1.89
Missing 1.09 0.76-
1.55
- omitted - omitted - omitted -
Over-
all, un-
ad-
justed
1.18 1.06-
1.32
- 1.18 1.06-
1.32
- 1.22 1.09-
1.36
- 1.20 1.06-1.35 -
*P value LR test, missing data were excluded from LR tests
Planned frequency of ESA application
In the analysis of on study mortality in all cancer patients there was some evidence for an effect modification of planned frequency of
ESA application and on study mortality in all cancer patients, i.e. patients receiving ESAs three times per week or more frequently were
less likely to die compared to patients receiving ESAs only once or less often per week. This effect remained after adjusting for age, sex,
Hb and tumor type. However, other aspects of study design were associated with the planned frequency of ESA application. Studies in
which ESA was applied three times per week (TIW) or more often had lower average starting doses of ESAs (62% of TIW studies with
ESA starting dose < 40000 per week). TIW studies were older, i.e. 63% of TIW studies randomized patients prior to calendar year
2000, whereas none of the studies that administered ESA QW or less frequently had completed randomization before 2000. In none of
the TIW studies survival was assessed as primary endpoint. There were no major differences with regard to underlying chemotherapy,
i.e. percentage of studies on chemotherapy, radiotherapy or no therapy was distributed equally across different application frequencies;
the same applies to the planned duration of the ESA treatment. In meta-regression analyses these factors were explored, for results see
table next page. Analyses were based both on unadjusted and adjusted HRs stemming from the 53 included studies.
Table 3a: Meta-regression analysis for planned frequency based on unadjusted hazard ratios for individual studies
176Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
On study
mortal-
ity
all cancer
patients
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus control
Addi-
tional in-
cluded
vari-
able(s)
endpoint planned weekly
ESA dose
year last patient
randomized
endpoint and
planned weekly
dose
last patient randomized, endpoint
and planned weekly dose
HR of
studies
adjusted
for
- - - - -
Studies
included
n = 53 n = 53 n = 53 n = 53 n = 53
Planned
fre-
quency
of
ESA ap-
plication
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Three
times per
week or
more fre-
quent
1.09 0.76-1.58 0.92 0.75-1.14 0.94 0.68-1.29 1.05 0.73-1.53 1.00 0.60-1.66
Once per
week
1.44 1.17-1.77 1.26 0.86-1.84 1.19 0.76-1.88 1.27 0.85-1.89 1.19 0.63-2.23
Every sec-
ond week
or less fre-
quent
0.93 0.50-1.73 0.94 0.59-1.52 0.90 0.49-1.64 0.80 0.39-1.62 0.75 0.29-1.93
Other 0.96 0.67-1.33 0.71 0.44-1.76 0.65 0.33-1.31 0.77 0.47-1.27 0.79 0.33-1.91
Test
for differ-
ences be-
tween
p = 0.0669 p = 0.1196 p = 0.0940 p = 0.1560 p = 0.4270
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sub-
groups*
*P value for test for differences between subgroups from meta-regression (Wald test)
Table 3b: Meta-regression analysis for planned frequency based on adjusted hazard ratios for individual studies
On study
mortal-
ity
all cancer
patients
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus con-
trol
Meta-regression
ESA versus control
Addi-
tional in-
cluded
vari-
able(s)
endpoint planned weekly
ESA dose
last patient ran-
domized
endpoint and
planned weekly
dose
year last patient randomized, end-
point and planned weekly dose
HR of
studies
adjusted
for
Age, sex, Hb, tu-
mor type
Age, sex, Hb, tu-
mor type
Age, sex, Hb, tu-
mor type
Age, sex, Hb, tu-
mor type
Age, sex, Hb, tumor type
Studies
included
n = 53 n = 53 n = 53 n = 53 n = 53
Planned
fre-
quency
of
ESA ap-
plication
HR 95% CI HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Three
times per
week or
more fre-
quent
1.14 0.78-1.67 0.93 0.74-1.17 0.99 0.69-1.41 1.08 0.74-1.59 0.97 0.57-1.68
Once per
week
1.46 1.18-1.80 1.34 0.91-1.99 1.17 0.72-1.91 1.39 0.92-2.09 1.16 0.60-2.26
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Every sec-
ond week
or less fre-
quent
0.88 0.46-1.67 0.92 0.56-1.50 0.87 0.46-1.65 0.80 0.38-1.66 0.67 0.25-1.80
Other 0.91 0.64-1.29 0.67 0.40-1.10 0.64 0.31-1.33 0.72 0.43-1.20 0.72 0.29-1.83
Test
for differ-
ences be-
tween
sub-
groups*
p = 0.0424 p = 0.0363 p = 0.1668 p = 0.0423 p = 0.3000
*P value for test for differences between subgroups from meta-regression (Wald test)
Exploratory analyses of interaction terms for overall survival, chemotherapy trials
In the overall survival analysis in chemotherapy trials, sex showed a statistically significant interaction term in the bivariate analysis.
Women were at increased risk to die when receiving ESAs (HR 1.10, 95% CI 1.01-1.21) compared to men (HR 0.96, 95% cI 0.87-
1.06, P value for interaction: 0.0370). When adjusting in addition for age, Hb at baseline and tumor category, the modifying effect for
sex remained (P value for interaction 0.0362). A potential explanation for this finding is the large number of female patients with breast
cancer included in the analysis. I.e. of the 9892 patients included in the multivariate model testing for interaction, 4303 (43%) patients
were diagnosed with breast cancer, of which 1998 (46%) had metastatic disease. When patients with breast cancer were removed from
the analysis, the modifying effect of sex on overall survival in chemotherapy patients was attenuated (P value LR test model with
& without interaction term for sex excluding breast cancer patients = 0.1571). In the next steps we also excluded patients with a)
gynecological cancers and b) prostate and testicular cancer, restricting the analysis to cancers that can occur both in male and female
patients. The effect of sex was further attenuated and the test statistic was not significant, however, 63% of the patient population was
excluded from the analysis with this strategy. In none of the analyses the modifying effect of sex on survival disappeared completely,
however, the differences observed were small.
Table 4: Overall survival in chemotherapy trials, tests for interaction, univariate and multivariate models
Over-
all
sur-
vival
in
che-
mo-
ther-
apy
trials
Bivariate
ESA versus control
Multivariate
ESA versus control
Multivariate
ESA versus control
Multivariate
ESA versus control
Multivariate
ESA versus control
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In-
terac-
tion
term
ESA*sex ESA*sex ESA*sex ESA*sex ESA*sex
Ad-
justed
for
- age, sex, Hb, tumor
type
age, sex, Hb, tumor
type
age, sex, Hb, tumor
type
age, sex, Hb, tumor
type
Pa-
tients
ex-
cluded
- - excluding breast can-
cer patients
excluding breast can-
cer and gynecological
cancer patients
excluding breast can-
cer, gynecological can-
cer as well as prostate
and testicular cancer
patients
Pa-
tients
in-
cluded
n = 10441 n = 9892 n = 6257 n = 5205 5128
ESA
ver-
sus
con-
trol
HR 95%
CI
P* HR 95%
CI
P* HR 95%
CI
P* HR 95%
CI
P* HR 95%
CI
P*
Sex
Male 0.96 0.87-
1.06 0.0370
0.97 0.87-
1.07 0.0362
0.97 0.87-
1.07 0.1571
0.97 0.87-
1.07 0.2071
0.97 0.87-
1.07
0.2169
Fe-
male
1.10 1.01-
1.21
1.12 1.02-
1.22
1.09 0.96-
1.23
1.07 0.94-
1.23
1.07 0.94-
1.23
Over-
all re-
sult,
unad-
justed
1.04 0.97-
1.11
- 1.04 0.97-
1.11
- 1.00 0.93-
1.08
- 1.00 0.91-
1.07
- 0.99 0.92-
1.08
-
*P value LR test comparing model with & without interaction term
Exploratory analysis for Hb change over time at study level in control arm
In this analysis we assessed the influence of myelosuppressive anticancer treatments. The only measures for myelosuppression available
were Hb values in the control arm over time. Other laboratory values, such as platelets, were not requested for the present analysis.
For each study we assessed whether the Hb decreased over time or not by plotting the Hb of the control arm of each study over time.
Studies with Hb decrease of > 1 g/dL from baseline within 50 days were categorized as “Hb decrease”, studies with Hb within +1 g/dL
to 1 g/dL margin from baseline within 50 days were categorized as “no change”. Studies with an Hb increase > 1 g/dL from baseline
within 50 days were categorized as “Hb increase”. We further differentiated whether the baseline Hb of the respective study was <
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10 g/dL, 10-12 g/dL or > 12 g/dL at baseline. Please note: the classification of the studies was made at study level; the Hb curve of
an individual patient was not assessed. All studies regardless of treatment population category were included in this analysis. Hb over
time is only a proxy for myelosuppression and red blood cell transfusions might confound the Hb levels over time. Overall, there is no
evidence for a difference between the explored groups.
Table 5: Exploratory analysis for on study mortality in all cancer patients, Hb change in control arm
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Hb increase 1.18 (95% CI 0.70-1.98)
Hb no change 1.17 (95% CI 1.04-1.32)
Hb decrease 1.14 (95% CI 0.91-1.43)
Unclear/not reported 0.62 (95% CI 0.16-2.43)
Overall 1.16 (95% CI 1.05-1.29)
LR test 0.8154
Table 6: Exploratory analysis for on study mortality in all cancer patients, Hb change in control arm
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Baseline Hb < 10 g/dL & Hb no change 1.08 (95% CI 0.90-1.30)
Baseline Hb < 10 g/dL & Hb increase 1.18 (95% CI 0.70-1.98)
Baseline Hb 10-12 g/dL & Hb decrease 1.02 (95% CI 0.70-1.50)
Baseline Hb 10-12 g/dL & Hb no change 1.13 (95% CI 0.91-1.40)
Baseline Hb > 12 g/dL & Hb decrease 1.21 (95% CI 0.91-1.61)
Baseline Hb > 12 g/dL & Hb no change 1.44 (95% CI 1.11-1.88)
Unclear/not reported 0.62 (95% CI 0.16-2.43)
Overall 1.16 (95% CI 1.05-1.29)
LR test 0.6180
Exploratory analysis for Hb change over time at study level in ESA arm
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For this analysis the Hb change over time in the ESA arm for each study was plotted. Studies with an Hb increase of > 1 g/dL
from baseline within 50 days were categorized as “increase”. Studies with Hb decrease of > 1 g/dL from baseline within 50 days were
categorized as “decrease”, studies with Hb within +1 g/dL to 1 g/dL margin from baseline within 50 days were categorized as “no
change”. We further differentiated whether the baseline Hb of the respective study was < 10 g/dL, 10-12 g/dL or > 12 g/dL in the ESA
arm. Please note: the classification of the studies was made at study level; the Hb curve of an individual patient was not assessed. All
studies regardless of treatment population category were included in this analysis. Overall, there is no evidence for a difference between
the explored groups.
Table 7: Exploratory analysis for on study mortality in all cancer patients, Hb change in ESA arm at study level
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Hb increase 1.12 (95% CI 0.98-1.29)
Hb no change 1.23 (95% CI 1.05-1.44)
Hb decrease 1.04 (95% CI 0.48-2.24)
Unclear/not reported 0.62 (95% CI 0.16-2.43)
Overall 1.16 (95% CI 1.05-1.29)
LR test 0.7120
Table 8: Exploratory analysis for on study mortality in all cancer patients, Hb change in ESA arm at study level
Two-stage meta-analysis based on random-effects Cox model ESA versus control
HR (95% CI)
Baseline Hb < 10 g/dL & Hb no change 1.00 (95% CI 0.50-2.00)
Baseline Hb < 10 g/dL & Hb increase 1.07 (95% CI 0.88-1.30)
Baseline Hb 10-12 g/dL & Hb no change 1.17 (95% CI 0.83-1.64)
Baseline Hb 10-12 g/dL & Hb increase 1.10 (95% CI 0.84-1.46)
Baseline Hb > 12 g/dL & Hb decrease 1.04 (95% CI 0.48-2.24)
Baseline Hb > 12 g/dL & Hb no change 1.25 (95% CI 1.02-1.53)
Baseline Hb > 12 g/dL & Hb increase 1.93 (95% CI 0.66-5.67)
Unclear/not reported 0.62 (95% CI 0.16-2.43)
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Overall 1.16 (95% CI 1.05-1.29)
LR test 0.8420
Exploratory analysis for longest follow-up available in studies with “cross-over”
In twelve studies patients in both the control and the active treatment arm were allowed to receive ESAs after a defined treatment
period. For the main analysis we included only events and time under observation during this defined treatment period in the analysis.
In the overall survival, which looked at the longest follow-up available, these studies were included only based on the events and the
time period of the defined treatment period. For the purpose of a sensitivity analysis we included the longest follow-up of these studies
for the overall survival analysis as well. The percentage of patients in both the control and the ESA arm who were receiving ESAs during
the “cross-over” period, varied between studies. For details see tables below. When including cross-over trials based on the longest
follow-up available the overall estimates were attenuated for both all cancer patients and chemotherapy trials. A cut off depending on
a percentage of patients receiving ESAs was not applied in order to decide whether a specific study would be included in the analysis
based on the on study or the longest follow-up estimate. These cut-offs were not applied because they had not been defined at the
protocol stage and the percentage of patients receiving ESAs during open label phase was continuously increasing.
Table 9: Studies with “cross-over”: percentage of total study population receiving ESA during open-label phase
Studies with “cross-over”: percentage of total study population receiving ESA during open-label phase
Study protocol Study number Total Comment
CC2574-P-174 60584 93% Data provided by company
J89-040 98358 81% Data provided by company
EPO-INT-3/ CC 2574-P-034 36274 76% Data provided by company
H87-032, 87-014/OEU-U20,
87-015/OEU-U21
98906 75% Data provided by company
I88-037, 87-016, 87-017 34917 75% Data provided by company
I88-036, 87-018, 87-019 70332 74% Data provided by company
EPO-INT-2/ CC 2574-P-467 11220 60% Data provided by company
20000219 53081 59% Data from clinical study report
980291 35466 48% Data from clinical study report
MF4321 45434 48% Data from clinical study report
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980291SCH2 26117 40% Data from clinical study report
EPO-INT-76/EPO-CA-489 17100 24% Data provided by company
Table 10: Sensitivity analyses including longest follow-up available for studies with “cross-over”
Two-stage log-rank fixed-ef-
fects meta-analysis
ESA versus control
HR (95% CI)
P value N included
Overall survival, all cancer pa-
tients
Overall survival, all cancer
patients, cross-over trials re-
stricted to on study mortality
1.06 (1.00-1.12) 0.0561 13933
Overall survival, all cancer pa-
tients, cross-over trials included
based on longest follow-up
available
1.04 (0.98-1.09) 0.1719 13933
Overall survival, chemother-
apy trials
Overall survival, chemotherapy
trials, cross-over trials restricted
to on study mortality
1.04 (0.97-1.11) 0.3081 10441
Overall survival, chemother-
apy trials, cross-over trials in-
cluded based on longest follow-
up available
1.02 (0.96-1.08) 0.5743 10441
Exploratory analysis for current license indication
It is difficult to conduct an analysis that matches the current license indication. The main limitation is that the current indication
recommends an Hb target of 12 g/dL. However, in none of the studies included in the present analysis the Hb ceiling was 12 g/dL
or below. The next limitation is that the “current license indication” is an ever changing definition. Based on these considerations an
analysis for the “current license indication” was not planned at the protocol for this meta-analysis (Bohlius 2008).
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Appendix 5. Funnel plots Baseline imbalances
The following figures present funnel plots of baseline imbalances.
ECOG Figure 23
Figure 23. Baseline imbalances ECOG
Level of EPO serum Figure 24
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Figure 24. Level of EPO serum
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BMI Figure 25
Figure 25. BMI
Time from cancer diagnosis to date of randomization Figure 26
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Figure 26. Time from cancer diagnosis to date of randomization
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Hemoglobin Figure 27
Figure 27. Hemoglobin
Hematocrit Figure 28
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Figure 28. Hematocrit
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Age Figure 29
Figure 29. Age
Sex Figure 30
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Figure 30. Sex
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ECOG low versus high Figure 31
Figure 31. ECOG low versus high
History of thromboembolic events Figure 32
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Figure 32. History of thromboembolic events
194Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
History of cardiovascular events Figure 33
Figure 33. History of cardiovascular events
History of hypertension Figure 34
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Figure 34. History of hypertension
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History of diabetes Figure 35
Figure 35. History of diabetes
Appendix 6. Assessment of interaction for mortality in all cancer patients during the active study
period
Mortality in all can-
cer patients during
the active study pe-
riod
ESA arm Control arm ESA versus control
Patients events sample % events sample % HR 95% CI P value*
Patient
level
charac-
teristics
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(Continued)
Hb at
base-
line (con-
tinuous)
0.82
Hb at
baseline
(cat. 1)
0.75
Hb ≤ 8
g/dL
791 90 448 20% 58 343 17% 1.28 0.92-1.78
Hb 8-≤
10 g/dL
3930 292 2222 13% 239 1708 14% 1.08 0.91-1.28
Hb 10-≤
12 g/dL
5004 300 2851 11% 220 2153 10% 1.22 1.03-1.46
Hb 12-≤
14 g/dL
2843 141 1433 10% 114 1410 8% 1.28 1.00-1.64
Hb > 14
g/dL
839 37 428 9% 30 411 7% 1.06 0.66-1.72
Un-
known
526 5 252 2% 4 274 1% 0.91 0.24-3.40
Hb at
baseline
(cat. 2)
0.79
Hb ≤ 8
g/dL
791 90 448 20% 58 343 17% 1.28 0.92-1.79
Hb 8-≤ 9
g/dL
1319 117 742 16% 101 577 18% 1.05 0.81-1.38
Hb 9-≤
10 g/dL
2611 175 1480 12% 138 1131 12% 1.11 0.89-1.39
Hb 10-≤
11 g/dL
2927 188 1699 11% 121 1228 10% 1.34 1.07-1.69
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(Continued)
Hb 11-≤
12 g/dL
2077 112 1152 10% 99 925 11% 1.07 0.82-1.41
Hb 12-≤
13 g/dL
1739 92 873 11% 80 866 9% 1.22 0.90-1.64
Hb 13-≤
14 g/dL
1104 49 560 9% 34 544 6% 1.45 0.93-2.24
Hb >14
g/dL
839 37 428 9% 30 411 7% 1.06 0.65-1.72
Un-
known
526 5 252 2% 4 274 1% 0.92 0.25-3.44
Malig-
nancy
type
Tumour
(cat. 1)
0.16
Haema-
tologi-
cal malig-
nancies
2403 128 1400 9% 79 1003 8% 1.20 0.91-1.60
Solid tu-
mours
10795 684 5848 12% 532 4947 11% 1.20 1.07-1.35
Other 693 49 369 13% 51 324 16% 0.81 0.54-1.20
Missing /
unknown
42 4 17 24% 3 25 12% 1.99 0.44-8.94
Tumour
(cat. 2)
0.47
Haema-
tologi-
cal malig-
nancies
2403 128 1400 9% 79 1003 8% 1.19 0.90-1.59
Breast
cancer
4302 224 2245 10% 164 2057 8% 1.34 1.10-1.65
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(Continued)
Head and
neck can-
cer
868 23 443 5% 20 425 5% 1.13 0.62-2.07
Lung
cancer
3076 292 1618 18% 243 1458 17% 1.17 0.99-1.39
Gastroin-
testinal
cancer
708 61 434 14% 44 274 16% 0.96 0.65-1.42
Gynaeco-
logical
cancer
1399 40 842 5% 27 557 5% 1.18 0.72-1.94
Geni-
tourinary
cancer
442 44 266 17% 34 176 19% 1.02 0.65-1.60
Other 693 49 369 13% 51 324 16% 0.81 0.54-1.20
Missing /
unknown
42 4 17 24% 3 25 12% 1.96 0.44-8.79
Sex
Male 5136 419 2854 15% 309 2282 14% 1.15 0.99-1.34 0.86
Female 8797 446 4780 9% 356 4017 9% 1.17 1.02-1.35
Age
Age con-
tinuous
0.87
Age cate-
gorical
0.50
< 18
years
123 0 55 0% 1 68 1% Not estimable Not estimable
≥18-35
years
346 11 191 6% 9 155 6% 0.83 0.34-2.01
≥35-45
years
1343 57 745 8% 34 598 6% 1.36 0.89-2.08
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(Continued)
≥45-55
years
3010 162 1614 10% 111 1396 8% 1.34 1.05-1.71
≥55-65
years
4193 256 2237 11% 222 1956 11% 1.07 0.89-1.28
≥65-75
years
3517 271 1970 14% 210 1547 14% 1.16 0.97-1.39
≥75
years
1389 108 816 13% 77 573 13% 1.27 0.94-1.70
Missing 12 0 6 0% 1 6 17% Not estimable Not estimable
Hct levels
at
baseline
Hct con-
tinuous
0.57
Hct cate-
gorical
0.01
≤23.5% 390 55 210 26% 24 180 13% 2.19 1.35-3.55
23.5-≤
29.4%
2788 199 1567 13% 191 1221 16% 0.96 0.78-1.17
29.4-≤
35.3%
4615 321 2692 12% 223 1923 12% 1.17 0.99-1.39
35.3-≤
41.2%
2458 176 1258 14% 130 1200 11% 1.41 1.12-1.76
> 41.2% 785 48 414 12% 40 371 11% 1.12 0.73-1.70
Missing 2897 66 1493 4% 57 1404 4% 1.09 0.76-1.55
Serum
Epo at
baseline
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(Continued)
Serum
Epo con-
tinuous
0.21
Serum
Epo cate-
gorical
0.54
<25
mU/ml
1497 95 876 11% 58 621 9% 1.33 0.96-1.85
25-<100
mU/ml
2908 195 1643 12% 171 1265 14% 0.98 0.80-1.21
100-
<200
mU/ml
740 73 451 16% 47 289 16% 1.08 0.75-1.57
200-
<500
mU/ml
325 29 190 15% 19 135 14% 1.29 0.72-2.31
> 500
mU/ml
181 21 103 20% 10 78 13% 1.26 0.59-2.69
Un-
known
8282 452 4371 10% 360 3911 9% 1.23 1.07-1.41
Perfor-
mance
score
ECOG
categori-
cal
0.63
ECOG 0 3392 86 1808 5% 76 1584 5% 1.15 0.85-1.57
ECOG 1 4900 327 2779 12% 250 2121 12% 1.14 0.97-1.35
ECOG 2 1678 241 933 26% 178 745 24% 1.21 1.00-1.47
ECOG 3 139 26 77 34% 18 62 29% 1.30 0.71-2.39
ECOG 4 3 1 2 50% 0 1 0% Not estimable Not estimable
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(Continued)
ECOG
missing
3821 184 2035 9% 143 1786 8% 1.12 0.90-1.39
ECOG
dichoto-
mous
0.56
ECOG 0,
1, 2
10083 655 5578 12% 505 4505 11% 1.18 1.05-1.33
ECOG 3,
4
142 27 79 34% 18 63 29% 1.42 0.78-2.59
ECOG
missing
3708 183 1977 9% 142 1731 8% 1.12 0.89-1.39
Body
mass in-
dex
≤ 19
kg/m²
865 76 424 18% 73 441 17% 1.00 0.73-1.39 0.72
19- ≤25
kg/m²
5487 374 2964 13% 277 2523 11% 1.21 1.04-1.42
25-≤ 30
kg/m²
3443 193 1864 10% 144 1579 9% 1.14 0.92-1.42
> 30
kg/m²
1650 74 867 9% 56 783 7% 1.26 0.89-1.79
Missing 2488 148 1515 10% 115 973 12% 1.22 0.95-1.57
History
of throm-
boem-
bolic
events
Yes 561 40 318 13% 42 243 17% 0.80 0.52-1.23 0.06
No 9059 637 5044 13% 474 4015 12% 1.23 1.09-1.39
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(Continued)
Missing /
not
reported
4313 188 2272 8% 149 2041 7% 1.09 0.87-1.35
History
of cardio-
vascular
events
Yes 3593 273 2002 14% 197 1591 12% 1.24 1.03-1.49 0.62
No 6729 404 3700 11% 319 3029 11% 1.17 1.01-1.35
Missing /
not
reported
3611 188 1932 10% 149 1679 9% 1.09 0.87-1.35
History
of hyper-
tension
Yes 2093 140 1219 11% 107 874 12% 1.15 0.90-1.49 0.76
No 7527 537 4143 13% 409 3384 12% 1.21 1.06-1.37
Missing /
not
reported
4313 188 2272 8% 149 2041 7% 1.09 0.88-1.35
His-
tory of di-
abetes
mellitus
Yes 709 62 372 17% 56 337 17% 1.12 0.78-1.61 0.70
No 7316 555 3927 14% 427 3389 13% 1.21 1.06-1.37
Missing /
not
reported
5908 248 3335 7% 182 2573 7% 1.11 0.91-1.34
Geo-
graphical
region
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(Continued)
Northern
America
3569 184 2004 9% 159 1565 10% 1.08 0.87-1.34 0.17
North-
ern,
Western
& South-
ern
Europe
7440 403 4030 10% 320 3410 9% 1.08 0.93-1.26
Eastern
Europe
1955 234 1030 23% 151 925 16% 1.44 1.17-1.77
Australia
& New
Zealand
342 20 216 9% 11 126 9% 1.42 0.68-2.97
Other 226 13 123 11% 13 103 13% 0.90 0.42-1.93
Missing /
not
reported
401 11 231 5% 11 170 6% 0.98 0.42-2.26
Tumour
stage
Metastatic
/
advanced
8113 692 4482 15% 527 3631 15% 1.20 1.07-1.34 0.76
Not
metastatic
/ not ad-
vanced
4039 63 2116 3% 45 1923 2% 1.28 0.87-1.87
Missing /
not
reported
1781 110 1036 11% 93 745 12% 0.92 0.69-1.22
Planned
Hb ceil-
ing
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(Continued)
Planned
Hb ceil-
ing (cat.
1)
0.98
≤Hb
13.0 g/dL
3043 209 1624 13% 157 1419 11% 1.19 0.97-1.47
Hb 13.0 -
≤15.0
g/dL
10193 599 5631 11% 468 4562 10% 1.16 1.03-1.32
Hb >15.0
g/dL
494 29 259 11% 23 235 10% 1.22 0.70-2.11
Other 203 28 120 23% 17 83 20% 1.12 0.61-2.06
Planned
Hb ceil-
ing (cat.
2)
0.88
≤Hb
13.0 g/dL
3043 209 1624 13% 157 1419 11% 1.19 0.97-1.47
Hb 13.0 -
≤14.0
g/dL
6816 381 3733 10% 322 3083 10% 1.12 0.97-1.31
Hb 14.0 -
≤15.0
g/dL
3377 218 1898 11% 146 1479 10% 1.25 1.01-1.54
>Hb 15.0
g/dL
494 29 259 11% 23 235 10% 1.22 0.70-2.11
Other 203 28 120 23% 17 83 20% 1.12 0.61-2.06
Study
level
charac-
teristics
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(Continued)
Treat-
ment
popula-
tion
Treat-
ment
popula-
tion (cat.
1)
Chemo-
therapy
10441 605 5676 11% 490 4765 10% 1.10 0.98-1.24 0.42
Ra-
diochemother-
apy
737 31 368 8% 20 369 5% 1.50 0.85-2.63
Radio-
therapy
799 19 408 5% 12 391 3% 1.52 0.74-3.14
Mixed 266 17 175 10% 7 91 8% 1.53 0.63-3.69
None 1690 193 1007 19% 136 683 20% 1.33 1.06-1.66
Treat-
ment
popula-
tion (cat.
2)
Chemo-
therapy
10441 605 5676 11% 490 4765 10% 1.10 0.98-1.24 0.27
Radio-
ther-
apy / ra-
diochemother-
apy
1536 50 776 6% 32 760 4% 1.51 0.97-2.35
Mixed 266 17 175 10% 7 91 8% 1.53 0.63-3.69
None 1690 193 1007 19% 136 683 20% 1.33 1.06-1.66
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(Continued)
Iron sup-
plemen-
tation
Fixed
iron sup-
plemen-
tation
2589 71 1293 5% 60 1296 5% 1.17 0.83-1.65 0.48
Iron sup-
plemen-
tation as
needed
11120 778 6232 12% 584 4888 12% 1.18 1.06-1.32
Other 224 16 109 15% 21 115 18% 0.79 0.41-1.51
Planned
ESA
treatment
duration
Up to 8
weeks
415 21 256 8% 17 159 11% 0.96 0.50-1.84 0.33
9-16
weeks
4800 244 2738 9% 204 2062 10% 1.08 0.89-1.30
> 17
weeks
3269 388 1701 23% 286 1568 18% 1.30 1.12-1.52
Until end
of
chemo-
or radio-
therapy
5449 212 2939 7% 158 2510 6% 1.09 0.88-1.34
Planned
weekly
ESA
dosage
< 100 µg
Darbepo-
etin or <
40000 IU
Epoetin
4197 238 2297 10% 193 1900 10% 0.98 0.81-1.19 0.12
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(Continued)
= 100 µg
Darbepo-
etin or =
40000 IU
Epoetin
3081 240 1545 16% 190 1536 12% 1.36 1.12-1.64
> 100 µg
Darbepo-
etin or >
40000 IU
Epoetin
3845 250 2076 12% 184 1769 10% 1.23 1.01-1.49
Other 2810 137 1716 8% 98 1094 9% 1.11 0.85-1.45
Planned frequency
of ESA application
Three
times per
week or
more fre-
quent
6131 311 3458 9% 238 2673 9% 1.01 0.85-1.20 0.03
Once per
week
3948 303 1972 15% 231 1976 12% 1.40 1.18-1.66
Every sec-
ond week
or less fre-
quent
3036 180 1795 10% 122 1241 10% 1.25 0.99-1.57
Other 818 71 409 17% 74 409 18% 0.93 0.67-1.29
Placebo
con-
trolled
trial
Yes 7657 594 4211 14% 456 3446 13% 1.21 1.07-1.37 0.38
No 6276 271 3423 8% 209 2853 7% 1.09 0.91-1.31
Ran-
domisa-
tion
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(Continued)
Adequate 3882 303 2047 15% 245 1835 13% 1.17 0.99-1.39 0.98
Unclear 10051 562 5587 10% 420 4464 9% 1.17 1.03-1.33
Conceal-
ment of
allocation
Adequate 10595 744 5839 13% 559 4756 12% 1.20 1.08-1.34 0.23
Unclear 3338 121 1795 7% 106 1543 7% 1.01 0.78-1.31
Endpoint
survival
Primary
endpoint
3116 247 1547 16% 195 1569 12% 1.30 1.08-1.57 0.41
Sec-
ondary
endpoint
4313 213 2282 9% 161 2031 8% 1.10 0.89-1.35
Safety
/adverse
events
6504 405 3805 11% 309 2699 11% 1.13 0.97-1.32
Year
of last pa-
tient ran-
domized
1990-
1994
1447 95 890 11% 67 557 12% 0.95 0.69-1.30 0.24
1995-
1999
1725 95 1001 9% 70 724 10% 0.96 0.70-1.32
2000-
2004
7620 431 4105 10% 337 3515 10% 1.26 1.10-1.46
2005-
2006
3141 244 1638 15% 191 1503 13% 1.18 0.98-1.43
Source of
data
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(Continued)
Manufac-
turer
12229 846 6789 12% 641 5440 12% 1.19 1.07-1.32 0.13
Clin-
ical study
group
1704 19 845 2% 24 859 3% 0.74 0.41-1.35
*P value for likelihood-ratio test, patients with missing data are excluded from the test, analysis based on one-
stage Cox fixed-effects model stratified by study
ESA=erythropoiesis-stimulating agents
Appendix 7. Assessment of interaction for mortality in chemotherapy trials during the active study
period
Mortality in chemotherapy trials during the active study period
ESA arm Control arm ESA versus control
Sub-
groups
Patients events sample % events sample % HR 95% CI p value*
Patient
level
charac-
teristics
Hb at
base-
line (con-
tinuous)
0.87
Hb at
baseline
(cat 1)
0.90
Hb ≤ 8
g/dL
569 52 321 16% 34 248 14% 1.20 0.78-1.86
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(Continued)
Hb 8-≤
10 g/dL
2888 188 1606 12% 156 1282 12% 1.07 0.86-1.33
Hb 10-≤
12 g/dL
3748 213 2121 10% 171 1627 11% 1.10 0.90-1.34
Hb 12-≤
14 g/dL
2185 119 1108 11% 100 1077 9% 1.23 0.94-1.60
Hb >14
g/dL
555 29 286 10% 25 269 9% 0.96 0.56-1.65
Un-
known
496 4 234 2% 4 262 2% 0.76 0.19-3.05
Hb at
baseline
(cat 2)
0.99
Hb ≤ 8
g/dL
569 52 321 16% 34 248 14% 1.21 0.78-1.86
Hb 8-≤ 9
g/dL
949 72 549 13% 59 400 15% 1.01 0.72-1.44
Hb 9-≤
10 g/dL
1939 116 1057 11% 97 882 11% 1.10 0.84-1.44
Hb 10-≤
11 g/dL
2074 113 1179 10% 86 895 10% 1.11 0.84-1.47
Hb 11-≤
12 g/dL
1674 100 942 11% 85 732 12% 1.08 0.81-1.45
Hb 12-≤
13 g/dL
1359 80 679 12% 68 680 10% 1.26 0.91-1.74
Hb 13-≤
14 g/dL
826 39 429 9% 32 397 8% 1.19 0.74-1.89
Hb >14
g/dL
555 29 286 10% 25 269 9% 0.96 0.56-1.65
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(Continued)
Un-
known
496 4 234 2% 4 262 2% 0.77 0.19-3.07
Malig-
nancy
type
Tumour
(cat. 1)
0.18
Haema-
tologi-
cal malig-
nancies
1832 99 1034 10% 65 798 8% 1.12 0.81-1.54
Solid tu-
mours
7967 464 4311 11% 379 3656 10% 1.14 0.99-1.31
Other 600 38 314 12% 43 286 15% 0.74 0.48-1.15
Missing /
unknown
42 4 17 24% 3 25 12% 1.96 0.44-8.81
Tumour
(cat. 2)
0.15
Haema-
tologi-
cal malig-
nancies
1832 99 1034 10% 65 798 8% 1.11 0.81-1.53
Breast
cancer
4038 209 2076 10% 152 1962 8% 1.38 1.12-1.70
Head and
neck can-
cer
26 1 12 8% 2 14 14% 0.63 0.06-6.99
Lung
cancer
2237 187 1172 16% 173 1065 16% 1.03 0.83-1.26
Gastroin-
testinal
cancer
429 32 267 12% 26 162 16% 0.81 0.48-1.37
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(Continued)
Gynaeco-
logical
cancer
1077 28 681 4% 18 396 5% 1.06 0.59-1.95
Geni-
tourinary
cancer
160 7 103 7% 8 57 14% 0.61 0.22-1.72
Other 600 38 314 12% 43 286 15% 0.74 0.48-1.15
Missing /
unknown
42 4 17 24% 3 25 12% 1.92 0.43-8.62
Sex
Male 3125 241 1720 14% 209 1405 15% 0.99 0.82-1.19 0.14
Female 7316 364 3956 9% 281 3360 8% 1.18 1.01-1.39
Age
Age con-
tinuous
0.57
Age cate-
gorical
0.34
< 18
years
123 0 55 0% 1 68 1% Not estimable Not estimable
≥18-35
years
312 9 171 5% 8 141 6% 0.78 0.30-2.03
≥35-45
years
1135 45 620 7% 28 515 5% 1.34 0.83-2.14
≥45-55
years
2425 123 1311 9% 93 1114 8% 1.22 0.93-1.60
≥55-65
years
3233 175 1724 10% 172 1509 11% 0.93 0.75-1.15
≥65-75
years
2444 190 1359 14% 146 1085 13% 1.16 0.93-1.44
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≥75
years
758 63 430 15% 41 328 13% 1.28 0.86-1.90
Missing /
unknown
11 0 6 0% 1 5 20% Not estimable Not estimable
Hct levels
at
baseline
Hct con-
tinuous
0.57
Hct cate-
gorical
0.22
≤ 23.5% 275 29 144 20% 17 131 13% 1.61 0.88-2.94
23.5-≤
29.4%
2033 118 1135 10% 109 898 12% 0.96 0.74-1.25
29.4-≤
35.3%
3281 208 1882 11% 163 1399 12% 1.02 0.83-1.25
35.3-≤
41.2%
1801 152 931 16% 115 870 13% 1.36 1.07-1.73
> 41.2% 459 39 249 16% 33 210 16% 1.07 0.67-1.71
Missing /
unknown
2592 59 1335 4% 53 1257 4% 1.04 0.72-1.52
Serum
Epo at
baseline
Serum
Epo con-
tinuous
0.91
Serum
Epo cate-
gorical
0.20
< 25
mU/ml
1032 68 608 11% 41 424 10% 1.34 0.91-1.98
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25-<100
mU/ml
2083 110 1162 9% 114 921 12% 0.79 0.61-1.03
100-
<200
mU/ml
518 45 314 14% 28 204 14% 1.14 0.71-1.84
200-
<500
mU/ml
227 18 134 13% 11 93 12% 1.18 0.56-2.51
≥ 500
mU/ml
99 8 57 14% 4 42 10% 1.01 0.30-3.39
Missing /
unknown
6482 356 3401 10% 292 3081 9% 1.18 1.01-1.38
Perfor-
mance
score
ECOG
categori-
cal
0.58
ECOG 0 3025 77 1582 5% 66 1443 5% 1.23 0.89-1.71
ECOG 1 3784 237 2105 11% 185 1679 11% 1.10 0.91-1.34
ECOG 2 1140 137 623 22% 114 517 22% 1.07 0.84-1.38
ECOG 3 105 15 57 26% 13 48 27% 0.98 0.46-2.07
ECOG 4 3 1 2 50% 0 1 0% Not estimable Not estimable
ECOG
missing /
unknown
2384 138 1307 11% 112 1077 10% 1.04 0.80-1.33
ECOG
dichoto-
mous
1.00
ECOG 0,
1, 2
7949 451 4310 10% 365 3639 10% 1.12 0.98-1.29
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ECOG 3,
4
108 16 59 27% 13 49 27% 1.12 0.54-2.34
ECOG
missing
2384 138 1307 11% 112 1077 10% 1.03 0.80-1.33
Body
mass in-
dex
≤ 19
kg/m²
607 43 292 15% 45 315 14% 0.95 0.63-1.45 0.63
19-≤ 25
kg/m²
4283 262 2318 11% 208 1965 11% 1.11 0.93-1.34
25-≤ 30
kg/m²
2698 143 1468 10% 116 1230 9% 1.01 0.79-1.30
> 30
kg/m²
1294 60 686 9% 44 608 7% 1.32 0.89-1.94
Missing /
not
reported
1559 97 912 11% 77 647 12% 1.22 0.90-1.65
History
of throm-
boem-
bolic
events
Yes 375 27 207 13% 29 168 17% 0.76 0.45-1.28 0.14
No 6292 400 3469 12% 320 2823 11% 1.14 0.98-1.32
Missing /
not
reported
3774 178 2000 9% 141 1774 8% 1.08 0.86-1.35
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History
of cardio-
vascular
events
Yes 2319 161 1295 12% 126 1024 12% 1.11 0.88-1.41 0.93
No 5050 266 2721 10% 223 2329 10% 1.10 0.92-1.31
Missing /
not
reported
3072 178 1660 11% 141 1412 10% 1.08 0.86-1.35
History
of hyper-
tension
Yes 1396 111 798 14% 81 598 14% 1.18 0.89-1.57 0.61
No 5271 316 2878 11% 268 2393 11% 1.08 0.92-1.28
Missing /
not
reported
3774 178 2000 9% 141 1774 8% 1.08 0.86-1.35
His-
tory of di-
abetes
mellitus
Yes 430 36 219 16% 37 211 18% 1.01 0.64-1.61 0.74
No 5149 350 2786 13% 286 2363 12% 1.10 0.94-1.29
Missing /
not
reported
4862 219 2671 8% 167 2191 8% 1.12 0.91-1.37
Geo-
graphical
region
Northern
America
2083 92 1088 8% 95 995 10% 0.95 0.71-1.26 0.35
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North-
ern,
Western
& South-
ern
Europe
6082 341 3342 10% 267 2740 10% 1.05 0.90-1.24
Eastern
Europe
1413 135 734 18% 98 679 14% 1.34 1.03-1.73
Australia
& New
Zealand
286 14 184 8% 7 102 7% 1.59 0.64-3.95
Other 189 13 106 12% 13 83 16% 0.90 0.42-1.94
Missing /
not
reported
388 10 222 5% 10 166 6% 1.02 0.42-2.45
Tumour
stage
Metastatic
/
advanced
6054 491 3325 15% 388 2729 14% 1.16 1.01-1.32 0.61
Not
metastatic
/ not ad-
vanced
2902 25 1491 2% 24 1411 2% 1.00 0.57-1.75
Missing /
not
reported
1485 89 860 10% 78 625 12% 0.82 0.60-1.12
Planned
Hb ceil-
ing
Planned
Hb ceil-
ing (cat 1)
0.28
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≤Hb
13.0 g/dL
1631 47 841 6% 49 790 6% 0.83 0.56-1.25
Hb 13.0 -
≤15.0
g/dL
8451 523 4630 11% 415 3821 11% 1.14 1.00-1.30
Hb >15.0
g/dL
280 20 150 13% 21 130 16% 0.90 0.48-1.67
Other 79 15 55 27% 5 24 21% 1.43 0.52-3.93
Planned
Hb ceil-
ing (cat 2)
0.38
≤Hb
13.0 g/dL
1631 47 841 6% 49 790 6% 0.83 0.56-1.25
Hb 13.0 -
≤14.0
g/dL
5930 323 3200 10% 277 2730 10% 1.10 0.93-1.29
Hb 14.0 -
≤15.0
g/dL
2521 200 1430 14% 138 1091 13% 1.22 0.98-1.52
>Hb 15.0
g/dL
280 20 150 13% 21 130 16% 0.90 0.48-1.67
Other 79 15 55 27% 5 24 21% 1.43 0.52-3.93
Study
level
charac-
teristics
Iron sup-
plemen-
tation
Fixed
iron sup-
plemen-
tation
1904 40 947 4% 40 957 4% 1.00 0.64-1.55 0.52
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Iron sup-
plemen-
tation as
needed
8313 549 4620 12% 429 3693 12% 1.12 0.99-1.28
Other 224 16 109 15% 21 115 18% 0.79 0.41-1.51
Planned
ESA
treatment
duration
up to 8
weeks
143 3 114 3% 2 29 7% 0.38 0.06-2.30 0.20
9-16
weeks
3823 183 2075 9% 167 1748 10% 1.01 0.82-1.25
> 17
weeks
2280 252 1184 21% 192 1096 18% 1.27 1.05-1.53
Until end
of
chemo-
or radio-
therapy
4195 167 2303 7% 129 1892 7% 1.00 0.79-1.26
Planned
weekly
ESA
dosage
< 100 µg
Darbepo-
etin or <
40000 IU
Epoetin
3733 208 2023 10% 174 1710 10% 0.96 0.78-1.18 0.29
<= 100 µg
Darbepo-
etin or =
40000 IU
Epoetin
2200 179 1101 16% 144 1099 13% 1.29 1.04-1.61
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> 100 µg
Darbepo-
etin or >
40000 IU
Epoetin
1998 86 987 9% 76 1011 8% 1.11 0.82-1.51
Other 2510 132 1565 8% 96 945 10% 1.08 0.83-1.42
Planned frequency
of ESA application
Three
times per
week or
more fre-
quent
5016 267 2853 9% 210 2163 10% 0.97 0.81-1.17 0.05
Once per
week
3067 242 1528 16% 185 1539 12% 1.35 1.12-1.64
Every sec-
ond week
or less fre-
quent
1540 25 886 3% 21 654 3% 0.92 0.51-1.68
Other 818 71 409 17% 74 409 18% 0.93 0.67-1.29
Placebo
con-
trolled
trial
Yes 5473 379 2996 13% 307 2477 12% 1.13 0.97-1.32 0.53
No 4968 226 2680 8% 183 2288 8% 1.05 0.86-1.28
Ran-
domisa-
tion
Adequate 3258 244 1693 14% 202 1565 13% 1.11 0.92-1.34 0.88
Unclear 7183 361 3983 9% 288 3200 9% 1.09 0.93-1.28
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Conceal-
ment of
allocation
Adequate 8252 545 4501 12% 423 3751 11% 1.15 1.01-1.30 0.07
Unclear 2189 60 1175 5% 67 1014 7% 0.81 0.57-1.16
Endpoint
survival
Primary
endpoint
2731 221 1352 16% 177 1379 13% 1.29 1.06-1.57 0.11
Sec-
ondary
endpoint
3222 189 1730 11% 147 1492 10% 1.04 0.84-1.30
Safety
/adverse
events
4488 195 2594 8% 166 1894 9% 0.96 0.78-1.18
Year
of last pa-
tient ran-
domized
1990-
1994
1057 65 650 10% 48 407 12% 0.86 0.59-1.26 0.16
1995-
1999
1725 95 1001 9% 70 724 10% 0.96 0.70-1.32
2000-
2004
6112 374 3263 11% 298 2849 10% 1.22 1.05-1.43
2005-
2006
1547 71 762 9% 74 785 9% 0.93 0.67-1.29
Source of
data
Manufac-
turer
8851 587 4889 12% 467 3962 12% 1.12 0.99-1.26 0.18
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Clin-
ical study
group
1590 18 787 2% 23 803 3% 0.73 0.39-1.36
*P value for likelihood-ratio test, patients with missing data are excluded from the test, analysis based on one-stage Cox fixed-effects
model stratified by study
ESA= erythropoiesis-stimulating agents
Appendix 8. Assessment of interaction for overall survival in all cancer patients
Overall survival in
all cancer patients
ESA arm Control arm ESA versus control
Sub-
groups
Patients events sample % events sample % HR 95% CI P value*
Patient
level
charac-
teristics
Hb at
baseline
Hb at
base-
line (con-
tinuous)
0.75
Hb at
baseline
(cat 1)
0.63
Hb ≤ 8
g/dL
791 176 448 39% 147 343 43% 1.08 0.87-1.35
Hb 8-
≤10 g/dL
3930 725 2222 33% 672 1708 39% 1.02 0.92-1.14
Hb 10-
≤12 g/dL
5004 967 2851 34% 777 2153 36% 1.11 1.01-1.22
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Hb 12-
≤14 g/dL
2843 566 1433 39% 553 1410 39% 1.06 0.95-1.20
Hb >14
g/dL
839 155 428 36% 155 411 38% 0.94 0.75-1.18
Un-
known
526 54 252 21% 46 274 17% 1.22 0.82-1.82
Hb at
baseline
(cat 2)
0.83
Hb ≤ 8
g/dL
791 176 448 39% 147 343 43% 1.08 0.87-1.35
Hb 8-≤9
g/dL
1319 256 742 35% 252 577 44% 1.05 0.88-1.25
Hb 9-
≤10 g/dL
2611 469 1480 32% 420 1131 37% 1.02 0.89-1.16
Hb 10-
≤11 g/dL
2927 542 1699 32% 414 1228 34% 1.16 1.02-1.32
Hb 11-
≤12 g/dL
2077 425 1152 37% 363 925 39% 1.06 0.92-1.22
Hb 12-
≤13 g/dL
1739 377 873 43% 371 866 43% 1.04 0.90-1.20
Hb 13-
≤14 g/dL
1104 189 560 34% 182 544 33% 1.12 0.91-1.37
Hb >14
g/dL
839 155 428 36% 155 411 38% 0.94 0.75-1.18
Un-
known
526 54 252 21% 46 274 17% 1.23 0.83-1.83
Malig-
nancy
type
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Tumour
(cat. 1)
0.23
Haema-
tologi-
cal malig-
nancies
2403 378 1400 27% 286 1003 29% 1.19 1.02-1.39
Solid tu-
mours
10795 2103 5848 36% 1916 4947 39% 1.04 0.98-1.11
Other 693 158 369 43% 145 324 45% 0.99 0.82-1.20
Missing /
unknown
42 4 17 24% 3 25 12% 2.14 0.48-9.62
Tumour
(cat. 2)
0.21
Haema-
tologi-
cal malig-
nancies
2403 378 1400 27% 286 1003 29% 1.18 1.01-1.38
Breast
cancer
4302 563 2245 25% 481 2057 23% 1.13 1.00-1.28
Head and
neck can-
cer
868 235 443 53% 208 425 49% 1.14 0.91-1.42
Lung
cancer
3076 986 1618 61% 975 1458 67% 0.98 0.89-1.07
Gastroin-
testinal
cancer
708 124 434 29% 103 274 38% 0.89 0.68-1.16
Gynaeco-
logical
cancer
1399 115 842 14% 87 557 16% 1.13 0.85-1.50
Geni-
tourinal
cancer
442 80 266 30% 62 176 35% 1.24 0.89-1.73
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Other 693 158 369 43% 145 324 45% 0.99 0.82-1.20
Missing /
unknown
42 4 17 24% 3 25 12% 2.12 0.47-9.50
Sex
Male 5136 1323 2854 46% 1193 2282 52% 1.01 0.94-1.10 0.15
Female 8797 1320 4780 28% 1157 4017 29% 1.10 1.02-1.19
Age
Age con-
tinuous
0.38
Age cate-
gorical
0.26
< 18
years
123 0 55 0% 1 68 1% Not estimable Not estimable
≥18-35
years
346 37 191 19% 27 155 17% 0.89 0.54-1.46
≥35-45
years
1343 196 745 26% 147 598 25% 1.02 0.82-1.26
≥45-55
years
3010 536 1614 33% 439 1396 31% 1.16 1.03-1.32
≥55-65
years
4193 818 2237 37% 793 1956 41% 1.01 0.91-1.11
≥65-75
years
3517 780 1970 40% 711 1547 46% 1.04 0.94-1.15
≥75
years
1389 276 816 34% 231 573 40% 1.20 1.00-1.43
Missing 12 0 6 0% 1 6 17% Not estimable Not estimable
Hct levels
at
baseline
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Hct con-
tinuous
0.90
Hct cate-
gorical
0.03
≤ 23.5% 390 82 210 39% 55 180 31% 1.66 1.18-2.34
23.5-≤
29.4%
2788 476 1567 30% 479 1221 39% 0.94 0.83-1.07
29.4-≤
35.3%
4615 945 2692 35% 732 1923 38% 1.10 0.99-1.21
35.3-≤
41.2%
2458 579 1258 46% 558 1200 47% 1.07 0.95-1.21
> 41.2% 785 169 414 41% 165 371 44% 1.02 0.82-1.26
Missing /
unknown
2897 392 1493 26% 361 1404 26% 1.08 0.93-1.24
Serum
Epo at
baseline
Serum
Epo con-
tinuous
0.14
Serum
Epo cate-
gorical
0.81
< 25
mU/ml
1497 341 876 39% 309 621 50% 0.97 0.84-1.14
25-100
mU/ml
2908 586 1643 36% 548 1265 43% 1.02 0.90-1.14
100-200
mU/ml
740 187 451 41% 130 289 45% 1.10 0.88-1.38
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200-500
mU/ml
325 60 190 32% 51 135 38% 1.18 0.81-1.72
> 500
mU/ml
181 31 103 30% 22 78 28% 1.08 0.63-1.88
Un-
known
8282 1438 4371 33% 1290 3911 33% 1.09 1.01-1.17
Perfor-
mance
score
ECOG
categori-
cal
0.41
ECOG 0 3392 351 1808 19% 341 1584 22% 1.06 0.91-1.23
ECOG 1 4900 984 2779 35% 814 2121 38% 1.09 0.99-1.20
ECOG 2 1678 490 933 53% 433 745 58% 1.01 0.89-1.15
ECOG 3 139 48 77 62% 35 62 56% 1.18 0.76-1.82
ECOG 4 3 2 2 100% 0 1 0% Not estimable Not estimable
ECOG
missing
3821 768 2035 38% 727 1786 41% 1.02 0.93-1.14
ECOG
dichoto-
mous
0.50
ECOG 0,
1, 2
10083 1847 5578 33% 1604 4505 36% 1.08 1.01-1.15
ECOG 3,
4
142 50 79 63% 35 63 56% 1.25 0.81-1.93
ECOG
missing
3708 746 1977 38% 711 1731 41% 1.02 0.92-1.13
Body
mass in-
dex
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≤ 19
kg/m²
865 187 424 44% 195 441 44% 0.95 0.78-1.17 0.72
19-≤ 25
kg/m²
5487 1098 2964 37% 945 2523 37% 1.06 0.97-1.15
25-≤ 30
kg/m²
3443 642 1864 34% 543 1579 34% 1.09 0.97-1.22
> 30
kg/m²
1650 250 867 29% 224 783 29% 1.03 0.86-1.24
Missing 2488 466 1515 31% 443 973 46% 1.10 0.97-1.26
History
of throm-
boem-
bolic
events
Yes 561 128 318 40% 107 243 44% 1.03 0.80-1.33 0.90
No 9059 1720 5044 34% 1509 4015 38% 1.05 0.98-1.12
Missing /
not
reported
4313 795 2272 35% 734 2041 36% 1.08 0.98-1.20
History
of cardio-
vascular
events
Yes 3593 758 2002 38% 648 1591 41% 1.07 0.96-1.19 0.69
No 6729 1141 3700 31% 1010 3029 33% 1.04 0.96-1.13
Missing /
not
reported
3611 744 1932 39% 692 1679 41% 1.07 0.97-1.19
History
of hyper-
tension
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Yes 2093 420 1219 34% 373 874 43% 1.01 0.88-1.16 0.57
No 7527 1428 4143 34% 1243 3384 37% 1.06 0.98-1.14
Missing /
not
reported
4313 795 2272 35% 734 2041 36% 1.08 0.98-1.20
His-
tory of di-
abetes
mellitus
Yes 709 163 372 44% 158 337 47% 1.05 0.84-1.31 0.94
No 7316 1456 3927 37% 1250 3389 37% 1.06 0.98-1.14
Missing /
not
reported
5908 1024 3335 31% 942 2573 37% 1.06 0.97-1.16
Geo-
graphical
region
Northern
America
3569 490 2004 24% 470 1565 30% 1.11 0.98-1.27 0.90
North-
ern,
Western
& South-
ern
Europe
7440 1529 4030 38% 1322 3410 39% 1.05 0.98-1.13
Eastern
Europe
1955 514 1030 50% 469 925 51% 1.03 0.91-1.17
Australia
& New
Zealand
342 40 216 19% 28 126 22% 1.08 0.66-1.75
Other 226 48 123 39% 46 103 45% 0.95 0.63-1.43
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Missing /
not
reported
401 22 231 10% 15 170 9% 1.47 0.75-2.89
Tumour
stage
Metastatic
/
advanced
8113 1918 4482 43% 1698 3631 47% 1.05 0.98-1.12 0.86
Not
metastatic
/ not ad-
vanced
4039 420 2116 20% 408 1923 21% 1.06 0.93-1.22
Missing /
not
reported
1781 305 1036 29% 244 745 33% 1.04 0.87-1.23
Planned
Hb ceil-
ing
Planned
Hb ceil-
ing (cat 1)
0.40
≤Hb
13.0 g/dL
3043 437 1624 27% 399 1419 28% 1.09 0.95-1.25
Hb 13.0 -
≤15.0
g/dL
10193 2019 5631 36% 1782 4562 39% 1.04 0.97-1.11
Hb >15.0
g/dL
494 159 259 61% 152 235 65% 1.21 0.97-1.51
Other 203 28 120 23% 17 83 20% 1.13 0.61-2.07
Planned
Hb ceil-
ing (cat 2)
0.60
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≤Hb
13.0 g/dL
3043 437 1624 27% 399 1419 28% 1.09 0.95-1.25
Hb 13.0 -
≤14.0
g/dL
6816 1142 3733 31% 1013 3083 33% 1.03 0.95-1.13
Hb 14.0 -
≤15.0
g/dL
3377 877 1898 46% 769 1479 52% 1.05 0.95-1.15
>Hb 15.0
g/dL
494 159 259 61% 152 235 65% 1.21 0.97-1.51
Other 203 28 120 23% 17 83 20% 1.13 0.61-2.07
Study
level
charac-
teristics
Treat-
ment
popula-
tion
Treat-
ment
popula-
tion
Chemo-
therapy
10441 1888 5676 33% 1667 4765 35% 1.04 0.97-1.11 0.11
Ra-
diochemother-
apy
737 204 368 55% 211 369 57% 0.91 0.75-1.10
Radio-
therapy
799 220 408 54% 196 391 50% 1.17 0.96-1.42
Mixed 266 17 175 10% 7 91 8% 1.53 0.63-3.69
None 1690 314 1007 31% 269 683 39% 1.22 1.04-1.44
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Treat-
ment
popula-
tion
Chemo-
therapy
10441 1888 5676 33% 1667 4765 35% 1.04 0.97-1.11 0.25
Radio-
ther-
apy / ra-
diochemother-
apy
1536 424 776 55% 407 760 54% 1.03 0.90-1.18
Mixed 266 17 175 10% 7 91 8% 1.53 0.63-3.69
None 1690 314 1007 31% 269 683 39% 1.22 1.04-1.44
Iron sup-
plemen-
tation
Fixed
iron sup-
plemen-
tation
2589 468 1293 36% 467 1296 36% 1.00 0.87-1.13 0.48
Iron sup-
plemen-
tation as
needed
11120 2075 6232 33% 1782 4888 36% 1.07 1.00-1.14
Other 224 100 109 92% 101 115 88% 1.17 0.89-1.55
Planned
ESA
treatment
duration
Up to 8
weeks
415 55 256 21% 47 159 30% 1.09 0.74-1.62 0.74
9-16
weeks
4800 667 2738 24% 644 2062 31% 1.02 0.91-1.14
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> 17
weeks
3269 816 1701 48% 747 1568 48% 1.11 1.00-1.22
Until end
of
chemo-
or radio-
therapy
5449 1105 2939 38% 912 2510 36% 1.05 0.96-1.14
Planned
weekly
ESA
dosage
< 100 µg
Darbepo-
etin or <
40000 IU
Epoetin
4197 832 2297 36% 669 1900 35% 1.04 0.94-1.15 0.88
= 100 µg
Darbepo-
etin or =
40000 IU
Epoetin
3081 557 1545 36% 536 1536 35% 1.08 0.96-1.22
> 100 µg
Darbepo-
etin or >
40000 IU
Epoetin
3845 876 2076 42% 808 1769 46% 1.08 0.98-1.19
Other 2810 378 1716 22% 337 1094 31% 1.02 0.88-1.18
Planned frequency
of ESA application
Three
times per
week or
more fre-
quent
6131 1067 3458 31% 840 2673 31% 1.07 0.98-1.18 0.07
Once per
week
3948 911 1972 46% 886 1976 45% 1.06 0.97-1.17
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Every sec-
ond week
or less fre-
quent
3036 347 1795 19% 286 1241 23% 1.20 1.02-1.40
Other 818 318 409 78% 338 409 83% 0.90 0.77-1.05
Placebo
con-
trolled
trial
Yes 7657 1578 4211 37% 1403 3446 41% 1.09 1.01-1.17 0.29
No 6276 1065 3423 31% 947 2853 33% 1.02 0.93-1.12
Ran-
domisa-
tion
Adequate 3882 739 2047 36% 636 1835 35% 1.07 0.96-1.19 0.80
Unclear 10051 1904 5587 34% 1714 4464 38% 1.05 0.99-1.13
Conceal-
ment of
allocation
Adequate 10595 2176 5839 37% 1901 4756 40% 1.07 1.00-1.14 0.49
Unclear 3338 467 1795 26% 449 1543 29% 1.02 0.89-1.16
Endpoint
survival
Primary
endpoint
3116 732 1547 47% 715 1569 46% 1.02 0.92-1.13 0.39
Sec-
ondary
endpoint
4313 1164 2282 51% 985 2031 48% 1.04 0.96-1.14
Safety
/adverse
events
6504 747 3805 20% 650 2699 24% 1.13 1.01-1.25
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Designed
for long-
term fol-
low-up
Yes 8974 2213 4619 48% 1972 4355 45% 1.06 1.00-1.13 0.64
No 4959 430 3015 14% 378 1944 19% 1.03 0.89-1.18
Year
of last pa-
tient ran-
domized
1990-
1994
1447 100 890 11% 70 557 13% 0.96 0.70-1.31 0.13
1995-
1999
1725 312 1001 31% 224 724 31% 0.97 0.81-1.16
2000-
2004
7620 1453 4105 35% 1296 3515 37% 1.13 1.04-1.21
2005-
2006
3141 778 1638 47% 760 1503 51% 0.99 0.89-1.09
Source of
data
Manufac-
turer
12229 2434 6789 36% 2151 5440 40% 1.06 1.00-1.13 0.57
Clin-
ical study
group
1704 209 845 25% 199 859 23% 1.00 0.83-1.22
*P value for likelihood-ratio test (test for interaction), patients with missing data are excluded from this test, analysis based on one-
stage Cox fixed-effects model stratified by study
ESA= erythropoiesis-stimulating agents
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Appendix 9. Assessment of interaction for overall survival in chemotherapy trials
Overall survival chemotherapy trials
Sub-
groups
Patients ESA arm Control arm ESA versus control
events sample % events sample % HR 95% CI P value*
Patient
level
charac-
teristics
Hb at
baseline
Hb at
base-
line (con-
tinuous)
0.49
Hb at
baseline
(cat. 1)
Hb ≤ 8
g/dL
569 121 321 38% 100 248 40% 1.08 0.83-1.41 0.88
Hb 8-
≤10 g/dL
2888 533 1606 33% 504 1282 39% 0.99 0.88-1.12
Hb 10-
≤12 g/dL
3748 706 2121 33% 572 1627 35% 1.06 0.95-1.18
Hb 12-
≤14 g/dL
2185 401 1108 36% 377 1077 35% 1.08 0.94-1.24
Hb >14
g/dL
555 83 286 29% 70 269 26% 1.13 0.82-1.55
Un-
known
496 44 234 19% 44 262 17% 1.08 0.71-1.65
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(Continued)
Hb at
baseline
(cat. 2)
Hb ≤ 8
g/dL
569 121 321 38% 100 248 40% 1.08 0.83-1.42 0.98
Hb 8-≤9
g/dL
949 182 549 33% 175 400 44% 1.00 0.81-1.23
Hb 9-
≤10 g/dL
1939 351 1057 33% 329 882 37% 0.99 0.85-1.16
Hb 10-
≤11 g/dL
2074 375 1179 32% 290 895 32% 1.08 0.93-1.27
Hb 11-
≤12 g/dL
1674 331 942 35% 282 732 39% 1.03 0.88-1.20
Hb 12-
≤13 g/dL
1359 287 679 42% 275 680 40% 1.09 0.92-1.28
Hb 13-
≤14 g/dL
826 114 429 27% 102 397 26% 1.09 0.83-1.43
Hb >14
g/dL
555 83 286 29% 70 269 26% 1.13 0.82-1.55
Un-
known
496 44 234 19% 44 262 17% 1.09 0.71-1.66
Malig-
nancy
type
Tumour
(cat. 1)
Haema-
tologi-
cal malig-
nancies
1832 335 1034 32% 264 798 33% 1.13 0.96-1.33 0.33
Solid tu-
mours
7967 1410 4311 33% 1271 3656 35% 1.03 0.96-1.12
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Other 600 139 314 44% 129 286 45% 0.90 0.71-1.15
Missing /
unknown
42 4 17 24% 3 25 12% 2.12 0.47-9.54
Tumour
(cat. 2)
Haema-
tologi-
cal malig-
nancies
1832 335 1034 32% 264 798 33% 1.12 0.95-1.32 0.33
Breast
cancer
4038 536 2076 26% 454 1962 23% 1.15 1.01-1.30
Head and
neck can-
cer
26 3 12 25% 3 14 21% 0.49 0.10-2.43
Lung
cancer
2237 705 1172 60% 695 1065 65% 0.96 0.87-1.07
Gastroin-
testinal
cancer
429 84 267 31% 65 162 40% 0.89 0.64-1.24
Gynaeco-
logical
cancer
1077 64 681 9% 39 396 10% 1.16 0.77-1.73
Geni-
tourinay
cancer
160 18 103 17% 15 57 26% 1.05 0.52-2.10
Other 600 139 314 44% 129 286 45% 0.91 0.72-1.16
Missing /
unknown
42 4 17 24% 3 25 12% 2.09 0.47-9.40
Sex
Male 3125 806 1720 47% 750 1405 53% 0.96 0.87-1.06 0.04
Female 7316 1082 3956 27% 917 3360 27% 1.10 1.01-1.21
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(Continued)
Age
Age con-
tinuous
0.41
Age cate-
gorical
< 18
years
123 0 55 0% 1 68 1% Not estimable Not estimable 0.40
≥18-35
years
312 32 171 19% 23 141 16% 0.95 0.55-1.62
≥35-45
years
1135 150 620 24% 120 515 23% 0.97 0.76-1.23
≥45-55
years
2425 392 1311 30% 323 1114 29% 1.15 0.99-1.33
≥55-65
years
3233 594 1724 34% 573 1509 38% 0.98 0.87-1.10
≥65-75
years
2444 539 1359 40% 489 1085 45% 1.03 0.91-1.17
≥75
years
758 181 430 42% 137 328 42% 1.17 0.94-1.47
Missing 11 0 6 0% 1 5 20% Not estimable Not estimable
Hct levels
at
baseline
Hct con-
tinuous
0.25
Hct cate-
gorical
≤ 23.5% 275 51 144 35% 42 131 32% 1.36 0.90-2.05 0.24
23.5-≤
29.4%
2033 340 1135 30% 338 898 38% 0.93 0.80-1.08
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29.4-≤
35.3%
3281 689 1882 37% 531 1399 38% 1.05 0.94-1.18
35.3-≤
41.2%
1801 400 931 43% 386 870 44% 1.05 0.91-1.20
> 41.2% 459 84 249 34% 66 210 31% 1.30 0.94-1.79
Missing /
unknown
2592 324 1335 24% 304 1257 24% 1.07 0.91-1.25
Serum
Epo at
baseline
Serum
Epo con-
tinuous
1.00
Serum
Epo cate-
gorical
< 25
mU/ml
1032 235 608 39% 225 424 53% 0.91 0.76-1.09 0.49
25-100
mU/ml
2083 434 1162 37% 415 921 45% 0.94 0.82-1.08
100-200
mU/ml
518 143 314 46% 92 204 45% 1.17 0.90-1.52
200-500
mU/ml
227 47 134 35% 39 93 42% 1.13 0.74-1.73
> 500
mU/ml
99 14 57 25% 15 42 36% 0.76 0.36-1.58
Un-
known
6482 1015 3401 30% 881 3081 29% 1.10 1.01-1.21
Perfor-
mance
score
242Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
ECOG
categori-
cal
ECOG 0 3025 320 1582 20% 309 1443 21% 1.06 0.90-1.24 0.34
ECOG 1 3784 820 2105 39% 671 1679 40% 1.07 0.96-1.18
ECOG 2 1140 337 623 54% 309 517 60% 0.96 0.82-1.12
ECOG 3 105 37 57 65% 29 48 60% 0.94 0.57-1.53
ECOG 4 3 2 2 100% 0 1 0% Not estimable Not estimable
ECOG
missing
2384 372 1307 28% 349 1077 32% 1.03 0.89-1.19
ECOG
dichoto-
mous
ECOG 0,
1, 2
7949 1477 4310 34% 1289 3639 35% 1.04 0.97-1.13 0.92
ECOG 3,
4
108 39 59 66% 29 49 59% 1.02 0.63-1.65
ECOG
missing
2384 372 1307 28% 349 1077 32% 1.02 0.88-1.19
Body
mass in-
dex
≤ 19
kg/m²
607 107 292 37% 116 315 37% 0.86 0.66-1.12 0.52
19-≤ 25
kg/m²
4283 796 2318 34% 685 1965 35% 1.03 0.93-1.14
25-≤ 30
kg/m²
2698 477 1468 32% 393 1230 32% 1.07 0.94-1.23
> 30
kg/m²
1294 177 686 26% 161 608 26% 1.00 0.81-1.24
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(Continued)
Missing 1559 331 912 36% 312 647 48% 1.11 0.95-1.30
History
of throm-
boem-
bolic
events
Yes 375 96 207 46% 72 168 43% 1.10 0.81-1.50 0.68
No 6292 1136 3469 33% 972 2823 34% 1.03 0.94-1.12
Missing /
not
reported
3774 656 2000 33% 623 1774 35% 1.04 0.93-1.17
History
of cardio-
vascular
events
Yes 2319 481 1295 37% 385 1024 38% 1.06 0.92-1.21 0.78
No 5050 802 2721 29% 701 2329 30% 1.03 0.93-1.14
Missing /
not
reported
3072 605 1660 36% 581 1412 41% 1.03 0.92-1.15
History
of hyper-
tension
Yes 1396 318 798 40% 255 598 43% 1.03 0.87-1.21 0.91
No 5271 914 2878 32% 789 2393 33% 1.04 0.94-1.14
Missing /
not
reported
3774 656 2000 33% 623 1774 35% 1.04 0.93-1.17
His-
tory of di-
abetes
mellitus
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(Continued)
Yes 430 85 219 39% 92 211 44% 0.97 0.72-1.31 0.62
No 5149 937 2786 34% 751 2363 32% 1.05 0.96-1.16
Missing /
not
reported
4862 866 2671 32% 824 2191 38% 1.03 0.94-1.14
Geo-
graphical
region
Northern
America
2083 306 1088 28% 315 995 32% 1.05 0.90-1.23 0.93
North-
ern,
Western
& South-
ern
Europe
6082 1131 3342 34% 929 2740 34% 1.05 0.96-1.15
Eastern
Europe
1413 363 734 49% 346 679 51% 0.99 0.85-1.14
Australia
& New
Zealand
286 27 184 15% 21 102 21% 1.01 0.57-1.80
Other 189 45 106 42% 44 83 53% 0.92 0.61-1.40
Missing /
not
reported
388 16 222 7% 12 166 7% 1.54 0.71-3.32
Tumour
stage
Metastatic
/
advanced
6054 1379 3325 41% 1221 2729 45% 1.03 0.96-1.12 0.60
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Not
metastatic
/ not ad-
vanced
2902 248 1491 17% 234 1411 17% 1.09 0.91-1.31
Missing /
not
reported
1485 261 860 30% 212 625 34% 0.93 0.77-1.12
Planned
Hb ceil-
ing
Planned
Hb ceil-
ing (cat.
1)
≤Hb
13.0 g/dL
1631 105 841 12% 97 790 12% 1.06 0.80-1.40 0.57
Hb 13.0 -
≤15.0
g/dL
8451 1664 4630 36% 1464 3821 38% 1.03 0.96-1.10
Hb >15.0
g/dL
280 104 150 69% 101 130 78% 1.20 0.91-1.58
Other 79 15 55 27% 5 24 21% 1.45 0.53-4.00
Planned
Hb ceil-
ing (cat.
2)
≤Hb
13.0 g/dL
1631 105 841 12% 97 790 12% 1.06 0.80-1.40 0.77
Hb 13.0
≤14.0
g/dL
5930 969 3200 30% 855 2730 31% 1.03 0.94-1.13
Hb 14.0
≤15.0
g/dL
2521 695 1430 49% 609 1091 56% 1.02 0.92-1.14
246Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
>Hb 15.0
g/dL
280 104 150 69% 101 130 78% 1.20 0.91-1.58
Other 79 15 55 27% 5 24 21% 1.45 0.53-4.00
Study
level
charac-
teristics
Iron sup-
plemen-
tation
Fixed
iron sup-
plemen-
tation
1904 248 947 26% 233 957 24% 1.12 0.94-1.35 0.41
Iron sup-
plemen-
tation as
needed
8313 1540 4620 33% 1333 3693 36% 1.02 0.94-1.09
Other 224 100 109 92% 101 115 88% 1.17 0.89-1.55
Planned
ESA
treatment
duration
Up to 8
weeks
143 5 114 4% 3 29 10% 0.69 0.13-3.56 0.72
9-16
weeks
3823 591 2075 28% 590 1748 34% 0.99 0.88-1.11
> 17
weeks
2280 566 1184 48% 531 1096 48% 1.06 0.94-1.19
Until end
of
chemo-
or radio-
therapy
4195 726 2303 32% 543 1892 29% 1.07 0.96-1.20
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Planned
weekly
ESA
dosage
< 100 µg
Darbepo-
etin or <
40000 IU
Epoetin
3733 794 2023 39% 645 1710 38% 1.03 0.92-1.14 0.37
= 100 µg
Darbepo-
etin or =
40000 IU
Epoetin
2200 292 1101 27% 264 1099 24% 1.19 1.00-1.40
> 100 µg
Darbepo-
etin or >
40000 IU
Epoetin
1998 498 987 50% 496 1011 49% 0.99 0.88-1.12
Other 2510 304 1565 19% 262 945 28% 1.01 0.86-1.20
Planned frequency of
ESA application
Three
times per
week or
more fre-
quent
5016 846 2853 30% 652 2163 30% 1.04 0.94-1.16 0.16
Once per
week
3067 646 1528 42% 614 1539 40% 1.10 0.99-1.23
Every sec-
ond week
or less fre-
quent
1540 78 886 9% 63 654 10% 1.19 0.85-1.67
Other 818 318 409 78% 338 409 83% 0.90 0.77-1.05
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Placebo
con-
trolled
trial
Yes 5473 1118 2996 37% 1010 2477 41% 1.03 0.95-1.12 0.77
No 4968 770 2680 29% 657 2288 29% 1.05 0.95-1.17
Ran-
domisa-
tion
Adequate 3258 649 1693 38% 553 1565 35% 1.04 0.93-1.17 0.90
Unclear 7183 1239 3983 31% 1114 3200 35% 1.04 0.96-1.12
Conceal-
ment of
allocation
Adequate 8252 1679 4501 37% 1476 3751 39% 1.02 0.95-1.10 0.26
Unclear 2189 209 1175 18% 191 1014 19% 1.16 0.95-1.41
Endpoint
survival
Primary
endpoint
2731 586 1352 43% 556 1379 40% 1.08 0.96-1.22 0.58
Sec-
ondary
endpoint
3222 886 1730 51% 738 1492 49% 1.00 0.91-1.11
Safety
/adverse
events
4488 416 2594 16% 373 1894 20% 1.05 0.91-1.21
Designed
for long-
term fol-
low-up
Yes 6509 1539 3355 46% 1350 3154 43% 1.05 0.98-1.13 0.47
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No 3932 349 2321 15% 317 1611 20% 0.99 0.84-1.15
Year
of last pa-
tient ran-
domized
1990-
1994
1057 70 650 11% 51 407 13% 0.88 0.61-1.27 0.18
1995-
1999
1725 312 1001 31% 224 724 31% 0.97 0.81-1.16
2000-
2004
6112 1135 3263 35% 1012 2849 36% 1.10 1.01-1.20
2005-
2006
1547 371 762 49% 380 785 48% 0.94 0.82-1.09
Source of
data
Manufac-
turer
8851 1701 4889 35% 1485 3962 37% 1.05 0.97-1.12 0.54
Clin-
ical study
group
1590 187 787 24% 182 803 23% 0.98 0.80-1.20
*P value for likelihood-ratio test (test for interaction), patients with missing data are excluded from this test, analysis based on one-
stage Cox fixed-effects model stratified by study
ESA= erythropoiesis-stimulating agents
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